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RESUMEN	
Las	 enfermedades	 infecciosas	 son	 causadas	 por	 microorganismos	 patógenos	 (bacterias,	
parásitos,	hongos	o	virus)	y	pueden	ser	transmitidas	directa	o	indirectamente	de	una	persona	
a	otra.	Entre	ellas	destacan	las	enfermedades	zoonóticas,	que	son	aquellas	que	se	transmiten	
entre	animales	vertebrados,	incluidos	los	humanos.	Éste	es	el	caso	del	virus	del	Nilo	Occidental	
(VNO),	miembro	del	género	Flavivirus	 (familia	Flaviviridae),	que	es	un	patógeno	neurotrópico	
que	puede	causar	encefalitis	y	 la	denominada	“fiebre	del	Nilo”	en	humanos.	Como	patógeno	
intracelular	obligado,	el	VNO	utiliza	factores	celulares	para	completar	su	ciclo	de	replicación,	el	
cual	está	íntimamente	asociado	con	el	metabolismo	lipídico	celular.	Así,	se	ha	descrito	que	el	
VNO	 reorganiza	 las	 membranas	 intracelulares	 del	 retículo	 endoplasmático	 de	 las	 células	
infectadas	 para	 desarrollar	 plataformas	 adecuadas	 para	 una	 correcta	 replicación	 viral	 y	 su	
posterior	expansión.	Con	estos	antecedentes,	el	objetivo	general	de	ésta	tesis	es	profundizar	
en	el	conocimiento	de	los	procesos	celulares	implicados	en	las	interacciones	patógeno-célula,	y	
más	 concretamente	en	el	 papel	de	 los	 lípidos	 celulares	en	 la	 replicación	 vírica,	 con	el	 fin	de	
buscar	dianas	celulares	para	el	desarrollo	de	estrategias	antivirales	innovadoras.	
Los	resultados	obtenidos	 indican	que	la	manipulación	farmacológica	del	metabolismo	lipídico	
celular	 es	 una	 potente	 estrategia	 alternativa	 para	 combatir	 el	 VNO;	 y	 que	 enzimas	 como	 la	
acetil-Coenzima	A		carboxilasa	o	la	esfingomielinasa	neutra,	así	como	la	vía	metabólica	de	las	
proteínas	 de	 unión	 de	 elementos	 reguladores	 del	 esterol	 celular	 (SREBPs),	 son	 objetivos	
apropiados	para	el	desarrollo	de	antivirales.		
Es	 esperable	 que	 los	 conocimientos	 alcanzados	 contribuyan	 al	 estudio	más	 detallado	 de	 las	
dinámicas	de	las	interacciones	lipídicas	a	lo	largo	del	ciclo	viral	y,	de	este	modo,	al	desarrollo	
de	 nuevas	 estrategias	 antivirales	 para	 combatir	 el	 VNO	 y	 otros	 flavivirus	 relacionados,	 tales	
como	Usutu,	dengue	o	Zika.	 	
 	
SUMMARY	
Infectious	 diseases	 are	 caused	 by	 pathogenic	microorganisms	 (bacteria,	 viruses,	 parasites	 or	
fungi)	 and	 can	 be	 spread,	 directly	 or	 indirectly,	 from	 one	 person	 to	 another.	 These	 include	
zoonotic	diseases	that	are	transmitted	between	vertebrates,	including	humans.	This	is	the	case	
of	West	Nile	 virus	 (WNV),	 a	member	 of	 the	 genus	Flavivirus	 (family	 Flaviviridae),	which	 is	 a	
neurotropic	pathogen	and	the	causative	agent	of	the	so-called	West	Nile	fever	in	humans	and	
encephalitis.	As	an	obligate	 intracellular	pathogen,	WNV	uses	cellular	 factors	 to	complete	 its	
replication	cycle,	which	is	intimately	associated	to	host	cell	lipid	metabolism.	Thus,	it	has	been	
described	 that	WNV	 rearranges	 intracellular	membranes	 from	 the	 endoplasmic	 reticulum	of	
infected	cells	to	develop	adequate	platforms	for	an	efficient	viral	replication	and	subsequent	
spread.	 Keeping	 this	 in	 mind,	 the	 general	 aim	 of	 this	 thesis	 was	 to	 achieve	 an	 accurate	
knowledge	of	the	cellular	processes	involved	in	pathogen	and	host	cell	interactions,	and	more	
precisely	 in	 the	 role	 of	 the	 cellular	 lipids	 in	 viral	 replication,	 in	 order	 to	 search	 for	 cellular	
targets	for	the	development	of	innovative	antiviral	strategies.	
The	 obtained	 results	 indicate	 that	 the	 pharmacological	 manipulation	 of	 cellular	 lipid	
metabolism	 is	 an	 alternative	 potential	 strategy	 to	 combat	 WNV,	 and	 that	 enzymes,	 as	 the	
acetyl-CoA	carboxylase	(ACC)	or	the	neutral	sphingomyelinase	(nSMase),	as	well	as	the	cellular	
sterol	 regulatory	 element	 binding	 proteins	 (SREBPs)	metabolic	 pathway,	 are	 suitable	 targets	
for	antiviral	development.		
It	 is	 expected	 that	 the	 knowledge	 gained	 will	 contribute	 to	 a	 more	 detailed	 study	 of	 the	
dynamics	 of	 the	 lipids	 interactions	 throughout	 the	 viral	 cycle	 and,	 in	 this	 way,	 to	 the	
development	 of	 new	 antiviral	 strategies	 to	 fight	 WNV	 and	 other	 related	 flavivirus,	 such	 as	
Usutu,	dengue,	and	Zika.	
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ABBREVIATIONS
ACC:	Acetyl-CoA	Carboxylase	
CDC:	Centers	for	Disease	Control	and	
Prevention	
CER:	Ceramides		
CERS:	Ceramide	Synthase		
CM:	Convoluted	Membranes	
DAAs:	Direct	Acting	Antivirals	
DENV:	Dengue	Virus	
DHCR7:	7-dehydrocholesterol	Reductase		
dsRNA:	doubled-strand	RNA		
E:	Envelope	
ECDC:	European	Centre	for	Disease	
Prevention	and	Control	
EM:	Electron	Microscopy	
ER:	Endoplasmic	Reticulum	
FA:	Fatty	Acyls	
FASN:	Fatty	Acid	Synthase	
GAGs:	Glycosaminoglycans		
GBS:	Guillain-Barré	syndrome	
GGTase1:	geranylgeranyl	transferase	type	I		
GLs:	Glycerolipids	
GPLs:	Glycerophospholipids		
HCV:	Hepatitis	C	Virus	
HMG-CoA	reductase:	hydroxyl	methyl	
glutaryl-CoA	reductase		
ILCNC:	International	Lipid	Classification	and	
Nomenclature	Committee	
JEV:	Japanese	Encephalitis	Virus	
KUNV:	Kunjin	Virus	
LDLR:	low-density	lipoprotein	receptor	
lyso-PC:	lysophospholipids	
M:	Membrane	
M4N:	tetra-O-methyl	nordihydroguaiaretic	
acid	
MEDICA	16:	3,3,14,14-
tetramethylhexadecanedioic	acid	
MVE:	Murray	Valley	Encephalitis	
NCR:	Non-Coding	Regions	
NDGA:	Nordihydroguaiaretic	Acid	
nm:	nanometers	
NS:	Non-Structural	
nSMase:	neutral	Sphingomyelinase	
nt:	nucleotide	
NTPase:	Nucleoside	5’	Triphosphatase			
PC:	Phosphatidylcholine		
PE:	Phosphatidylethanolamine		
pH:	Potential	of	Hydrogen	
PI:	Phosphatidylinositol		
PK:	Polyketides	
PRs:	Prenol	lipids		
PS:	Phosphatidylserine		
RC:	Replication	Complex	
RdRp:	RNA-dependent	RNA	polymerase	
RNA:	Ribonucleic	Acid	
RSPs:	Recombinant	Subviral	Particles	
(Partículas	Subvirales	Recombinantes)	
RTPase:	5’	RNA	triphosphatase	
RT-PCR:	Real	Time-PCR	
SCLs:	Saccharolipids	
SL:	Sphingolipids	
SLEV:	St.	Louis	Encephalitis	Virus	
SMase:	Sphingomyelinase	
SMS:	Sphingomyelin	Synthase		
SPTLC:	Palmitoyltransferase	
SREBP:	Sterol	Regulatory	Element	Binding	
Proteins	(Proteínas	de	unión	de	elementos	
reguladores	del	esterol	celular)	
STs:	Sterol	lipids		
TOFA:	5-(tetradecyloxy)-2-furoic	acid	
USA:	United	States	of	America	
USUV:	Usutu	Virus		
UTR:	Untranslated	Regions	
Vi:	Virions	
VNO:	Virus	del	Nilo	Occidental	
Vp:	Vesicle	Packets	
VZIKA:	Virus	de	Zika	
WNV:	West	Nile	Virus	
YFV:	Yellow	Fever	Virus	
ZIKV:	Zika	Virus		
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1.	West	Nile	Virus	(WNV)	
1.1	History	and	geographical	distribution	
The	West	Nile	virus	(WNV)	belongs	to	the	family	Flaviviridae	within	the	genus	Flavivirus.	This	
genus	comprises	over	70	viruses	serologically	classified	 into	eight	antigenic	complexes,	many	
of	 which,	 such	 as	 dengue	 virus	 (DENV),	 Zika	 virus	 (ZIKV),	 yellow	 fever	 virus	 (YFV),	 Japanese	
encephalitis	virus	(JEV),	or	St.	Louis	encephalitis	virus	(SLEV)	are	important	human	and	animal	
pathogens	(Gould	and	Solomon	2008).	Probably,	the	most	well-known	and	representative	virus	
belonging	to	this	genus	is	the	yellow	fever	virus,	which	gives	name	to	the	family	(“flavi”	comes	
from	 “flavus”	 that	 means	 yellow	 in	 Latin).	 Flaviviruses	 are	 arthropod-borne	 viruses	
(arboviruses)	 that	 in	many	 instances	are	 zoonotic.	 These	viruses	are	maintained	 in	nature	 in	
complex	 infectious	 cycles	 that	 involve	 different	 vectors	 (mainly	 mosquitoes	 and	 ticks)	 and	
vertebrate	 hosts	 (Figure	 1).	 Arthropod	 transmission	 of	 WNV	 includes	 uptake	 of	 virus	 by	 a	
vector	during	feeding	on	a	viremic	host,	subsequent	replication	and	dissemination	of	virus	 in	
the	 vector	 and,	 finally,	 transmission	 of	 the	 virus	 from	 the	 vector	 during	 feeding	 on	 an	
uninfected	 and	 susceptible	 host.	 WNV	 infections	 have	 been	 described	 in	 a	 wide	 variety	 of	
vertebrates,	being	the	most	important	birds,	especially	wild	birds,	since	they	are	the	principal	
Figure	 1:	 West	 Nile	 Virus	 transmission	 cycle.	 The	 WNV	 is	 transmitted	 to	 birds	 by	 infected	 mosquitoes	 and	
supplemented	 by	 bird-to-bird	 transmission.	 Vertical	 transmission	 among	 mosquitoes	 also	 occurs.	 Although	 the	
natural	host	 of	WNV	are	birds,	 it	occasionally	 infects	 several	 other	 vertebrates	 including	humans,	 in	which	non-
vectorial	transmission	has	also	been	documented.	
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hosts	of	the	virus.	The	high	and	long-term	viremia	observed	in	wild	birds	allows	transmission	of	
WNV	to	its	vectors,	which	are	mainly	ornitophilic	mosquitoes	of	the	Culex	species.	Migrations	
of	 birds	 have	 been	 shown	 to	 be	 instrumental	 in	 the	 introduction	 of	 WNV	 into	 previously	
unaffected	areas.	Beside	birds,	a	broad	range	of	other	vertebrate	species	have	been	described	
as	 susceptible	 to	 WNV	 infection	 as	 well	 (rodents,	 bats,	 horses,	 or	 human	 and	 non-human	
primates,	 among	 others).	 In	 any	 case,	 the	 susceptibilities	 of	 birds	 to	 WNV	 infection	 differ	
between	 families,	 being	 the	 species	 belonging	 to	 the	 Corvidae	 family	 the	 more	 susceptible	
(Komar	2003).	On	the	other	hand,	horses	usually	display	an	asymptomatic	infection,	with	only	
10%-12%	of	the	infected	animals	showing	signs	of	disease,	being	up	to	half	of	these	cases	fatal	
(van	 der	 Meulen,	 Pensaert	 et	 al.	 2005).	 Likewise,	 in	 humans	 infections	 are	 usually	
asymptomatic,	but	occasionally	WNV	pathogenesis	can	range	from	mild	 illness	such	as	fever,	
rash	 and	 joint	 pain,	 to	 more	 severe	 symptoms	 such	 as	 acute	 flaccid	 paralysis	 and	 fatal	
encephalitis	(Martin-Acebes	and	Saiz	2012).		
WNV	 was	 isolated	 for	 the	 first	 time	 in	 Uganda	 in	 1937	 from	 a	 febrile	 patient	 (Smithburn,	
Hughes	 et	 al.	 1940)	 and,	 since	 then,	 it	 has	 caused	 infrequent	 outbreaks	 typically	 associated	
with	mild	febrile	illnesses	from	the	1950s	through	the	1980s	in	Israel,	Egypt,	India,	France	and	
South	Africa	 (Hurlbut,	Rizk	et	 al.	 1956;	George,	Gourie-Devi	 et	 al.	 1984;	 Jupp	2001;	Balanca,	
Gaidet	et	al.	2009).	Decrease	 in	mosquito	control	efforts	coupled	with	social	 factors,	such	as	
increased	 transportation	 and	 dense	 urbanization,	 have	 contributed	 to	 the	 emergence	 or	
reemergence	of	WNV.	From	the	1990s	on,	the	frequency,	severity,	and	geographic	distribution	
of	 WNV	 outbreaks	 increased,	 and	 outbreaks	 of	 WNV	 encephalitis	 and	 meningitis	 affecting	
primarily	adults	hit	Romania	 in	1996,	Russia	 in	1999,	and	 Israel	 in	2000	 (Tsai,	Popovici	 et	al.	
1998;	Platonov,	Shipulin	et	al.	2001;	Weinberger,	Pitlik	et	al.	2001).	 Later	on,	 the	number	of	
affected	European	countries	have	increased,	so	that,	during	2016	(Figure	2)	214	cases	of	West	
Nile	fever	in	humans	were	reported	in	the	EU,	93	in	Romania,	68	in	Italy,	43	in	Hungary,	3	in	
Austria,	3	in	Spain,	2	in	Bulgaria,	and	one	each	in	Cyprus	and	Croatia.	In	neighboring	countries,	
267	cases	have	been	detected:	135	in	Russia,	84	in	Israel,	41	in	Serbia,	2	in	Syria,	2	in	Turkey,	
and	 one	 each	 in	 Egypt,	 Tunisia	 and	 Ukraine	
(http://ecdc.europa.eu/en/healthtopics/west_nile_fever/pages/index.aspx).	 In	 Spain,	 the	 first	
human	 case	 was	 reported	 in	 Extremadura	 and	 more	 probably	 was	 an	 imported	 case	 from	
Portugal	 (Kaptoul	 et	 al.,	 2007).	 Later,	 the	 virus	 was	 isolated	 from	 a	 captive	 eagle	 (Jimenez-
Clavero	et	al.,	2008).	In	2010,	the	first	outbreaks	were	reported	in	horses	in	Andalusia,	with	41	
diagnosed	cases	and	10	deaths	and	a	couple	of	non-fatal	human	cases	(García-Bocanegra	et	al,	
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2010).	Finally,	along	2016	summer	new	outbreaks	in	horses	were	reported	with	three	non-fatal	
human	cases	(http://ecdc.europa.eu/en/healthtopics/west_nile_fever/pages/index.aspx).	
	
Figure	 2:	Human	 cases	of	West	Nile	 fever	 Europe	and	 the	Mediterranean	basin	 (transmission	 season	2016	 and	
previous	transmission	seasons).	Data	collected	from	ECDC	(http://ecdc.europa.eu/).	
In	 the	 summer	 of	 1999	 WNV	 crossed	 the	 Atlantic	 and	 reached	 the	 Western	 Hemisphere,	
causing	 an	 outbreak	 in	 New	 York	 City	 (USA)	 that	 was	 responsible	 for	 62	 human	 cases	 of	
encephalitis,	including	seven	deaths	(Anderson,	Andreadis	et	al.	1999;	Lanciotti,	Roehrig	et	al.	
1999),	 25	 equine	 cases	 with	 nine	 deaths,	 and	 an	 enormous	 mortality	 of	 birds	 (Lanciotti,	
Roehrig	et	al.	1999).	The	nucleotide	sequence	of	 the	 invading	strain	was	closely	 related	 to	a	
1998	 isolate	 from	 Israel	 that	have	caused	 illness	 in	geese	 (Lanciotti,	Roehrig	et	al.	1999)	and	
contained	a	mutation	in	the	helicase	gene	that	it	has	been	proposed	to	cause	high	viremia	and	
mortality	in	American	crows	(Brault,	Huang	et	al.	2007).	The	current	situation	in	the	USA	is	that	
a	 total	 of	 47	 states	 and	 the	District	 of	 Columbia	have	 reported	West	Nile	 virus	 infections	 in	
people,	birds,	or	mosquitoes	in	2016	(Figure	3).	Overall,	2.038	cases	of	West	Nile	virus	disease	
in	 people	 have	 been	 reported	 to	 CDC	 during	 2016.	Of	 these,	 1.114	 (56%)	were	 classified	 as	
neuroinvasive	 disease	 (such	 as	meningitis	 or	 encephalitis)	 and	 898	 (44%)	 were	 classified	 as	
non-neuroinvasive	disease	(https://www.cdc.gov/westnile/index.html).	Since	its	 instruction	in	
the	 USA,	 the	 virus	 rapidly	 spread	 to	 the	 neighbouring	 countries	 of	 Canada	 and	 Mexico.	
However,	few	human	cases	have	been	reported	there,	as	well	as	in	Central	and	South	America.	
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In	 brief,	 in	 80	 years	 since	 its	 first	 isolation,	 the	 virus	has	propagated	 to	 a	 vast	 region	of	 the	
globe	 and	 is	 now	 considered	 the	 most	 important	 causative	 agent	 of	 viral	 encephalitis	
worldwide.	
	
Figure	 3:	 Human	 cases	 of	West	 Nile	 fever	 in	 the	 United	 States	 of	 America	 (average	 annual	 incidence	 of	WNV	
neuroinvasive	disease	report	to	CDC	from	1999	to	2015.	Data	collected	from	CDC	(https://www.cdc.gov/)).	
	
1.2	Prevention	and	treatment	of	West	Nile	virus	infection	
Vaccines	 to	 protect	 humans	 against	 a	 number	 of	 flaviviruses	 such	 as	 tick-borne	 encephalitis	
virus,	JEV	or	YFV,	are	available	(Ulbert	and	Magnusson	2014;	Hajj	Hussein,	Chams	et	al.	2015).	
Within	 the	 JEV	 serocomplex,	 JEV	 is	 the	 only	 flavivirus	 targeted	 by	 commercially	 available	
vaccines	 for	 humans,	 and	 immunization	 is	 performed	 using	 attenuated,	 inactivated	 or	
recombinant	 chimeric	 viruses	 (Halstead	 and	 Thomas	 2010;	 Ishikawa,	 Yamanaka	 et	 al.	 2014).	
Since	 2001,	 several	 vaccines	 based	 on	 different	 approaches	 against	WNV	 have	 been	 tested	
(Ishikawa,	 Yamanaka	et	 al.	 2014;	Ulbert	 and	Magnusson	2014),	 being	 some	of	 them	already	
approved	for	equine	use.	 In	any	case,	and	although	there	 is	currently	no	 licensed	vaccine	for	
humans,	 several	 clinical	 trials	have	been	conducted	exhibiting	good	 immunogenic	properties	
  Introduction 
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(Ledgerwood,	Pierson	et	al.	2011;	Dayan,	Bevilacqua	et	al.	2012;	Durbin,	Wright	et	al.	2013).	
One	 of	 the	 major	 drawbacks	 for	 vaccines	 implementation	 is	 their	 cost	 effectiveness.	 An	
evaluation	 of	 it	 conducted	 in	 2006	 concluded	 that	 introduction	 of	 WNV	 vaccine	 into	 the	
routine	immunization	program	in	the	USA	would	not	be	worthy	because	of	the	relatively	low	
incidence	rates	(Zohrabian,	Hayes	et	al.	2006).	
Regarding	 antiviral	 compounds,	 nowadays	 not	 a	 single	 one	 is	 available,	which	 limits	 current	
treatments	against	WNV	to	only	 supportive	care	measures,	 such	as	 intravenous	antipyretics,	
fluids,	respiratory	support,	and	prevention	of	secondary	infections.	Despite	this	fact,	intensive	
research	during	past	decades	has	made	significant	progress	in	the	design	and	development	of	
several	 treatment	 methods	 for	 WNV	 infection.	 Current	 approaches	 and	 recent	 progress	
include	 therapeutic	 antibodies	 (Ben-Nathan,	 Lustig	 et	 al.	 2003;	 Engle	 and	 Diamond	 2003;	
Zhang,	Vogt	et	al.	2009;	Beigel,	Nordstrom	et	al.	2010)	and	antiviral	drugs	targeting	both	viral	
replication	 and	 the	 host	 cell	 metabolism	 (Botting	 and	 Kuhn	 2012;	 Lim	 and	 Shi	 2013;	
Baharuddin,	Hassan	et	al.	2014).		
In	 this	 line,	both	viral	 (structural	and	non-structural)	and	host	proteins	constitute	 targets	 for	
developing	antiviral	 therapeutics,	 as	 they	are	essential	 for	WNV	 infection	or	 replication.	 The	
search	 for	antiviral	compounds	against	WNV	 includes	not	only	new	drugs	discovery,	but	also	
the	 repurposing	of	 drugs	 approved	 for	other	purposes	by	 testing	 inhibitory	 compounds	 that	
act	 on	 related	 flaviviruses,	 such	 as	 DENV	 or	 hepatitis	 C	 virus	 (HCV),	 as	 well	 as	 drugs	 used	
against	non-related	illness.	
Regarding	 direct	 acting	 antivirals	 (DAAs)	 targeting	 viral	 replication,	 their	 viral	 target	 protein	
should	be	essential	for	the	viral	life	cycle	and	should	have	a	low	rate	of	‘allowed’	(non-lethal,	
but	 resistance-conferring)	 mutations.	 This	 second	 feature	 is	 especially	 important	 for	
flaviviruses	 because,	 as	 any	 other	 RNA	 viruses,	 their	 RNA	 polymerases	 do	 not	 have	 a	
proofreading	activity	(Boldescu,	Behnam	et	al.	2017).	Even	though	the	mutation	rate	of	these	
viruses	 leads	 to	 a	 relatively	 large	 proportion	 of	 non-functional	 progeny	 virions,	 it	 is	 an	
advantage	for	an	efficient	immune	evasion	and	the	development	of	drug	resistances.	The	most	
promising	viral	targets	are	the	NS3	protease	and	the	NS5	polymerase,	and,	to	a	lesser	degree,	
the	E	glycoprotein,	 the	capsid	protein,	NS4B,	NS3	helicase	and	NS5	methyltransferase.	Other	
targets,	such	as	NS5	guanylyltransferase	and	the	NS3–NS5	interaction,	currently	seem	to	have	
limited	potential	(Boldescu,	Behnam	et	al.	2017).	It	does	exist	a	wide	panel	of	options	for	DAAs	
development	 that	 are	 being	 evaluated,	 ranging	 from	 small	molecules	 (natural	 and	 synthetic	
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compounds),	 antiviral	 peptides,	 and	 siRNAs	 to	 RNA-dependent	 RNA	 polymerase	 Inhibitors,	
among	others	(Botting	and	Kuhn	2012;	Lim	and	Shi	2013;	Baharuddin,	Hassan	et	al.	2014).		
Another	 antiviral	 approaches	 include	 targeting	 host	 cell	metabolism	 and	 physiology	 and	 the	
modulation	of	the	host	immune	system	by	using	antiviral	cytokines	or	cell	enzymes	inhibitors	
as	 potential	 therapeutics	 against	 WNV	 (Martin-Acebes,	 Merino-Ramos	 et	 al.	 2014;	 Merino-
Ramos,	Vazquez-Calvo	et	al.	2015). These	approaches	have	some	advantages	over	DAAs:	their	
effect	 is	 less	 prone	 to	 the	development	of	 resistance	by	mutations	 in	 the	 viral	 genome	 that	
frequently	 appear	 in	 RNA	 viruses,	 and	 they	 could	 confer	 broad-spectrum	 antiviral	 activity	
because	certain	host	factors	are	usurped	by	a	large	number	of	different	viruses.	Nevertheless,	
broad-spectrum	activity	must	be	carefully	confirmed	on	a	case-by-case	basis	for	each	antiviral	
agent	 to	 avoid	 activation	 of	 other	 viral	 co-infections	 and,	 if	 possible,	 to	 cover	 co-circulating	
flaviviruses.	
Considering	the	worldwide	distribution	of	WNV	and	the	evidence	of	its	potential	to	change	in	
pathogenicity	and	transmissibility,	and	being	aware	that	prevention	from	insect	bites	remains	
the	 major	 defense	 against	 it,	 there	 is	 an	 urgent	 need	 to	 develop	 safe	 and	 effective	 novel	
vaccines	and	antiviral	drugs	against	WNV	 infection.	Therefore,	a	better	understanding	of	 the	
flavivirus	 life	cycle	and	 its	pathogenesis	 is	essential	 to	develop	effective	strategies	to	combat	
these	pathogens.	
1.3	Molecular	classification	
First	 classifications	 of	WNV	 were	 based	 on	 cross-neutralization	 reactions	 and	 revealed	 that	
WNV	 belongs	 to	 the	 Japanese	 encephalitis	 serocomplex.	 Recent	 advances	 on	 its	 molecular	
phylogeny	 disclosed	 the	 existence	 of	 up	 to	 five	 distinct	 genetic	 lineages	 of	WNV	 (Figure	 4),	
being	 lineage	1	 and	2	 the	most	 clinically	 relevant.	 Lineage	1	 is	widely	distributed	and	highly	
neurovirulent	 and	 is	 subdivided	 into	 three	 clades.	 Clade	 1a	 includes	 African,	 European	 and	
American	isolates	(including	NY99	isolate	used	during	this	doctoral	thesis),	clade	1b	groups	the	
Kunjin	virus	(KUNV)	that	is	restricted	to	Australia,	and	clade	1c	is	found	in	Central	Asia	through	
the	 central	 highlands	 of	 India	 (Lanciotti,	 Ebel	 et	 al.	 2002).	 	 Until	 recently,	 lineage	 2	 strains	
seemed	 to	be	confined	enzootic	 in	Africa	and	Madagascar	and	 to	be	 less	neurovirulent	 than	
those	included	in	lineage	1.	However,	lineage	2	strains	were	the	cause	of	recent	outbreaks	in	
Europe	in	2004	(Hungary)	and	2008	(Austria)	and,	for	the	first	time,	caused	a	major	epidemic	in	
2010	 in	 Greece	 (Bakonyi,	 Ivanics	 et	 al.	 2006;	 Chaskopoulou,	 Dovas	 et	 al.	 2013).	 Since	 then,	
outbreaks	involving	WNV	lineage	2	have	been	reported	in	several	European	countries	including	
Italy,	Serbia	(including	Serbia	Novi	Sad/12	isolate	used	along	this	doctoral	thesis),	and	again	in	
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Greece	(Petric,	Hrnjakovic	Cvjetkovic	et	al.	2012;	Chaskopoulou,	L'Ambert	et	al.	2016).	Some	of	
these	viral	strains	have	appeared	to	become	progressively	more	virulent	for	birds	and	humans	
(Malkinson,	 Banet	 et	 al.	 2002).	 On	 the	 other	 hand,	 lineages	 3	 and	 4	 strains	 have	 been	
described	 from	 single	 isolates	 from	 Central	 Europe,	 but	 their	 taxonomic	 status	 and	medical	
importance	are	unclear,	whereas	lineage	5	appears	to	be	confined	to	India	(Kramer,	Styer	et	al.	
2008).		
	
Figure	 4:	 Representative	 phylogram	 showing	 the	 relationships	 between	 strains	 of	 the	 genus	 Flavivirus.	 Major	
WNV	 lineages	are	 represented.	Accession	numbers	are	displayed	 in	 the	 tree	as	well	 as	 the	year	of	 isolation.	The	
scale	 indicates	 0.4	 nt	 substitutions/site.	 The	 tree	was	 based	on	 complete	NS5	nucleotide	 sequence,	 built	 from	a	
multiple	alignment	using	Clustal	omega	and	Phylogeny.fr	(Dereeper,	Guignon	et	al.	2008).	
	
1.4	Viral	genome,	structure,	and	physical	properties	of	the	virion	
The	WNV	 genome	 is	 constituted	 by	 a	 single	 stranded	 RNA	molecule	 of	 positive	 polarity	 of	
about	11.000	nt	in	length	(Lanciotti,	Roehrig	et	al.	1999)	that	encodes	a	polyprotein	in	a	single	
open	 reading	 frame	 flanked	by	 two	untranslated	 regions,	UTR	 (Figure	 5).	 This	 polyprotein	 is	
proteolitically	 processed	by	 viral	 and	 cellular	 proteases,	 rendering	 10	major	 viral	 proteins:	 3	
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structural	 and	 7	 non-structural	 (Murray,	 Jones	 et	 al.	 2008).	 This	 viral	 polyprotein	 contains	
multiple	transmembrane	domains	that	determine	whether	individual	mature	viral	proteins	are	
located	on	the	cytoplasmic	or	luminal	side	of	the	endoplasmic	reticulum	(ER)	membrane	after	
cleavage	from	the	polyprotein	(Figure	5).		
	
Figure	5:	Genomic	organization	in	WNV,	polyprotein	processing	and	virion	structure.	Schematic	representation	of	
WNV	genome	and	particle.	A)	The	viral	genome	is	represented	with	its	single	ORF	that	encodes	3	structural	(C,	prM	
and	 E)	 and	 7	 nonstructural	 proteins	 (NS1,	 NS2A,	 NS2B,	 NS3,	 NS4A,	 NS4B	 and	NS5)	 flanked	 by	 two	 untranslated	
regions	at	the	5’	and	3’	end	of	the	molecule.	It	also	has	a	cap	at	5’	end.	B)	Translation	of	the	viral	genome	results	in	
a	 polyprotein	 that	 is	 cleaved	 by	 cellular	 and	 viral	 proteases.	 The	 proposed	 topologies	 of	 the	 viral	 proteins	 with	
respect	 to	 the	 ER	 lumen	 and	 cytoplasm	 and	 the	 proteases	 responsible	 for	 their	 cleavages	 are	 indicated.	 Figure	
adapted	 from	 (Apte-Sengupta,	 Sirohi	 et	 al.	 2014)	 C)	 WNV	 mature	 particle	 display	 a	 herringbone	 pattern	 of	 E	
glycoprotein	 dimers.	 The	 E	 glycoprotein	 monomers	 are	 colored	 in	 magenta,	 green,	 and	 orange	 to	 facilitate	 the	
interpretation	of	their	distribution.	Figure	modified	from	(Martin-Acebes,	Vazquez-Calvo	et	al.	2016).		
	
Cryoelectron	microscopy	has	unveiled	that	WNV	particles	are	smooth	and	spherical	(Figure	5),	
of	 about	 50	 nm	 in	 diameter,	 and	 contain	 an	 electron	 dense	 core,	 of	 about	 30	 nm	diameter	
(Mukhopadhyay,	 Kim	 et	 al.	 2003),	 composed	 by	 the	 viral	 genomic	 RNA	 coupled	 with	 the	 C	
(capsid)	 structural	 	protein	and	surrounded	by	a	 lipid	bilayer	derived	 from	the	host	cell.	This	
lipid	bilayer	is	flecked	with	the	other	two	structural	viral	proteins,	the	E	(envelope)	and	the	M	
(membrane)	proteins	that	form	an	outer	shell	of	 icosahedral	symmetry	(Mukhopadhyay,	Kim	
et	al.	2003).	The	E	protein	is	the	major	surface	protein	of	the	viral	particle	(Figure	5),	interacts	
with	 viral	 receptors,	 and	 mediates	 virus-cell	 membrane	 fusion.	 The	 M	 protein	 is	 a	 small	
proteolytic	 fragment	of	prM	protein	after	being	cleaved	by	a	furin-like	protease	 in	the	trans-
Golgi	 network	 (Murray,	 Jones	 et	 al.	 2008).	 The	 prM	 functions	 to	 protect	 the	 fusogenic	 E	
protein	 during	 transit	 through	 the	 acidic	 compartments	 of	 the	 secretory	 pathway,	 and	 its	
cleavage	is	an	essential	step	for	maturation	of	the	virus	into	the	infectious	form	(Brinton	2002).		
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The	 7	 non-structural	 proteins	 (NS1,	 NS2A,	 NS2B,	 NS3,	 NS4A,	 NS4B,	 and	 NS5)	 function	 as	
coordinators	of	the	intracellular	aspects	of	virus	replication,	assembly,	and	modulation	of	the	
host	defense	mechanisms.	NS1	 is	 an	essential	 cofactor	 for	 virus	 replication	and	 inhibition	of	
complement-mediated	 immune	 response	 (Avirutnan,	 Fuchs	et	 al.	 2010).	NS3	 contains	 serine	
protease,	 nucleoside	 5’	 triphosphatase	 (NTPase),	 RNA	 helicase,	 and	 5’	 RNA	 triphosphatase	
(RTPase)	 activities	 (Gorbalenya,	 Donchenko	 et	 al.	 1989;	 Wengler	 1991;	 Wengler	 1993;	
Chappell,	 Stoermer	et	 al.	 2008),	while	NS2B	 serves	 as	 a	 cofactor	 for	 the	protease	activity	of	
NS3	 (Gayen,	 Chen	 et	 al.	 2012).	 NS5	 is	 necessary	 for	 genome	 replication	 and	 capping	 of	
emerging	RNA,	as	 it	contains	methyltransferase	and	RNA-dependent	RNA	polymerase	(RdRp)	
domains	(Brinton	2013;	Lindenbach	2013).	NS2A,	NS2B,	NS4A	and	NS4B	are	small,	hydrophobic	
proteins,	which	structures	and	functions	have	not	been	yet	fully	characterized.	Each	of	these	
proteins	has	several	transmembrane	domains	and	facilitates	the	assembly	and/or	anchoring	of	
viral	 replication	 complexes	 on	 the	 ER	 membrane	 (Mackenzie,	 Khromykh	 et	 al.	 1998;	
Westaway,	Mackenzie	 et	 al.	 2002).	NS2A	 is	 involved	 in	 the	 production	 of	 intracellular	 virus-
induced	 membranous	 structures,	 and	 in	 virion	 assembly	 (Kummerer	 and	 Rice	 2002;	 Leung,	
Pijlman	et	al.	2008;	Xie,	Gayen	et	al.	2013).	NS4A	 induces	membrane	rearrangement	 (Miller,	
Kastner	et	al.	2007;	Carpp,	Galler	et	al.	2011),	whereas	NS4B	plays	a	major	role	on	modulating	
the	 host	 immune	 response	 by	 suppressing	 the	 α/β	 interferon	 signaling	 (Munoz-Jordan,	
Laurent-Rolle	et	al.	2005).	
The	C,	NS3,	and	NS5	proteins	are	located	on	the	cytoplasmic	side,	while	the	prM,	E,	and	NS1	
proteins	 are	 in	 the	 lumen	 of	 the	 ER	 and,	 with	 the	 exception	 of	 short	 regions	 between	
transmembrane	domains,	the	NS2A,	NS2B,	NS4A	and	NS4B	proteins	are	located	within	the	ER	
membrane	bilayer	(Figure	5)	(Lindenbach	2013).	
1.5	Replication	cycle	and	virus	cell	host	interactions	
Viral	 penetration	 into	 the	 host	 cell	 is	 followed	 by	 genome	 uncoating,	 expression	 and	
replication,	 assembly	 of	 new	 virions	 and	 their	 egress	 (Figure	 6).	 These	 steps	 occur	 in	 close	
association	with	 cellular	 structures	 and	membranes.	 In	 this	 line,	 several	 host	 lipid	metabolic	
pathways	 have	 recently	 been	 identified	 and	 characterized	 as	 essential	 for	 viral	 replication.	
Figure	6	details	the	lipids	involved	at	each	step	of	the	viral	cycle	(blue	boxes).	
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Figure	6:	Flavivirus	life	cycle	from	the	entry	of	the	viral	particle,	through	its	genome	replication	and	viral	particle	
maturation,	 until	 their	 release.	 Note	 that	 the	 genome	 replication	 occurs	 on	membranous	 structures	 formed	 by	
virus-induced	 perturbations	 of	 the	 ER	 membrane.	 Blue	 boxes	 highlight	 the	 lipids	 involved	 at	 each	 step.	 Image	
collected	from	(Martin-Acebes,	Vazquez-Calvo	et	al.	2016).	
	
The	 WNV	 infectious	 cycle	 starts	 when	 the	 envelope	 protein	 (E)	 engages	 unknown	 surface	
cellular	 receptors.	 Among	 the	 proposed	 receptors	 are	 glycosaminoglycans	 (GAGs),	 c-type	
lectins,	and	integrins	(Chu	and	Ng	2004;	Chu	and	Ng	2004).	Then,	the	virus	penetrates	into	the	
host	cells	by	receptor	mediated	endocytosis.	The	 low	pH	environment	within	 the	endosomal	
vesicles	 triggers	 viral	 fusion	with	 the	 endosomal	membrane	 leading	 to	 virion	 uncoating	 and	
release	of	the	genomic	RNA	into	the	cytoplasm	(Chu	and	Ng	2004;	Pierson	and	Kielian	2013).	
The	efficiency	of	the	fusion	process	is	 likely	affected	by	the	specific	 lipid	composition	of	both	
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the	viral	envelope	and	the	target	cellular	membrane	(Gollins	and	Porterfield	1986).	Flavivirus	
replication	begins	when	the	viral	(+)	RNA	genome	is	recognized	as	messenger	RNA.	Therefore,	
the	 genome	 can	 be	 translated	 by	 the	 host	 cell	 translation	 machinery	 to	 yield	 a	 single	
polyprotein.			
The	 translation	 of	 this	 viral	 polyprotein	 occurs	 on	 the	 ER	 membranes,	 or	 on	 membranes	
derived	 from	 the	ER	 (Figure	6),	which	 is	 the	 site	of	 glycerophospholipids,	 sterols,	 ceramides,	
and	glycosphingolipids	biosynthesis	 (Villareal,	Rodgers	et	al.	2015).	 Flaviviruses,	as	any	other	
plus-stranded	 RNA	 virus,	 remodel	 intracellular	 membranes	 developing	 organelle-like	
structures	 to	 create	 adequate	platforms	 for	 viral	 replication	 (Miller	 and	Krijnse-Locker	2008;	
Paul	and	Bartenschlager	2013).	 It	 is	 known	 that	 flavivirus	 replication	and	viral	RNA	synthesis	
occurs	 in	 close	 association	with	 these	 virus-induced	 intracellular	membranes	 structures	 that	
cover	the	genome	amplification	machinery,	the	so-called	replication	complex	(RC),	containing	
viral	 proteins,	 viral	 RNA,	 and	 probably	 host	 cell	 factors.	 RCs	 may	 promote	 efficient	 viral	
replication	 by	 anchoring	 the	 replication	 machinery	 in	 membrane	 compartments	 or	 by	
protecting	 it	 from	 host	 defense	 mechanisms	 (Mackenzie,	 Khromykh	 et	 al.	 2007;	 Gillespie,	
Hoenen	 et	 al.	 2010).	 Electron	 microscopy	 (EM)	 showed	 that	 flaviviral	 infection	 induces	 an	
extended	 network	 of	modified	 ER	membranes	 of	 various	morphologies	 (Figure	 6),	 including	
convoluted	membranes,	or	vesicle	packets	(VP),	that	are	invaginations	of	vesicle-like	structures	
into	 the	 lumen	 of	 the	 ER	 (Welsch,	 Miller	 et	 al.	 2009;	 Gillespie,	 Hoenen	 et	 al.	 2010;	 Apte-
Sengupta,	 Sirohi	 et	 al.	 2014).	 In	 addition,	 these	 membranes	 increase	 the	 efficiency	 of	 viral	
processes	by	concentrating	reactants	and	catalysts,	and	by	scaffolding	molecular	interactions.	
The	 functions	 of	 these	 membranes	 in	 the	 biological	 processes	 are	 dictated	 by	 the	
physicochemical	properties	of	their	lipids	component,	including,	but	not	limited	to,	membrane	
curvature	and	 fluidity	 (Villareal,	Rodgers	et	al.	2015).	The	 localization	of	doubled-strand	RNA	
intermediates	(dsRNA),	which	are	produced	during	replication	of	the	viral	RNA,	as	well	as	NS	
proteins,	 in	 these	 invaginations	 is	 consistent	with	 the	 replication	of	 the	 flavivirus	 genome	 in	
these	structures	(Westaway,	Khromykh	et	al.	1999).	
Once	 the	 genomic	 RNA	 has	 been	 replicated,	 it	 interacts	 with	 C	 proteins,	 and	 buds	 into	 the	
lumen	as	immature	virus	particles	through	the	ER-derived	membranes	studded	with	prM	and	E	
proteins.	 During	 egress	 from	 infected	 cells,	 flaviviruses	 undergo	 dramatic	 structural	 changes	
through	maturation	steps	in	the	Golgi	complex,	which	are	characterized	by	the	formation	of	a	
herringbone	 arrangement	 of	 E	 proteins	 that	 lay	 flat	 against	 the	 surface	 of	 the	 virion,	 and	
cleavage	of	 the	prM	protein	by	 the	 cellular	protease	 furin.	 The	 result	 is	 a	 relatively	 smooth,	
infectious	mature	virion	(Mukhopadhyay,	Kim	et	al.	2003).		
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Figure	7:	Intracellular	membrane	rearrangements	in	WNV	infected	cells	compared	to	uninfected	cells.	Scale	bars:	
200	 nm.	 Electron	micrograph	 showing	 uninfected	 cells	 (A)	 and	membrane	 alteration	 on	WNV	 infected	 cells	 (B):	
vesicle	packets	(VP),	and	virions	(Vi).	Image	modified	from	(Martin-Acebes,	Merino-Ramos	et	al.	2014).	
	
2.	Lipids	and	flaviviruses	
As	commented	above,	host	cell	 factors,	noticeably	 lipids,	play	pivotal	roles	 in	viral	 infections.	
Although	many	 host	 lipid	metabolic	 pathways	 were	 characterized	 decades	 ago,	 it	 has	 been	
recently	when	they	have	been	associated	with	viral	infections.	
Lipids	display	remarkable	structural	diversity,	driven	by	factors	such	as	variable	chain	length,	a	
multitude	of	oxidative,	reductive,	substitutional	and	ring-forming	biochemical	transformations,	
as	 well	 as	 modifications	 with	 sugar	 residues	 and	 other	 functional	 groups	 of	 different	
biosynthetic	origin.	Within	the	cell,	 thousands	of	molecular	 lipid	species	exist	that	have	been	
classified	by	the	International	Lipid	Classification	and	Nomenclature	Committee	(ILCNC)	into	8	
categories:	 fatty	 acyls,	 glycerolipids,	 glycerophospholipids,	 sphingolipids,	 sterol	 lipids,	 prenol	
lipids,	saccharolipids,	and	polyketides	(Table)	(Fahy,	Cotter	et	al.	2011).		
Lipids	are	the	main	components	of	cellular	membranes	where,	as	commented	above,	they	play	
many	roles	due	to	their	physicochemical	properties	(differences	in	the	length	of	hydrocarbon	
chains,	the	degrees	and	locations	of	unsaturation,	the	sign,	magnitude,	location,	and	density	of	
charges,	the	polarity,	hydrogen-bonding	capability,	and	size	of	the	head-group)	(Jarsch,	Daste	
et	al.	2016).		
A B 
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Table	1:	 Lipid	 categories	 and	 characteristics.	The	 International	 Lipid	Classification	 and	Nomenclature	Committee	
(ILCNC)	 divided	 lipids	 into	 8	 primary	 categories.	 Data	 collected	 from	 (Fahy,	 Subramaniam	 et	 al.	 2005;	 Villareal,	
Rodgers	et	al.	2015).	
Category	 Basic	Features	
Fatty	acyls	(FA)		 Synthesized	 by	 chain	 elongation	 of	 an	 acetyl-CoA	 primer	 with	 malonyl-CoA	 (or	
methylmalonyl-CoA)	 groups	 that	 may	 contain	 a	 cyclic	 functionality	 and/or	 are	
substituted	 with	 heteroatoms.	 The	 FA	 structure	 represents	 the	 major	 lipid	 building	
block	 of	 complex	 lipids	 and	 therefore	 is	 one	 of	 the	 most	 fundamental	 categories	 of	
biological	lipids.	It	is	an	energy	source	for	the	cell,	important	for	signaling	prostaglandin	
formation	and	membrane	fluidity.	
Glycerolipids	(GLs)		 Enclose	all	glycerol-containing	lipids.	This	category	is	dominated	by	the	mono-,	di-	and	
tri-substituted	 glycerols,	 the	 most	 well-known	 being	 the	 fatty	 acid	 esters	 of	 glycerol	
(acylglycerols).	 Hydrolysis	 of	 these	 ester	 bonds,	 yields	 free	 FA	 that	 can	 undergo	 β-
oxidation	and	produce	ATP	in	the	mitochondria.	They	are	very	abundant	and	important	
as	membrane	constituents,	metabolic	fuels,	and	signaling	molecules.	
Glycerophospholipids	
(GPLs)		
Shares	 with	 the	 GLs	 a	 common	 glycerol	 backbone.	 One	 alcohol	 of	 the	 core	 glycerol	
molecule	 forms	 a	 phosphate	 ester	 linkage.	 Phospholipids	 may	 be	 subdivided	 into	
distinct	 classes	 based	 on	 the	 nature	 of	 the	 polar	 “head	 group”.	 The	 simplest	 GPL	 is	
phosphatidic	 acid.	 Additional	 substituents	 on	 the	 phosphate	 yield,	 respectively,	
phosphatidylcholine	(PC),	phosphatidylethanolamine	(PE),	phosphatidylserine	(PS),	and,	
phosphatidylinositol	(PI).	They	are	ubiquitous	in	nature	and	are	key	components	of	the	
lipid	bilayer	of	cells.		
Sphingolipids	(SLs)		 Complex	 family	 of	 compounds	 that	 share	 a	 common	 structural	 feature,	 a	 sphingoid	
base	backbone	that	is	synthesized	de	novo	from	serine	and	a	long-chain	fatty	acyl-CoA,	
and	 then	 converted	 into	 ceramides	 (CER),	 phosphosphingolipids,	 glycosphingolipids,	
and	 other	 species,	 including	 protein	 adducts.	 CER	 are	 a	 major	 subclass	 of	 sphingoid	
base	derivatives	with	an	amide-linked	 fatty	acid	and	are	generally	precursors	of	more	
complex	SPs,	such	as	sphingosines	and	sphingomyelin.	Sphingosines	are	 important	 for	
cell	to	cell	signaling	and	cellular	adherence	to	matrices,	and	are	critical	for	protection	of	
nerve	 cells	 via	 formation	 of	 the	 axon	 insulator.	 They	 interact	 with	 cholesterol	 to	
modulate	lipid	bilayer	fluidity,	especially	at	the	plasma	membrane.	
Sterol	lipids	(STs)		 They	 have	 a	 fused	 four	 rings	 core	 structure	 and	 are	 subdivided	 on	 the	 basis	 of	 the	
number	 of	 carbons	 in	 the	 core	 skeleton.	 They	 are	 critical	 for	membrane	 architecture	
and	formation	of	lipid-ordered-domains	(“lipid	rafts”),	which	are	important	for	signaling	
and	 dynamic	 movement	 of	 the	 cell.	 	Additionally,	 the	 sterol	 lipid	 backbone	 is	 the	
precursor	 to	 steroid	 hormones	 and	 vitamin	 D.	 The	 archetype	 sterol	 found	 in	 most	
cellular	membranes	is	cholesterol,	which	is	critical	for	the	entry	and	replication	of	many	
viruses.	
Prenol	lipids	(PRs)		 Derived	from	condensation	of	 isoprene	subunits.	Notably,	prenol	 lipids	are	precursors	
to	vitamins	A,	E,	and	K,	and	also	function	as	antioxidants.	Polyprenols	are	important	for	
shuttling	oligosaccharides	across	cell	membranes.		
Saccharolipids	(SCLs)		 Similar	to	glycerolipids,	but	with	a	sugar	backbone	replacing	the	glycerol	backbone.		
	
	
	
Polyketides	(PK)		 Derived	from	condensation	of	ketoacyl	units,	they	are	commonly	found	in	bacteria	and	
fungi.	They	are	synthesized	by	multi-domain	protein	complexes	composed	of	polyketide	
synthases,	which	bear	similarities	to	fatty	acid	synthases	(FASN).	Many	polyketides	have	
anti-bacterial	or	anti-fungal	properties,	and	some	of	them	inhibit	influenza	virus.	
	
	
	
The	number	of	molecular	species	of	lipids	present	in	any	cell	membrane	is	much	greater	than	
would	 be	 required	 just	 to	 maintain	 a	 physical	 bilayer	 structure.	 This	 is	 because	 lipids,	 in	
addition	to	being	a	barrier	to	make	compartments,	perform	a	wide	variety	of	other	functions	
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including	 lipid	 dynamics,	 hydrophobic	 thickness,	 intrinsic	 bending	 tendency,	 surface	
electrostatics,	phase	behavior,	and	others	(Epand	2007;	Jarsch,	Daste	et	al.	2016).	Membranes	
are	 involved	 in	 fusion	 and	 fission,	 as	 well	 as	 protrusion	 and	 invagination,	 exocytosis	 and	
endocytosis,	 and	 cell	 division,	 in	 which	 the	 planar	 bilayer	 membrane	 transforms	 into	 other	
shapes,	at	least	transiently	and	locally	(Kimura,	Jennings	et	al.	2016).	
Formation	of	 these	curved	membrane	structures	can	be	 facilitated	by	certain	 lipid	molecular	
species	as	well	as	by	proteins	 (Epand	2007);	 (Villareal,	Rodgers	et	al.	2015).	Head-group	size	
and	tail	saturation	influence	the	surface	area	that	a	lipid	occupies	in	a	membrane.	A	lipid	with	
a	small	head-group	(PE)	and	unsaturated	tails	forms	a	conical	shape,	whilst	large	head-groups	
(PI)	with	saturated	tails	form	an	inverted	cone,	and	large	head-groups	with	saturated	or	singly	
unsaturated	side	chains	have	a	cylindrical	shape	(PC).	Lipids	with	small	head-groups	will	tend	
to	localize	in	regions	of	negative	curvature,	whereas	species	with	large	head-groups	localize	in	
regions	of	positive	curvature	(Figure	8).	
	
	
Figure	8:	Formation	of	curve	membranes.	The	accumulation	of	certain	lipids	can	induce	membrane	bilayer	bending.	
Figure	from	(Villareal,	Rodgers	et	al.	2015).	
	
What	 is	more,	 lipids	play	physical,	 chemical,	and	biological	 regulatory	 roles	 in	 living	systems.	
Studies	of	signaling	lipids	are	revealing	that	many	biological	processes	are	dependent	rather	on	
specific	lipid	species	than	on	the	entire	group	of	lipids	of	a	particular	class	(Kimura,	Jennings	et	
al.	2016).	Even	so,	most	of	the	studies	made	on	this	subject	are	still	crude	(Lee,	Lin	et	al.	2008;	
Munger,	Bennett	et	al.	2008).	In	fact,	even	small	changes	in	the	structure	of	the	molecules	can	
result	 in	 significant	 changes	 in	 biological	 function.	 The	 influence	 of	 the	 alteration	 of	 the	
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content	 of	 a	 broad	 range	 of	 lipid	metabolites	 in	 cells	 infected	with	 a	 variety	 of	 human	 viral	
pathogens	 has	 been	 proved	 (Mackenzie,	 Khromykh	 et	 al.	 2007;	 Soto-Acosta,	 Mosso	 et	 al.	
2013).	Besides,	 it	 is	known	that	 lipid	membranes	are	structural	components	of	all	enveloped	
virions	 and	 that	 they	 serve	 as	 replication	 platforms	 (Heaton	 and	 Randall	 2011).	 Thus,	 since	
viruses	lack	the	appropriate	machinery	to	perform	their	own	lipid	synthesis,	they	are	forced	to	
co-opt	for	enzymes	involved	in	this	process	to	complete	their	replication	cycles.	Among	these	
enzymes,	the	most	relevant	are	those	related	to	FA,	such	as	acetyl-CoA	carboxylase	(ACC)	and	
fatty	acid	synthase	(FASN)	(Martin-Acebes,	Blazquez	et	al.	2011);	those	related	to	SL,	such	as	
serine	 palmitoyltransferase	 (SPTLC),	 ceramide	 synthase	 (CERS)	 (Aktepe,	 Pham	 et	 al.	 2015),	
sphingomyelin	 synthase	 (SMS)	 (Martin-Acebes,	 Gabande-Rodriguez	 et	 al.	 2016)	 and	
sphingomyelinase	(SMase);	and	those	to	ST,	such	as	7-dehydrocholesterol	reductase	(DHCR7),	
hydroxyl	methyl	glutaryl-CoA	reductase	(HMG-CoA	reductase)	and	geranylgeranyl	transferase	
type	I	(GGTase1)	(Mackenzie,	Khromykh	et	al.	2007)	(Figure	9).		
	
Figure	9:	Flavivirus	interaction	with	cell	lipid	metabolism.	Flaviviruses	exert	an	influence	on	fatty	acids,	cholesterol,	
sphingolipids,	glycerophospholipids	and	lipid	droplets	(Martin-Acebes,	Vazquez-Calvo	et	al.	2016).	
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It	 has	 been	 proposed	 that	 the	 lipid	 rearrangements	 that	 viruses	 exert	 over	 cell	 lipid	
metabolism	 are	 aimed	 to	 create	 an	 adequate	 environment	 for	 proper	 viral	 replication	 and	
particle	biogenesis.	In	addition,	viruses	can	dramatically	orchestrate	a	profound	reorganization	
of	 the	 host	 cell	 lipid	 metabolism	 to	 adequate	 cellular	 function	 to	 their	 own	 requirements	
(Figure	 9).	 Furthermore,	 the	 localization	 of	 viral	 gene	 expression,	 replication	 of	 the	 viral	
genome,	 and	 viral	 assembly	 to	 membranes	 compartmentalizes	 them,	 thus	 protecting	 them	
from	 host	 defense	 systems	 and	 gaining	 competence	 of	 viral	 processes	 by	 concentrating	
reactants.	In	any	case,	plenty	of	questions	are	still	unanswered	to	unveil	the	tight	relationship	
between	lipids	and	viral	infections	and,	because	of	that,	this	was	the	focus	of	our	research	on	
this	topic.	
3.	Usutu	Virus	(USUV)	
As	shown	in	Figure	4,	Usutu	virus	(USUV)	is	also	a	Flavivirus	closely	related	to	WNV	(Bakonyi,	
Gould	et	al.	2004).	Both	viruses	share	common	genetics	and	antigenic	features,	both	have	an	
African	origin,	and	both	have	lately	emerged	in	Europe	(Ashraf,	Ye	et	al.	2015).	
	
Figure	 10:	 Map	 showing	 the	 geographic	 locations	 of	 USUV-related	 epidemiological	 studies	 on	 birds	 and	
mosquitoes	 in	 Europe.	Data	 from	 (Ashraf,	 Ye	 et	 al.	 2015;	 Santini,	 Vilibic-Cavlek	 et	 al.	 2015;	 Cadar,	 Luhken	 et	 al.	
2017).	
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USUV	was	first	described	in	1959	as	a	part	of	a	study	of	viral	prevalence	in	arthropods	in	South	
Africa,	 near	 the	 Usutu	 river,	 from	 where	 it	 took	 its	 name	 (Woodall	 1964).	 Since	 then,	 it	
presence	 has	 been	 described	 in	 several	 African	 countries,	 including	 Senegal,	 Central	 African	
Republic,	 Nigeria,	 Uganda,	 Burkina	 Faso,	 Cote	 d'	 Ivore,	 and	 Morocco	 (Nikolay,	 Diallo	 et	 al.	
2011).	 USUV	 was	 reported	 to	 be	 circulating	 only	 in	 Africa	 until	 2001,	 when	 it	 emerged	 in	
Central	 Europe	 (Weissenbock,	 Kolodziejek	 et	 al.	 2002).	 Although	 retrospective	 studies	 have	
demonstrated	that	USUV	was	circulating	in	Italy,	at	least,	since	1996	(Weissenbock,	Bakonyi	et	
al.	 2013).	 From	 that	 moment	 on,	 USUV	 has	 been	 detected	 in	 several	 European	 countries	
(Figure	 10)	 generally	 associated	 with	 episodes	 of	 avian	 mortality	 (Ashraf,	 Ye	 et	 al.	 2015;	
Santini,	Vilibic-Cavlek	et	al.	2015;	Cadar,	Luhken	et	al.	2017;	Cadar,	Maier	et	al.	2017).		
USUV	vectors	are	ornithophilic	mosquitoes,	mainly	of	 the	Culex	 species,	and	 its	natural	hosts	
are	 birds,	mostly	 blackbirds	 (Turdas	merula).	 Nevertheless,	 from	 time	 to	 time,	 it	 can	 infects	
other	 vertebrates	 as	 humans,	 where	 infections	 are	mainly	 asymptomatic,	 although	 patients	
may	 sporadically	 present	 symptoms	 ranging	 from	 fever,	 rash,	 or	 jaundice	 to	
meningoencephalitis	(Pecorari,	Longo	et	al.	2009;	Santini,	Vilibic-Cavlek	et	al.	2015).	Currently	
no	vaccine	or	therapy	exists	against	this	pathogen.		
	
4.	Zika	virus	(ZIKV)	
Another	medically	 relevant	Flavivirus	 (Figure	4)	 that	 recently	has	been	a	worldwide	headline	
new	is	the	Zika	virus	(ZIKV).	As	the	above	described	WNV	and	USUV,	ZIKV	is	a	small	enveloped	
single	stranded	positive	RNA	virus	(Wang,	Thurmond	et	al.	2017).	The	virus	was	isolated	for	the	
first	time	in	April	1947	from	the	serum	of	a	febrile	sentinel	rhesus	monkey	that	was	caged	in	
the	canopy	of	the	Zika	forest,	near	Lake	Victoria	(Dick,	Kitchen	et	al.	1952),	hence	its	name.		
Mosquitoes,	 mainly	 of	 the	 Aedes	 species,	 are	 the	 arthropod	 vectors	 of	 the	 ZIKV	 natural	
transmission	 cycle	 (Saiz,	 Vazquez-Calvo	 et	 al.	 2016).	 Early	 studies	 indicated	 that	 non-human	
primates	were	 the	 primary	 vertebrate	 hosts,	with	 occasional	 participation	 of	 humans	 in	 the	
transmission	cycle,	even	in	highly	enzootic	areas	(Haddow	and	Dick	1948;	Haddow,	Williams	et	
al.	 1964);	 however,	 nowadays	 humans	 are	 their	 main	 hosts.	 ZIKV	 can	 also	 infect	 other	
vertebrates	 like	 rodents,	birds,	 reptiles,	 goats,	 sheep,	 and	 cattle,	 although	 their	 role	on	viral	
spread	seems	to	be	negligible	(Saiz,	Vazquez-Calvo	et	al.	2016).	
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Figure	11:	Map	showing	worldwide	autochthonous	and	imported	ZIKV	human	cases	during	the	2015-2016	global	
outbreak	(Saiz,	Vazquez-Calvo	et	al.	2016).	
	
The	virus	was	mainly	confined	to	the	African	continent	until	it	was	detected	in	south-east	Asia	
the	1980’s,	then	in	the	Micronesia	in	2007	and,	more	recently	in	the	Americas	in	2015	(Figure	
11)	where	it	has	caused	a	global	outbreak	infecting	millions	of	people	(Saiz,	Vazquez-Calvo	et	
al.	 2016).	 ZIKV	 infection	 was	 characterized	 by	 causing	 a	 mild	 disease	 presented	 with	 fever,	
headache,	rash,	arthralgia,	and	conjunctivitis,	with	exceptional	reports	of	an	association	with	
Guillain-Barré	 syndrome,	 GBS	 (Ansar	 and	 Valadi	 2015;	 Blazquez	 and	 Saiz	 2016).	 However,	
during	 the	 recent	 outbreaks	 in	 America,	 a	 twenty	 times	 increase	 in	 the	 number	 of	 cases	 of	
microcephaly	in	fetus	and	newborns,	and	an	astonishing	number	of	GBS	associated	cases	have	
been	 linked	 to	 ZIKV	 infection	 (Blazquez	 and	 Saiz	 2016).	 As	 for	 any	 flavivirus,	 and	beside	 the	
great	effort	made	by	the	scientific	community	during	recent	months	(Saiz	and	Martin-Acebes	
2017),	there	are	neither	specific	drugs	licensed	nor	vaccines	against	ZIKV.	
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El	principal	objetivo	de	esta	tesis	doctoral	era	el	obtener	un	conocimiento	más	detallado	del	
proceso	 celular	 implicado	 en	 las	 interacciones	 de	 los	 flavivirus	 con	 la	 célula	 hospedadora	 y,	
más	concretamente,	en	el	papel	que	juegan	los	lípidos	celulares	en	la	replicación	viral,	para	la	
búsqueda	de	dianas	celulares	antivirales		
Los	objetivos	específicos	fueron:	
1 La	evaluación	del	 impacto	de	la	 infección	por	el	VNO	en	el	contenido	lipídico	de	la	célula	
hospedadora.	
2 La	caracterización	de	la	composición	lipídica	de	la	envuelta	del	VNO.	
3 La	determinación	del	papel	de	ciertos	lípidos	específicos	en	la	biogénesis	del	VNO.	
4 El	 análisis	 del	 efecto	 de	 inhibidores	 de	 la	 vía	 de	 la	 biosíntesis	 de	 ácidos	 grasos	 en	 la	
infección	con	el	VNO	y	con	el	VUSU.	
5 El	 análisis	 del	 efecto	 de	 inhibidores	 de	 la	 vía	 de	 las	 proteínas	 de	 unión	 a	 elementos	
reguladores	del	esterol	(SREBP)	en	la	infección	con	el	VNO	y	con	el	VZIKA.	
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The	main	goal	of	this	thesis	was	to	gain	a	detailed	knowledge	of	the	cellular	processes	involved	
in	 flavivirus	 and	host	 cell	 interactions,	 and	more	precisely	 in	 the	 role	of	 the	 cellular	 lipids	 in	
viral	replication,	to	search	for	cellular	antiviral	targets.	
The	specifics	goals	of	this	thesis	were:	
1 To	evaluate	the	impact	of	WNV	infection	on	the	lipid	content	of	the	host	cell.	
2 To	characterize	the	lipid	composition	of	the	WNV	envelope.	
3 To	determine	the	role	of	specific	lipids	in	WNV	biogenesis.	
4 To	 analyze	 the	 effect	 of	 inhibitors	of	 the	 cellular	 fatty	 acid	 biosynthetic	 pathway	on	 the	
infection	by	WNV	and	USUV.	
5 To	analyze	the	effect	of	inhibitors	of	the	cellular	sterol	regulatory	element	binding	proteins	
(SREBP)	pathway	on	infection	by	WNV	and	ZIKV.	
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INTRODUCTION	TO	THE	ARTICLES	PROVIDED	FOR	THE	DOCTORAL	THESIS	
AND	PhD	FELLOW	CONTRIBUTION.	
Articles	provided	for	the	doctoral	thesis	
Article	 I:	Martín-Acebes	MA*,	Merino-Ramos	T*,	 Blázquez	 AB,	 Casas	 J,	 Escribano-Romero	 E,	
Sobrino	 F,	 Saiz	 JC.	 “The	 composition	 of	 West	 Nile	 virus	 lipid	 envelope	 unveils	 a	 role	 of	
sphingolipid	 metabolism	 in	 flavivirus	 biogenesis”.	 J	 Virol.	 2014	 Oct;88(20):12041-54.	 doi:	
10.1128/JVI.02061-14.	 PMID:	 25122799	 (*Martín-Acebes	 MA	 and	Merino-Ramos	T	 equally	
contributed	to	this	article.)	
Article	 II:	Merino-Ramos	T,	 Vázquez-Calvo	Á,	 Casas	 J,	 Sobrino	 F,	 Saiz	 JC,	Martín-Acebes	MA.	
“Modification	of	 the	host	cell	 lipid	metabolism	 induced	by	hypolipidemic	drugs	 targeting	 the	
acetyl	 coenzyme	 A	 carboxylase	 impairs	 West	 Nile	 virus	 replication”.	 Antimicrob	 Agents	
Chemother.	2015	Oct	26;60(1):307-15.	doi:	10.1128/AAC.01578-15.	PMID:	26503654.	
Article	III:	Merino-Ramos	T,	Jiménez	de	Oya	A,	Saiz	JC,	Martín-Acebes	MA.	“Antiviral	activity	of	
Nordihydroguaiaretic	acid	and	 its	derivative	 tetra-O-methyl	nordihydroguaiaretic	acid	against	
West	Nile	virus	and	Zika	virus”. Antimicrob	Agents	Chemother.	2017	May	15	pii: AAC.00376-17.	
doi: 10.1128/AAC.00376-17. 
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Breve	 introducción	 a	 los	 artículos	 y	 su	 contribución	 al	 campo/Brief	 introduction	 to	 the	
articles	included	and	its	contribution	to	the	field.	
Artículo	I	
Martín-Acebes	MA*,	Merino-Ramos	T*,	Blázquez	AB,	Casas	J,	Escribano-Romero	E,	Sobrino	F,	
Saiz	 JC.	 “The	 composition	 of	 West	 Nile	 virus	 lipid	 envelope	 unveils	 a	 role	 of	 sphingolipid	
metabolism	 in	 flavivirus	 biogenesis”.	 J	 Virol.	 2014	 Oct;88(20):12041-54.	 doi:	
10.1128/JVI.02061-14.	 PMID:	 25122799	 (*Martín-Acebes	 MA	 and	Merino-Ramos	T	 equally	
contributed	to	this	article.)	
	
Como	 se	describía	 en	 la	 introducción,	 distintos	 pasos	del	 ciclo	 de	 vida	 viral	dependen	de	 su	
asociación	 con	 las	membranas	 plasmáticas,	 las	 cuales	 a	menudo	 se	 encuentran	modificadas	
durante	la	infección.	De	hecho,	varios	estudios	han	demostrado	que	la	biología	celular	de	los	
flavivirus	está	 íntimamente	relacionada	con	las	membranas	intracelulares,	y	el	requerimiento	
de	lípidos	específicos,	como	el	colesterol	y	los	ácidos	grasos	se	ha	documentado	como	esencial	
para	la	replicación	viral	y	la	biogénesis	de	partículas	infecciosas	(Martin-Acebes,	Vazquez-Calvo	
et	al.	2016).	Una	estrategia	atractiva	e	innovadora	para	inhibir	patógenos	virales	es	manipular	
dianas	 del	 hospedador	 de	 las	 cuales	 dependen.	 Para	 desarrollar	 estrategias	 antivirales	 que	
inhiban	esos	procesos	de	infección	por	flavivirus	a	través	de	efectos	estrechamente	dirigidos	a	
la	síntesis	 lipídica	del	hospedador,	primero	se	deben	definir	 los	 lípidos	específicos	 implicados	
en	la	infección	por	flavivirus	y	por	tanto	se	necesita	un	mayor	entendimiento	elemental	de	las	
funciones	 de	 los	 lípidos	 en	 la	 replicación	 y	 biogénesis.	 El	 conocimiento	 detallado	 de	 cómo	
moléculas	específicas	están	implicadas	en	la	replicación	viral,	permitiría	un	diseño	racional	de	
antivirales	 dirigidos	 a	 dianas	 selectivas	 del	 hospedador.	 Esto	 puede	 ser	 llevado	 a	 cabo	
reduciendo	la	toxicidad	para	el	hospedador	a	través	de	la	identificación	de	lípidos	que	puedan	
ser	 modulados	 sin	 interferir	 con	 las	 funciones	 del	 hospedador,	 y/o	 actuando	 sobre	 pasos	
intermedios	de	la	síntesis	lipídica,	metabolismo	o	tráfico	de	sustancias,	para	los	cuales	los	virus	
tienen	más	 sensibilidad	 que	 la	 célula	 hospedadora.	 Aunque	 la	 composición	 de	 las	 envueltas	
lipídicas	de	unos	pocos	virus	ha	sido	caracterizada,	en	el	Artículo	I	se	caracteriza	por	primera	
vez	 la	 composición	 de	 la	 envuelta	 del	 VNO.	 El	 artículo	 describe	 que	 las	 envueltas	 están	
enriquecidas	 en	 esfingolípidos	 y	 que	 muestran	 niveles	 reducidos	 de	 fosfatidilcolina	 (un	
glicerofosfolípido).	 La	 consiguiente	 inhibición	 de	 la	 nSMasa	 (la	 cual	 cataliza	 la	 hidrólisis	 de	
esfingomielina	 a	 ceramida)	 reduce	 la	 liberación	 de	 viriones	 de	 flavivirus	 y	 de	 partículas	
subvirales	recombinantes,	confirmando	la	relevancia	de	los	esfingolípidos	en	la	biogénesis	del	
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VNO.	El	impacto	en	la	infección	por	VNO	sobre	dos	componentes	de	las	membranas	celulares	
(glicerofosfolípidos	 y	 esfingolípidos),	 así	 como	 la	 comparación	 de	 la	 envuelta	 lipídica	 de	 los	
viriones	del	VNO	y	de	las	partículas	subvirales	recombinantes,	revelaron	que	ambos	tienen	una	
composición	lipídica	única.	El	Artículo	I	también	describe	cómo	la	composición	lipídica	celular	
se	ve	alterada	por	la	infección	viral.	
Durante	el	desarrollo	de	esta	investigación	realicé,	 junto	al	Dr.	Martín-Acebes,	 la	mayoría	del	
trabajo	experimental	desarrollado,	por	 lo	que	ambos	somos	co-primeros	autores,	 tal	y	como	
se	 reseña	en	el	artículo,	y	contribuí	al	diseño	de	una	parte	significativa	de	 los	experimentos.	
Llevé	 a	 cabo	 las	 infecciones	 de	 células	 (Vero,	 HeLa	 y	 C6/36)	 con	 virus	 (VNO	 y	 USUTU)	 y	 su	
tratamiento	 con	 concentraciones	 crecientes	 de	 distintos	 fármacos	 (GW4869,	 Spiroepoxido	 y	
glutatión)	 determinando	 la	 toxicidad	 de	 los	 mismos	 en	 las	 distintas	 células	 utilizadas	 y	
titulando	 las	 progenies	 víricas	 obtenidas.	 Purifiqué	 las	 partículas	 subvirales	 recombinantes	
(RSPs)	 y	 los	 viriones.	 Obtuve	 y	 cuantifiqué	 el	 ARN	 de	 doble	 cadena	 mediante	
inmunofluorescencia	en	 células	 infectadas,	 tratadas	o	no	 con	 fármaco.	Así	mismo,	obtuve	el	
ARN	viral	y	lo	analicé	por	RT-PCR	cuantitativa.	Finalmente	llevé	a	cabo	parte	del	análisis	de	los	
datos	y	contribuí	a	la	escritura	del	artículo	detallando	los	resultados	obtenidos.	
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Article	I	
Martín-Acebes	MA*,	Merino-Ramos	T*,	Blázquez	AB,	Casas	J,	Escribano-Romero	E,	Sobrino	F,	
Saiz	 JC.	 “The	 composition	 of	 West	 Nile	 virus	 lipid	 envelope	 unveils	 a	 role	 of	 sphingolipid	
metabolism	 in	 flavivirus	 biogenesis”.	 J	 Virol.	 2014	 Oct;88(20):12041-54.	 doi:	
10.1128/JVI.02061-14.	 PMID:	 25122799	 (*Martín-Acebes	 MA	 and	Merino-Ramos	T	 equally	
contributed	to	this	article.)	
	
As	described	in	the	introduction,	different	steps	of	the	virus	life	cycle	depend	on	its	association	
with	 the	 cytoplasmic	membranes,	which	are	often	modified	during	 infection.	 In	 fact,	 several	
studies	have	shown	that	the	cellular	biology	of	flaviviruses	is	intimately	linked	to	modifications	
of	the	intracellular	membranes,	and	the	requirement	of	specific	lipids,	such	as	cholesterol	and	
fatty	 acids,	 has	 been	 documented	 as	 essential	 for	 virus	 replication	 and	 infectious	 particle	
biogenesis	(Martin-Acebes,	Vazquez-Calvo	et	al.	2016).	An	attractive	and	innovative	strategy	to	
inhibit	 viral	 pathogens	 is	 to	manipulate	 the	 host	 targets	 on	which	 they	 depend.	 To	 develop	
antiviral	 strategies	 to	 inhibit	 these	 flaviviral	 processes	 through	 tighter	 focused	 effects	 on	
specific	host	 lipid	 synthesis,	 the	 specific	 lipids	 that	are	 implicated	 in	 flavivirus	 infection	must	
first	 been	 defined,	 and,	 thus,	 a	 better	 elemental	 understanding	 of	 the	 lipid	 roles	 in	 viral	
replication	 and	 biogenesis	 is	 needed.	 Knowing	 in	 detail	 how	 specific	 lipid	 molecules	 are	
involved	 in	 viral	 replication,	 a	 rational	 design	 of	 selective	 host-targeted	 antivirals	 could	 be	
performed.	This	can	be	achieved	by	reducing	host	toxicity	through	the	 identification	of	 lipids	
that	can	be	modulated	without	interfering	with	host	cell	functions,	and/or	by	targeting	steps	in	
lipid	synthesis,	metabolism,	or	trafficking	for	which	viruses	have	a	greater	sensitivity	than	the	
host	 cell.	Although	 the	 lipid	 composition	of	 the	 viral	 envelopes	of	 a	 few	distinct	 viruses	had	
been	characterized,	in	Article	I	the	WNV	envelope	composition	was	characterized	for	the	first	
time.	The	article	describes	that	envelopes	were	enriched	in	sphingolipids	and	showed	reduced	
levels	of	phosphatidylcholine	(a	glycerophospholipid).	Subsequent	inhibition	of	nSMase	(which	
catalyzed	 the	 hydrolysis	 of	 sphingomyelin	 into	 ceramide)	 reduced	 the	 release	 of	 flavivirus	
virions	and	virus-like	particles,	 confirming	 the	 relevance	of	 sphingolipids	 in	 the	biogenesis	of	
WNV.	The	impact	of	WNV	infection	on	two	important	components	of	the	cellular	membranes	
(glycerophospholipids	 and	 sphingolipids),	 as	well	 as	 the	 comparison	 of	 the	 lipid	 envelope	 of	
WNV	 virions	 and	 recombinant-subviral	 particles,	 revealed	 that	 they	 have	 a	 unique	
composition.	Article	 I	also	described	how	the	cellular	 lipid	composition	 is	altered	by	the	viral	
infection.		
Articles   
		
36	
	
Along	the	development	of	this	research,	together	with	Dr.	Martín-Acebes,	we	developed	most	
of	 the	 experimental	 work	 detailed.	 For	 this	 reason,	 we	 have	 both	 the	 co-authorship	 of	 the	
publication.	As	 it	 is	described	 in	the	article,	 I	contributed	to	the	experimental	design.	 I	made	
the	 cells	 infections	 (Vero,	HeLa	 and	C6/36)	with	 viruses	 (WNV	and	USUV)	 and	 its	 treatment	
with	 increasing	 concentrations	 of	 different	 drugs	 (GW4869,	 Spiroepoxide	 and	 Glutathione).	
Previously,	 I	determined	drug	 toxicity	 in	 the	 same	cell	 lines	and	afterwards,	 I	made	 the	viral	
titration.	 I	 purified	 recombinant	 subviral	 particles	 (RSPs)	 and	 virions,	 and	 obtained	 and	
quantified	dsRNA	 intermediates	by	 immunofluorescence	 in	 infected	cells	 treated	or	not	with	
drugs.	 Likewise,	 I	 made	 viral	 RNA	 extractions	 and	 analyzed	 them	 by	 quantitative	 RT-PCR.	
Finally,	 I	 did	 a	 part	 of	 the	 data	 analysis	 and	 contributed	 to	 the	 article	writing,	 detailing	 the	
obtained	results.	
The Composition of West Nile Virus Lipid Envelope Unveils a Role of
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ABSTRACT
West Nile virus (WNV) is an emerging zoonotic mosquito-borne flavivirus responsible for outbreaks of febrile illness andme-
ningoencephalitis. The replication ofWNV takes place on virus-modifiedmembranes from the endoplasmic reticulum of the
host cell, and virions acquire their envelope by budding into this organelle. Consistent with this view, the cellular biology of this
pathogen is intimately linked to modifications of the intracellular membranes, and the requirement for specific lipids, such as
cholesterol and fatty acids, has been documented. In this study, we evaluated the impact ofWNV infection on two important
components of cellular membranes, glycerophospholipids and sphingolipids, by mass spectrometry of infected cells. A signifi-
cant increase in the content of several glycerophospholipids (phosphatidylcholine, plasmalogens, and lysophospholipids) and
sphingolipids (ceramide, dihydroceramide, and sphingomyelin) was noticed inWNV-infected cells, suggesting that these lipids
have functional roles duringWNV infection. Furthermore, the analysis of the lipid envelope ofWNV virions and recombinant
virus-like particles revealed that their envelopes had a unique composition. The envelopes were enriched in sphingolipids (sph-
ingomyelin) and showed reduced levels of phosphatidylcholine, similar to sphingolipid-enriched lipid microdomains. Inhibi-
tion of neutral sphingomyelinase (which catalyzes the hydrolysis of sphingomyelin into ceramide) by either pharmacological
approaches or small interfering RNA-mediated silencing reduced the release of flavivirus virions as well as virus-like particles,
suggesting a role of sphingomyelin-to-ceramide conversion in flavivirus budding and confirming the importance of sphingolip-
ids in the biogenesis ofWNV.
IMPORTANCE
West Nile virus (WNV) is a neurotropic flavivirus spread by mosquitoes that can infect multiple vertebrate hosts, including hu-
mans. There is no specific vaccine or therapy against this pathogen licensed for human use. Since the multiplication of this virus
is associated with rearrangements of host cell membranes, we analyzed the effect ofWNV infection on different cellular lipids
that constitute important membrane components. The levels of multiple lipid species were increased in infected cells, pointing
to the induction of major alterations of cellular lipid metabolism byWNV infection. Interestingly, certain sphingolipids, which
were increased in infected cells, were also enriched in the lipid envelope of the virus, thus suggesting a potential role during virus
assembly. We further verified the role of sphingolipids in the production ofWNV bymeans of functional analyses. This study
provides new insight into the formation of flavivirus infectious particles and the involvement of sphingolipids in theWNV life
cycle.
West Nile virus (WNV) is a mosquito-borne flavivirus that isdistributed worldwide and that is responsible for recurrent
outbreaks of febrile illness and encephalitis. The virus is main-
tained in nature in an enzootic infectious cycle between birds and
mosquitoes, which act as its vectors, although it can also infect
multiple vertebrate hosts, including horses and humans (1, 2).
The continuing spread of WNV due to a variety of ecological fac-
tors, combined with the lack of specific therapeutics or vaccines
for human use, makes the identification of the viral and host pro-
cesses that control the biology of this pathogen important to im-
prove the design of specific antiviral strategies (3).
As a flavivirus,WNV is an enveloped plus-strandRNAvirus (1,
2). A feature that it shares with other plus-strand RNA viruses is
replication in the cytoplasm of infected cells in tight association
with intracellular membrane rearrangements (4). In the case of
flaviviruses and, hence, WNV, the membranes associated with
virus replication are from the endoplasmic reticulum (ER) (5).
Even more, flavivirus particles are assembled by invagination and
budding of the ER membrane into the lumen of this organelle, so
the ER also provides themembrane source forWNVenvelopment
(6). Although the lipid composition of the viral envelopes of a few
distinct viruses has been characterized (7–10), to our knowledge,
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themolecular composition of the flavivirus envelope has not been
analyzed. Only certain lipids in the flavivirus envelope (choles-
terol and phosphatidylserine) have been identified, and these have
been identified by functional studies rather than by analytical ap-
proaches (11, 12).
Lipids are the main components of cellular membranes, play-
ing key roles in viral infections by acting as signalingmolecules, as
well as by determining the physical properties of the membranes,
such as fluidity, thickness, or shape (13, 14). In fact, the strong
manipulation of cellular lipid metabolism by different viruses has
recently been documented (15–17). Accordingly, enrichment in
specific lipids contributes to the generation of amembrane curva-
ture adequate for the correct assembly of the replication complex
or virus budding, and the cone-shaped or inverted cone-shaped
lipids, which can govern membrane bending, budding processes,
or fusion events, are of particular interest (18–20). Although dif-
ferences in the lipid requirements between viruses of the same
family have been noted (21), the dependence on certain lipids,
such as fatty acids (15, 22, 23) or phosphatidylinositol 4-phos-
phate (PI4P) (21, 24), can be shared by unrelated enveloped and
nonenveloped viruses. These observations suggest that each virus
creates its own characteristic cellular microenvironment for rep-
lication by developing specialized virus-induced organelle-like
structures within infected cells (4, 24, 25). Regarding flaviviruses,
major rearrangements of cellular lipid metabolism have been ob-
served in dengue virus (DENV)-infected cells (26, 27), and several
studies have highlighted the importance of both fatty acids and
cholesterol forWNV andDENV infection (22, 28–31), as well as a
lack of a requirement for PI4P (21, 29).
In this study, we have analyzed the effect of WNV infection on
the cellular content of 11 lipid classes. Our results revealed an
increase in the cellular content of multiple lipid species upon
WNV infection, which is consistent with major lipid metabolic
changes in WNV-infected cells. The proportions of these metab-
olites in the envelope ofWNVvirions and virus-like particles were
also determined, unveiling a unique composition of the viral en-
velope and pointing to specific roles of some of these lipids for
virus assembly. Supporting this view, a direct link between specific
lipids (sphingolipids) and WNV biogenesis was found by means
of functional analyses.
MATERIALS AND METHODS
Cells, viruses, infections, and virus titrations. All infectious virus ma-
nipulations were performed in our biosafety level 3 (BSL-3) facilities. The
origins ofWNV strainNY99, Usutu virus (USUV) strain SAAR-1776, and
Sindbis virus (SINV) have been previously described (32). Vero andHeLa
cells were grown at 37°C in a 5%CO2 atmosphere in Dulbecco’s modified
minimum essential medium (DMEM) supplemented with 2 mM glu-
tamine, penicillin-streptomycin, and 5 or 10% fetal bovine serum, respec-
tively. Cells of a HeLa cell line stably transfected with plasmid pcDNA 3.1
(!) (Invitrogen, Carlsbad, CA) encoding the 25 last amino acids of the
WNV NY99 C protein followed by the sequence of premembrane/mem-
brane (prM) and envelope (E) proteins (HeLa3-WNV cells) were ob-
tained by limiting dilution and grown in complete culture medium sup-
plemented with 500 "g/ml G-418 (T. Merino-Ramos, A. B. Blázquez, E.
Escribano-Romero, R. Cañas-Arranz, F. Sobrino, J. C. Saiz, and M. A.
Martín-Acebes, submitted for publication). This line constitutively se-
cretedWNV recombinant subviral particles (RSPs). C6/36mosquito cells
were cultured in M3 medium supplemented with 4 mM glutamine, gen-
tamicin, penicillin-streptomycin, nonessential amino acids, amphoteri-
cin B, and 10% fetal bovine serum at 28°C without CO2. For infections in
liquidmedium, the viral inoculumwas incubatedwith cellmonolayers for
1 h at the temperature appropriate for cell growth, and then the inocu-
lum was removed and fresh medium containing or not containing 1%
fetal bovine serum was added. The viral titer was determined at 24 h
postinfection (p.i.) for WNV and USUV and 8 h p.i. for SINV by
plaque assay on Vero cells (29, 32, 33). Cell-associated virus was ex-
tracted from infected cells by three cycles of freeze and thaw and
titrated as described above. The multiplicity of infection (MOI) used
in each experiment was expressed as the number of PFU/cell and is
indicated in the corresponding figure legend.
Antibodies. Mouse monoclonal antibodies against the WNV enve-
lope (E) protein (Millipore, Temecula, CA), #-actin (Sigma, St. Louis,
MO), and GM130 (ECM Biosciences, Versailles, KY) and rabbit sera
againstWNVMprotein (Imgenex, San Diego, CA), calnexin (StressMarq
Biosciences Inc., Victoria, Canada), mannosidase II (Millipore), and sph-
ingomyelin phosphodiesterase 3 (SMPD3), also named neutral sphingo-
myelinase 2 (nSMase2; ECMBiosciences), were used as primary antibod-
ies. Anti-mouse or anti-rabbit IgG coupled to Alexa Fluor 594 or 488
(Invitrogen, Carlsbad, CA) and goat anti-mouse or anti-rabbit IgG cou-
pled to horseradish peroxidase (Pierce Biotechnology, Rockford, IL) were
used as secondary antibodies.
Drug treatments. Brefeldin A (BFA), golgicide A (GCA), GW4869,
and glutathione were from Sigma. Spiroepoxide was from Santa Cruz
Biotechnology (Santa Cruz, CA). BFA, GCA, GW4869, and spiroepoxide
stock solutions were prepared in dimethyl sulfoxide, while glutathione
was directly dissolved in culture medium. Working concentrations of
GW4869 were prepared as described previously (34). Control cells were
treated in a parallel manner with the same amount of drug vehicle. For
estimation of RSP release, the medium from HeLa3-WNV cells was re-
placed by serum-free medium containing the drugs. Cells were incubated
for 4 h, and the amount of RSPs released to the culture medium was
determined by an enzyme-linked immunodot assay using a monoclonal
antibody directed againstWNVE glycoprotein, as described below. In the
case of virus infections, drugs were added after the first hour of infection,
when the viral inoculum was replaced by medium containing 1% fetal
bovine serum. The lack of toxicity of drug concentrations during the
assays was evaluated by determination of the cellular ATP content with a
CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI).
siRNA experiments. HeLa or HeLa3-WNV cells were transfected in
serum-free culture medium with 100 nM endoribonuclease-prepared
small interfering RNAs (esiRNAs) against human SMPD3 (MISSION;
Sigma) or an equivalent amount of MISSION small interfering RNA
(siRNA) universal negative control 1 (MISSION; Sigma) using an siRNA
transfection reagent (MISSION; Sigma), as indicated by the manufac-
turer. To estimate the release of WNV RSPs, the culture medium of
HeLa3-WNV cells was replaced by fresh serum-free medium, and the
amount of RSPs in the culture medium was determined after 4 h of incu-
bation by an enzyme-linked immunodot assay. For viral infections, trans-
fected cells were infected (MOI, 1 PFU/cell) as described above for infec-
tions in liquid medium, and subsequent experiments were performed at
48 h posttransfection. The extent of siRNA silencing was analyzed by
Western blotting (29, 35) using specific antibodies against nSMase2.
Purification of RSPs and virions. HeLa3-WNV cells were incubated
for 48 h in serum-free medium (to avoid the possible interference of
serum with subsequent lipid determinations), and RSPs were purified by
sucrose gradient centrifugation essentially as described previously (36).
Briefly, culture medium from HeLa3-WNV cells was clarified by centrif-
ugation at 15,000 $ g for 30 min at 4°C and then centrifuged through a
20% sucrose cushion for 3.5 h at 112,000$ g at 4°C. The pellet containing
RSPs was resuspended in phosphate-buffered saline (PBS), loaded onto a
12-ml 20 to 60% linear sucrose gradient, and centrifuged at 256,000$ g
for 18 h at 4°C. For purification ofWNVparticles,HeLa cells were infected
withWNV(MOI, 5 PFU/cell) in serum-freemediumand incubated for 48
h. The culture medium was cleared of cell debris by centrifugation at
850$ g for 15min at 4°C and centrifuged through a 20% sucrose cushion
at 112,000 $ g for 3.5 h at 4°C. The pellet containing the virions was
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loaded onto a six-step discontinuous 20 to 60% sucrose gradient and
centrifuged at 55,500$ g for 18 h at 4°C. Gradients were fractioned from
the top, and the E-protein content of each fraction was determined by
enzyme-linked immunodot assay as described below. Only the fraction
with the highest E-protein content was selected for lipid analyses.
Immunofluorescence and confocalmicroscopy.Cells grown on glass
coverslips were fixed with 4% paraformaldehyde in PBS for 15 min and
processed for immunofluorescence as described previously (29, 35). Cells
were observed using a Leica TCS SPE confocal laser scanning microscope
and an HCX PL Apo $63/1.4 oil immersion objective. Images were ac-
quired using Leica advanced fluorescence software and processed with
Adobe Photoshop CS2 software (Adobe Inc., San Jose, CA). The optical
slice thickness for all confocal images displayed was 1 airy unit.
Transmission electron microscopy. Negative staining of RSPs was
performed in dialyzed samples containing the peak amount of E protein
within the gradient, as described previously (36). For immunolabeling
and negative staining, samples were adsorbed to ionized collodion-car-
bon-coated grids, washed with PBS, and blocked with 10% fetal bovine
serum inPBS for 5min. The gridswere incubatedwith primary antibodies
diluted in 5% fetal bovine serum in PBS for 30min, washed five timeswith
PBS, and incubated with protein A coupled to 5-nm colloidal gold diluted
in 5% fetal bovine serum in PBS for 30min. Samples were then fixed with
1% glutaraldehyde in PBS for 5 min, washed three times with bidistilled
water, and negatively stainedwith 1%uranyl acetate for 2min.HeLa orVero
cells infectedwithWNVwere fixed in 4%paraformaldehyde–2%glutaralde-
hyde in0.1Mphosphatebuffer (pH7.4)at24hp.i. andprocessed for electron
microscopy as described previously (29, 35). Samples were examined using a
JEOL JEM-1010 electron microscope (JEOL, Japan) operated at 80 kV, and
images were acquired using a digital camera (4K64K TemCam-F416; Tietz
Video and Image Processing Systems GmbH, Gauting, Germany).
Enzyme-linked immunodot assay.Cell culture medium (usually 5 to
10 "l) was adsorbed to a nitrocellulose membrane by vacuum using a
Bio-Dot apparatus (Bio-Rad, Hercules, CA). For quantification of the
amount of RSPs in the culturemedium and in order to verify that samples
were within the linear range, a standard curve was prepared using different
dilutions. The membrane was blocked with 3% skimmed milk in PBS and
incubated with monoclonal anti-E antibody diluted in 1% skimmedmilk in
PBS. After three washes with PBS, the membranes were incubated with sec-
ondary antibodies coupled to horseradish peroxidase and washed, and pro-
teinswere detectedby chemiluminescenceusing ImageQuant LAS4000mini
equipment (GEHealthcare, Buckinghamshire, United Kingdom).
Quantitative RT-PCR. Viral RNA was extracted with a NucleoSpin
viral RNA isolation kit (Macherey-Nagel, Düren, Germany). The number
of viral RNA copies was determined by quantitative reverse transcription-
PCR (RT-PCR) (37) and is given as the number of genomic equivalents
corresponding to the number of PFU/ml by comparison with the amount
of RNA extracted from previously titrated samples (38).
Lipid analysis. HeLa cells were infected or not infected (mock in-
fected) with WNV (MOI, 50 PFU/cell) in serum-free medium as de-
scribed above for infections in liquid medium, detached from the flasks,
and resuspended in PBS at 24 h p.i. The number of cells in each samplewas
determined, and aliquots containing 2.7$ 106 cells were subjected to lipid
extractions. The amount of protein in each sample was also determined by
the Bradford assay. Lipids were extracted using a modified Bligh and Dyer
protocol. Cell pellets were resuspended in 100 "l of PBS and 750 "l of a
methanol-chloroform (1:2, vol/vol) solution containing 0.01%butylated hy-
droxytoluene (BHT) and internal standards (1,2-diheptadecanoyl-sn-
glycero-3-phosphocholine, 1,2-diheptadecanoyl-sn-glycero-3-
phosphoethanolamine, 1,2-diheptadecanoyl-sn-glycero-3-phosphoserine,
1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-heptade-
canoyl-2-hydroxy-sn-glycero-3-phosphoethanoamine, and 1-heptade
canoyl-2-hydroxy-sn-glycero-3-phosphoserine, 200 pmol each, fromAvanti
Polar Lipids). Samples were extracted at 48°C overnight and centrifuged
at 13,000 $ g for 5 min. Then, the supernatant was transferred to a new
vial, evaporated to dryness, and stored at%20°C in an argon atmosphere
until the analysis of glycerophospholipids (39). On the other hand, 100"l
of PBS and 750 "l of a methanol-chloroform (2:1, vol/vol) solution con-
taining 0.01% BHT and internal standards (N-lauroyl-D-erythro-sphin-
gosine, N-lauroyl-D-erythro-sphingosylphosphorylcholine, and D-gluco-
syl-#-1,1=-N-lauroyl-D-erythro-sphingosine, 200 pmol each, from Avanti
Polar Lipids)were added to the cell pellets. Sampleswere extracted at 48°C
overnight and cooled, 75 "l of 1 M KOH in methanol was added, and the
mixture was incubated for 2 h at 37°C. Following addition of 75"l of 1M
acetic acid, samples were centrifuged at 13,000 $ g for 5 min and the
supernatant was transferred to a new vial, evaporated to dryness, and
stored at%20°C in an argon atmosphere until the analysis of sphingolip-
ids (40).
Lipids were measured with an Acquity ultraperformance liquid chro-
matography (UPLC) system (Waters, USA) connected to a time-of-flight
(TOF; LCT Premier XE) detector controlled with Waters/Micromass
MassLynx (v.4.1) software. An Acquity UPLC BEH C8 column (particle
size, 1.7 "m; 100 mm by 2.1 mm; Waters, Ireland), a flow rate of 0.3
ml/min, and a column temperature of 30°C were used. The mobile phase
was methanol with 1 mM ammonium formate and 0.2% formic acid
(solution A)–water with 2mMammonium formate and 0.2% formic acid
(solution B). Gradient elution started at 80% solution A, was increased to
90% solution A over 3 min, was held for 3 min, was increased to 99%
solution A over 9 min, and was held for 3 min. Initial conditions were
attained in 2min, and the systemwas stabilized for 3min. The acquisition
range of the TOFdetector wasm/z 50 to 1,500, the capillary voltagewas set
to 3.0 kV, the desolvation temperature was 350°C, and the desolvation gas
flow rate was 600 liters/h (41).
Lipid identification was confirmed by the analysis of one sample from
each group with an ultra-high-performance liquid chromatography sys-
tem (Accela) coupled to a Thermo Fisher Scientific LTQ Orbitrap Velos
mass spectrometer (MS) controlled with Thermo Fisher Scientific/Xcali-
bur software using the same column and eluted with the following condi-
tions: gradient elution started at 85% solution A, was increased to 90%
solution A over 9 min, was held for 2 min, was increased to 99% solution
A over 6min, and was held for 2min. Initial conditions were attained in 2
min, and the system was stabilized for 3 min. The acquisition range of the
Orbitrap detector wasm/z 200 to 100, the source voltage was set to 3.5 kV,
the capillary temperature was 350°C, the sheath gas flow rate was 50 li-
ters/h, the auxiliary gas flow rate of 20 liters/h, and the sweep gas flow rate
was 2 liters/h (42).
Individual chromatographic peaks of distinct lipid species were
isolated from full-scanMS spectra when the theoretical exact masses of
the lipid species were selected. The spectra were extracted from a da-
tabase that was previously generated using the spectrum simulation
tool of Micromass MassLynx software on the basis of our previous
results (39). Then, a list of possible candidates fitting the specific exact
mass was generated using formula determination tools (elemental
composition search) of Micromass MassLynx software. The elemental
number was restricted to include C, H, O, N, and P. The formula
constraints were as follows: C, H, and O were !1, P was !0, and N was
!1, following the nitrogen rule. The number of double-bond equivalents
(DBEs) was set to be between %0.5 and 15.0. The search was based on
single mass analysis and considered only the m/z value of the monoiso-
topic peak. Positive identification of the lipids was based on accuratemass
measurement with an error &5 ppm, a low i-Fit parameter in the spec-
trum window, and its relative retention time by liquid chromatography
compared to that of the standard ('2%) (39). The following lipids from
Avanti Polar Lipids were used: 1,2-dihexadecanoyl-sn-glycero-3-phos-
phocholine, 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine, 1-hexa-
decanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine, 1-hexade-
canoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-
phosphocholine, 1-(9Z-octadecenoyl)-2-hydroxy-sn-glycero-3-
phosphocholine, 1-(1Z-octadecenyl)-2-(9Z-octadecenoyl9-sn-glycero-
3-phosphocholine, 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-
glycero-3-phosphoethanolamine, 1-hexadecanoyl-2-(9Z-octadecenoyl)-
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sn-glycero-3-phospho-L-serine, N-hexadecanoyl-D-erythro-sphingosine,
N-hexadecanoyl-D-erythro-sphingosylphosphorylcholine, and D-gluco-
syl-#-1,1=-N-hexadecanoyl-D-erythro-sphingosine In addition, identifi-
cations of lipids were made by searching their molecular weights against
entries in the Lipid MAPS database. As mentioned above, this identifica-
tion procedure was confirmed by the analysis of selected samples using
Thermo Fisher ScientificOrbitrap analyzers (resolution, 30,000 full width
at half maximum) (42).
The data presented are the products of 4 to 5 independent lipid extrac-
tions and determinations.
Annotation of lipid species.Glycerophospholipids were annotated as
lipid subclass and total fatty acyl chain length:total number of unsaturated
bonds. Plasmalogens (P) were annotated as described above, except that P
was added. Sphingolipids were annotated as lipid subclass and total fatty
acyl chain length:total number of unsaturated bonds. If the sphingoid
base residue was dihydrosphingosine (dihydro sphingomyelin or dihydro
ceramide), the lipid class contains the prefix dh (dihydro).
Data analysis.Analysis of variance (ANOVA)was performedwith the
SPSS (v.15) statistical package (SPSS Inc., Chicago IL), with Bonferroni’s
correction applied for multiple comparisons. Nonparametric compari-
sons were performed using the statistical package GraphPad Prism
(v.2.01; GraphPad Software Inc., La Jolla, CA). Data are presented as the
mean' standard deviation (SD). Differences with P values of&0.05 were
considered statistically significant.
RESULTS
Alteration of lipid content inWNV-infected cells.To analyze the
effect ofWNV infection on the lipid content of the host cell, HeLa
cells were infected or not infected at a high multiplicity of infec-
tion (MOI) and processed for lipid analysis at 24 h p.i. At this time
point, infectious virus release into the culturemediumwas already
detected (Fig. 1A). When the cells were observed by transmission
electronmicroscopy, they exhibited intracellular membrane rear-
rangements associated with flavivirus replication and assembly,
such as membrane sacs containing small virus-induced vesicles,
referred to as vesicle packets (VPs) (5, 29, 43), as well as electron-
dense virions (Fig. 1B). As expected, these rearrangements were
not observed in control uninfected cells. Eleven lipid classes
(seven glycerophospholipids [GPLs] and four sphingolipids
[SLs]) were included in the analysis. The GPLs analyzed were
phosphatidylcholine (PC), 1-alkenyl,2-acylglycerolphosphocho-
line (referred to as plasmalogen-PC [p-PC; plasmenylcholine]),
2-acylglycero-3-phosphocholine (lyso-PC), phosphatidylethano-
lamine (PE), plasmalogen-PE (p-PE), 2-acylglycero-3-phosphoe-
thanolamine (lyso-PE), and phosphatidylserine (PS). The four
SLs analyzed were ceramide (CER), dihydro-CER (dhCER), sph-
ingomyelin (SM), and dihydro-SM (dhSM). A tendency for an
increase in the content ofmost of the lipid classes analyzed per cell
(except for lyso-PE, aminor lipid class present in the extracts) was
noticed in WNV-infected cells (Fig. 1C). In fact, statistically sig-
nificant increases in the amounts of PC (1.7-fold), p-PC (1.9-
fold), lyso-PC (1.9-fold), p-PE (1.6-fold), CER (1.8-fold), dhCER
(1.3-fold), and SM (1.4-fold) were noted when infected cells were
compared to uninfected cells. Among the 11 lipid classes analyzed,
a total of 162 different molecular species were identified in HeLa
cells (the complete list of molecular species identified in this and
subsequent analyses is included inData Set S1 in the supplemental
material), with 54 (33.3%) molecular species being significantly
increased upon WNV infection (Fig. 1D). Interestingly, although
a tendency for a reduction of some lipid species was found, at the
level of resolution of this analysis, no statistically significant re-
duction in the content of individual lipid species could be deter-
mined, so we assumed that no major modifications in the level of
the rest of the lipid species occurred in infected cells. The molec-
ular species significantly increased in infected cells included 44
GPLs (13 PCs, 9 p-PCs, 3 lyso-PCs, 5 PEs, and 14 p-PEs) and 10
SLs (5 CERs, 1 dhCERs, and 4 SMs). Therefore, WNV infection
markedly alters the lipid metabolism of host cells.
GPL and SL content of the envelope of flavivirus virions and
RSPs. The lipid composition of viral envelopes can provide novel
clues to understand the biology of these pathogens (7, 9, 10).
Therefore, we studied the GPL and SL content of the viral enve-
lope of WNV. Since the coexpression of flavivirus structural gly-
coproteins (premembrane/membrane [prM/M] and envelope
[E]) results in the assembly and secretion of a sort of virus-like
particle termed a recombinant subviral particle (RSP) that pro-
vides a noninfectious model system to study the assembly and
secretion of flavivirus particles (44, 45), the analysis of the lipid
composition of RSPs was included in this study. A stable HeLa
clone (HeLa3-WNV cells) expressing WNV structural glycopro-
teins (Fig. 2A) that constitutively secrete WNV RSPs of about 30
nm in diameter into the culture medium (Fig. 2B) was used as a
source of RSPs. The identity of these structures was confirmed by
immunogold electronmicroscopy using an antibody against the E
glycoprotein (Fig. 2B inset). In this cell line, immunofluorescence
and confocal analysis revealed that the WNV envelope glycopro-
tein colocalized with markers of the ER (calnexin) and the Golgi
complex (mannosidase II) (Fig. 2C andD). Themolecularweights
of the proteinswere analyzed byWestern blotting using anti-E and
anti-M antibodies (Fig. 2E). As expected, using anti-E antibody, a
single band (about 53 kDa [46]) was observed in samples contain-
ing purified RSPs. In the case of anti-M antibody, two bands, one
band compatible with prMprotein and the other band compatible
with mature M protein (about 20 and 6 kDa, respectively [46]),
were observed. These results confirmed the correct expression of
WNV glycoproteins by cells of the HeLa3-WNV cell line.
Enzyme-linked immunodot assay is faster than Western blot-
ting and allows the analysis of up to 96 samples at once. This kind
of assay has successfully been applied to quantify the amount of
RSPs released into the culture medium by other flaviviruses (47).
Thus, a dot blot assay was used to detect the WNV RSPs released
into the culture medium from HeLa3-WNV cells (Fig. 2F). To
further validate this methodology, the amount of RSPs released
into the culturemedium upon treatment with the Golgi complex-
disturbing agents brefeldin A (BFA) or golgicide A (GCA) was
studied. Treatment of HeLa3-WNV cells with BFA or GCA im-
paired the release of RSPs into the culture medium (Fig. 3A). The
quantification of the blots revealed that BFA or GCA at con-
centrations of !5 "M significantly inhibited the release of
RSPs into the culture medium without exerting noticeable
toxic effects on the cells (Fig. 3B). Immunofluorescence analysis
of BFA- or GCA-treated cells confirmed the disruption of the
Golgi complex architecture that these drugs induced (Fig. 3C).
Golgi complex disassembly was concomitant with the accumula-
tion of E glycoprotein inside the cells (Fig. 3C), an observation
consistent with a reduction in the release of RSPs into the culture
mediumobserved in Fig. 3A and B.Overall, these observations are
consistent with previous data showing that flavivirus RSPs, as well
as infectious virions, are assembled by budding into the ER and
then traffic through the secretory pathway (44, 45). Therefore, in
theHeLa3-WNVcellmodel, the lipid envelope of RSPs is acquired
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from the ER in a manner parallel to that observed for infectious
virus (6).
Hence, the lipid composition of the envelope from sucrose
gradient-purified WNV and RSPs was analyzed by mass spec-
trometry and compared to that of total cellular membranes of
HeLa cells (Fig. 4A) following an approach similar to that de-
scribed for other viruses (7–10). The most abundant GPL in viri-
ons, RSPs, and total cellular membranes was PC, although both
RSPs and virions displayed significantly reduced contents of PC
relative to those of the total cellular membranes (about 0.57-fold
for both RSPs and virions). Among the SLs, a significant enrich-
ment in SMwas noticed in the envelope of RSPs and virions com-
pared to the amount in total cellular membranes (about 3.9- and
2.5-fold, respectively). These analyses also revealed that the lipid
composition of both virions and RSPs was very similar for all lipid
classes analyzed, except for p-PC, which appeared to be enriched
in virions compared with the amounts in both RSPs and total
cellular membranes. This could be related to the differences in the
sizes between virions (50 nm) and RSPs (30 nm), since vesicles
formed with p-PC are larger than those formed with PC (48).
Of the 162 lipid species identified in total cellular membranes,
about 95% and 93% were also detected in RSPs (n ( 155) and
virions (n( 152), respectively (see Data Set S1 in the supplemen-
talmaterial). Significant differences in the proportion of lipid spe-
cies between RSPs and virions were restricted to 3 lipid species
(lyso-PC, 18:2; CER, 18:0; dhSM, 24:0; these represented only
about 2% of the total species identified) (see Data Set S1 in the
supplemental material), supporting the suggestion that the lipid
FIG 1 WNV infection alters lipid metabolism. (A) Time course analysis of WNV infection. HeLa cells were infected with WNV (MOI, 50 PFU/cell), and the
amount of infectious virus released into the culture medium was determined by plaque assay at different times p.i. (B) Intracellular membrane rearrangements
in WNV-infected HeLa cells observed by transmission electron microscopy. A micrograph showing the ER from uninfected cells is included for comparison.
Characteristic features of flavivirus-infected cells, vesicle packets (VPs) and virions (Vi), were observed at 24 h p.i. (MOI, 50 PFU/cell). Bars, 200 nm. (C) Relative
amount of different classes of GPLs and SLs in HeLa cells infected or not infected with WNV (MOI, 50 PFU/cell) determined by mass spectrometry at 24 h p.i.
Statistically significant differences are indicated: *, P& 0.05; **, P& 0.005. (D) Fold differences in individual lipid species significantly increased in infected cells
analyzed as described in the legend to panel C. Dashed line, mean value for each lipid in uninfected cells. Data are presented as the mean' SD.
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envelopes of RSPs and virions share multiple common features.
Compared to the lipid species in total cellular membranes, virions
and RSPs displayed significantly altered proportions of 30 (19%)
and 36 (24%) lipid species, respectively, with 15 of them being
significantly altered in both virions and RSPs (Fig. 4B). Among
these common species altered, 5 corresponded to PE or its deriv-
ative, p-PE (4 were enriched [PE, 32:1; p-PE, 32:2; p-PE, 34:3;
p-PE, 36:3] and 1 was reduced [PE, 36:4]), and 6 corresponded to
PC (34:1, 34:3, 36:2, 38:5, 38:6, and 44:3, all of which were re-
duced). Regarding SLs, the enrichment of dhCER (24:0) and three
SM species (16:0, 24:0, and 24:2) was noticed. When lipids en-
riched in both RSPs and virions (Fig. 4B) were compared with
those increased in infected cells (Fig. 1D), only 5 matches were
found (p-PE, 34:3; p-PE, 36:3; dhCER, 24:0; SM, 24:0; SM, 24:1).
Interestingly, three of these species were SLs, suggesting that the
enrichment of these molecular species in infected cells could be
related to an increasing demand for these SLs for the assembly of
the viral envelope.
Involvement of SMandCER in flavivirus biogenesis.The SLs
are derived from sphingosine, a long-chain amino alcohol, which
is acylated with a long-chain fatty acid to give CER, which in turn
is the central core of SM. These lipids are important components
for membrane organization and shape, playing key roles in mul-
tiple cellular processes (49). Our analysis showed that different
FIG 2 WNV RSP as a noninfectious system to study flavivirus biogenesis. (A) Immunofluorescence analysis of the expression of the WNV E glycoprotein in
HeLa3-WNV cells. HeLa or HeLa3-WNV cells were subjected to immunofluorescence analysis using a monoclonal antibody directed against the E glycoprotein
(green) and observed by confocalmicroscopy. Nuclei were stainedwith ToPro3 (blue). Bars, 10"m. (B) RSPs produced byHeLa3-WNV cells. The RSPs released
into the culture medium were purified by sucrose gradient centrifugation and observed by negative staining and transmission electron microscopy. (Inset)
Immunogold staining of RSPs using a monoclonal antibody against the E protein. RSPs were detected using protein A coupled to 5-nm colloidal gold. Bars, 100
nm. (C andD)Localization of theWNVEglycoprotein at the ER (C) and theGolgi complex (D) ofHeLa3-WNVcells. Immunofluorescencewas performedusing
a monoclonal antibody directed against the E glycoprotein (green) in combination with rabbit polyclonal antibodies against calnexin (red) to stain the ER or
mannosidase II (red) to stain the Golgi complex. Nuclei were stained with ToPro3 (blue). HeLa cells not expressing viral proteins were included as negative
control. Bars, 10"m. (E)Western blot analysis of RSPs purified through a sucrose cushion from the culture medium of HeLa3-WNV cells. Cell culture medium
from control HeLa cells was processed and analyzed in parallel as a negative control. Western blotting was performed using anti-E or anti-M antibodies. (F)
Enzyme-linked immunodot assay using a monoclonal antibody against the E glycoprotein of culture supernatants from HeLa3-WNV cells. Culture medium
from HeLa cells not expressing viral glycoproteins was included as a negative control.
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SLs (CER, dhCER, and SM) were increased in infected cells (Fig.
1C); this was particularly the case for SM, which was found to be
enriched in the lipid envelope of both RSPs and virions (Fig. 4A).
The hydrolytic removal of the phosphocholine moiety of SM by
sphingomyelinases (SMases) to render CER has been associated
with the induction of membrane curvature in SL-enriched mem-
brane domains (50, 51). In fact, compounds that inhibit the activ-
ity of the neutral SMase 2 (nSMase2; also named sphingomyelin
phosphodiesterase 3 [SMPD3]) can inhibit budding processes
(18). Since these observations are compatible with the potential
roles of SLs during WNV infection, i.e., in virion budding and/or
assembly, we first addressed the effect of nSMase inhibition in
HeLa3-WNV cells, used as a model system to study flavivirus bio-
genesis in the absence of virus replication. To this end, we selected
three structurally unrelated nSMase inhibitors (18): GW4869, a
noncompetitive inhibitor of nSMase (34); spiroepoxide, a selec-
tive irreversible inhibitor of nSMase (52); and glutathione, a cel-
lular regulator of nSMase activity (53). Treatment of these cells
with either of these inhibitors significantly reduced the amount of
RSPs released into the culture medium without exerting notice-
able toxic effects on the cells (Fig. 5A to C). GW4869 was the drug
that produced significant inhibition at a lower concentration, so
this compound was selected for further experiments involving
virus infections (see below). As a complementary approach, the
effect of nSMase2 depletion using RNA interference was also an-
alyzed. Silencing of the expression of nSMase2 by transfection
with siRNA, which was verified by Western blotting (Fig. 5D),
significantly inhibited the release of RSPs into the culturemedium
(Fig. 5D and E). When the E-protein content in siRNA-trans-
fected cells was analyzed by Western blotting (Fig. 5D) or immu-
nofluorescence (Fig. 5F), no reductionwas observed in cells trans-
fected with siRNA against nSMase2. These results point to an
accumulation of viral proteins inside cells depleted of nSMase2,
which is consistent with the reduction in the release of RSPs from
cells depleted of nSMase2 that was observed. The extent of the
inhibition of RSP release in cells depleted of nSMase2 by siRNA
(Fig. 5E) was comparable to that exerted by treatment with
nSMase inhibitors (Fig. 5A to C), further supporting the require-
ment for nSMase function during the biogenesis of flaviviruses.
Interferencewith nSMase function reduces flavivirus release
from infected cells. The effect of the nSMase inhibitor GW4869
onWNV infectionwas assayed in twomammalian cell lines (HeLa
FIG3 Treatmentwith BFAorGCA impairs the secretion of RSPs into the culturemedium. (A)RSP release into the culturemediumbyHeLa3-WNVcells treated
(4 h) with the drugs was analyzed by enzyme-linked immunodot assay using amonoclonal antibody against the E glycoprotein. (B)Quantification of the amount
of RSPs released into the culture medium by treated HeLa3-WNV cells from panel A. For each drug concentration, the cellular ATP content is indicated as an
indicator of cell viability upon drug treatment. (C) Localization of theWNV E glycoprotein in infected HeLa cells treated with Golgi complex-disrupting agents.
HeLa3-WNV cells were treated with 10 "MBFA or GCA for 4 h. Immunofluorescence was performed using a monoclonal antibody directed against the WNV
E glycoprotein (red) in combination with a rabbit polyclonal antibody against mannosidase II (green) to stain the Golgi complex. Nuclei were stained with
ToPro3 (blue). The panels in the rightmost column display E glycoprotein staining with false coloring from dark purple to bright yellow by use of the fire lookup
table (LUT) scheme to highlight differences in the intensities of the signals. Bars, 10 "m.
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and Vero) and one mosquito cell line (C6/36) (Fig. 6A to C).
Treatment with GW4869 at concentrations of !5 "M signifi-
cantly inhibited the release of infectious WNV in these three cell
lines, confirming the requirement for nSMase for the production
of WNV in both mammalian and insect cells. The effect of this
inhibitor on infection with Usutu virus (USUV), a related emerg-
ing flavivirus, was also tested in HeLa cells (Fig. 6D). In these
experiments, inhibition of USUV similar to that of WNV at drug
concentrations of !5 "M was observed. To analyze whether the
requirement for nSMase function for virus productionwas shared
by other unrelated arboviruses, the effect of GW4869 on infection
with the alphavirus Sindbis virus (SINV) was analyzed (Fig. 6E).
Interestingly, the release of SINV infectious particles from HeLa
cells was not inhibited butwas significantly increased by treatment
with GW4869. This enhancing effect on virus titer was similar to
that previously reported when SINV infection was performed in
cells exhibiting an altered SL content induced by depletion of acid
SMase, which was associated with an increase in virion infectivity
(54). We next addressed the effect of depletion of nSMase2 on
infection with these three viruses by transfection with specific
siRNA (Fig. 6F). Silencing of nSMase2 expression significantly
inhibited the production of both WNV and USUV to an extent
comparable to that produced by treatment with GW4869. Con-
versely, a significant increase in SINV titer was found in cells
treated with siRNA against nSMase2. Therefore, these observa-
tions confirm the results obtained with GW4869 and highlight the
involvement of nSMase function during flavivirus infection.
Inhibition of nSMase activity reduces WNV-induced mem-
brane budding. The mechanism behind the reduction of WNV
growth upon nSMase inhibition using GW4869 was further
studied. The amount of viral particles released into the culture
medium showed a significant reduction, as determined by an
enzyme-linked immunodot assay analyzing the levels of E gly-
coprotein secreted in cells treated with GW4869 (Fig. 7A). This
result was consistent with the decrease in RSP and infectious virus
release observed (Fig. 5A and 6A). Analysis of infected cells treated
with GW4869 by immunofluorescence and confocal microscopy
showed an accumulation of E glycoprotein colocalized with the
ER marker calnexin (Fig. 7B). To rule out the possibility that the
effect of GW4869 on the biogenesis of WNV occurred in a step
after virus assembly or maturation, the amount of cell-associated
infectious virus or infectious virus released into the medium was
determined for cells treated with GW4869 (Fig. 7C). Whereas
treatment with GW4869 significantly reduced the amount of in-
fectiousWNV released, it did not induce an accumulation of cell-
associated infectious virus. When the amounts of cell-associated
viral RNA and viral RNA released into the mediumwere analyzed
(Fig. 7D), a significant reduction of viral RNA levels in the culture
mediumof cells treatedwithGW4869was observed. Conversely, a
significant accumulation of cell-associated viral RNAwas noticed.
Overall, these results are compatible with a reduction in the
amount of infectious virus released with a concomitant accumu-
lation of viral RNA but not the amount of infectious particles
inside GW4869-treated cells, a result which suggests that inhibi-
tion of nSMase function alters a process of flavivirus biogenesis
before the assembly and/or maturation of infectious particles. In-
terestingly, the extent of the inhibition of PFU release (about 60%;
Fig. 7C) was higher than the extent of the inhibition of total par-
ticle or viral RNA release (about 40%; Fig. 7A and D). This could
suggest that GW4869 not only decreases the amount of released
viral particles but also elevates the proportion of secreted nonin-
fectious particles.
As the inhibition of nSMase function can interfere with intracel-
lular budding processes, the effect of GW4869 on virus-mediated
budding was analyzed. To this end, infected cells were treated with
GW4869 and analyzed by transmission electron microscopy (Fig.
7E). Cells treatedwith the nSMase inhibitor displayed ultrastructural
features associatedwithflavivirus infection, i.e., the formationofVPs
FIG 4 Lipid composition of WNV RSPs and virions. (A) GPL and SL compositions of WNV RSPs and virions. The content of individual lipid classes of total
HeLa cells and WNV RSPs or virions was determined by summing the absolute abundances of all species identified. Values are standardized to the mole
percentage of all membrane lipids detected in the sample. Values multiplied by 10 for visibility are indicated. (B) Individual lipid species whose levels were
significantly altered in virions or RSPs in comparison to their levels in total cellular membranes. Data are presented as the mean' SD. Statistically significant
differences are indicated: *, P& 0.05.
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and thepresenceof electron-densevirions.VPsareproducedbybud-
ding into the ER, and the abundance of these structures can be quan-
tified by transmission electronmicroscopy in flavivirus-infected cells
(55).According to this view, these structureswereanalyzed todirectly
evaluate the effect of nSMase inhibition on viral budding. Themean
diameter of the virus-induced vesicles detected inside theVPs (about
80 nm) in control and GW4869-treated cells was indistinguishable
(Fig. 7F). However, when the number of vesicles inside VPs was
scored, a significant reduction in the number of vesicles inside each
VPinGW4869-treatedcells relative to thenumber incontrol infected
cellswasnoted(meannumbersofvesiclesperVP,1.9'0.2and5.8'
0.6, respectively; Fig. 7G), supporting the suggestion that viral bud-
ding into the ER was reduced upon inhibition of nSMase function.
DISCUSSION
Our results illustrate the alteration of the content of a wide
variety of lipid metabolites inWNV-infected cells. The increase
in the cellular content of PC, lysophospholipids (lyso-PC), SM,
and CER in HeLa cells infected with WNV is consistent with
previous results with mosquito cells infected with DENV (26).
Our analysis also revealed the enrichment of p-PC, p-PE, and
dhCER in WNV-infected cells. Apart from PC, which is a cy-
lindrical lipid, the rest of the lipids whose levels were found to
be increased in WNV-infected cells were conical. The increase
in the levels of these conical lipids could be related to their roles
in the establishment and maintenance of the cellular mem-
brane curvature necessary for proper viral replication complex
assembly, as well as for virion envelopment. The enrichment of
unsaturated PC species in DENV-infected cells has been sug-
gested to be associated with the development of more fluidic
membranes (26). Supporting this idea, all PC species whose
levels were increased in WNV-infected cells were unsaturated.
Likewise, the observed enrichment of SLs (CER, dhCER, and
SM) inWNV-infected cells is also compatible with the require-
FIG 5 Impairment of nSMase function inhibits the release of RSPs. (A to C) Treatment with the nSMase inhibitor GW4869 (A), spiroepoxide (B), or
glutathione (C) impairs the release of RSPs by HeLa3-WNV cells. The content of RSPs in the culture medium of cells treated (for 4 h) with the drugs was
determined by enzyme-linked immunodot assay using a monoclonal antibody against the E glycoprotein. The amount of RSPs determined by enzyme-
linked immunodot assay was quantified, and the cellular ATP content for each drug concentration is shown in the graphs. (D) Depletion of nSMase2 by
RNA interference. HeLa3-WNV cells were transfected with universal negative-control siRNA or with siRNA against nSMase2 for 48 h, and the amount of
nSMase2, E glycoprotein, and #-actin in cell lysates was analyzed by Western blotting using specific antibodies. RSP release into the culture medium after
4 h of incubation in cells transfected for 48 h with siRNA was analyzed by enzyme-linked immunodot assay using an anti-E antibody. (E) Quantification
of the amount of RSPs released into the culture medium by HeLa3-WNV cells transfected with siRNA control or against nSMase2 from panel D. The
cellular ATP content for each drug concentration is shown as an indicator of cell viability upon drug treatment. (F) Immunofluorescence analysis of the
expression of the WNV E glycoprotein in HeLa3-WNV cells transfected with siRNAs. HeLa or HeLa3-WNV cells transfected as described in the legend to
panel D were subjected to immunofluorescence analysis using an antibody directed against E glycoprotein (green) and observed by confocal microscopy.
Nuclei were stained with ToPro3 (blue). The panels on the right display E glycoprotein staining with false coloring from dark purple to bright yellow by
use of the fire lookup table (LUT) to highlight differences in the intensity of the signal. Bars, 10 "m. Data are presented as the mean ' SD. Statistically
significant differences are indicated: *, P & 0.05; **, P & 0.005.
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ment for these molecules in the membranes where virus repli-
cation and assembly take place. According to this hypothesis, it
has been documented that DENV and hepatitis C virus repli-
cation complexes are enriched in SLs (17, 26).
To identify the potential roles of the lipid classes analyzed in
the biogenesis of WNV particles, the proportion of each lipid in
both purified virions and RSPs was analyzed. All lipid classes an-
alyzed, including PS, which has been shown to play a functional
role during flavivirus entry, were detected in the envelopes of
WNV and RSPs (11). The high degree of similarity between the
lipid composition of RSPs and virions, along with their parallel
mechanisms of formation, reinforces the view that RSPs are a
valuable tool for the study of lipid involvement during the biogen-
esis of flaviviruses.
We next addressed the question of whether the lipid composi-
tion of the WNV envelope was similar to that of total host cell
membranes or if it reflected that of a particular membrane do-
main, following an approach similar to the approaches used for
the characterization of other viral envelopes (7, 10). This analysis
indicated that the envelopes of both RSPs and virions were en-
riched in SM and exhibited a reduction in the content of PC com-
pared to that of total cellularmembranes. Similar features, such as
an increase in the SM (or other SL) content and a depletion of PC,
have also been observed in the lipid envelopes of human immu-
nodeficiency virus type 1 (HIV-1) and influenza virus (7, 9). On
the contrary, the rhabdovirus vesicular stomatitis virus and the
alphavirus Semliki Forest virus exert little lipid selection when
they acquire their envelopes (8). The characteristics of the WNV
envelope also differed from those of the hepatitis C virus envelope,
which more closely resembles the composition of very low- and
low-density lipoproteins (10). Enrichment in SLs and a reduction
of PC levels are characteristics of liquid ordered membrane mi-
crodomains or membrane rafts (7, 9, 18, 56). Since membrane
raft-like microdomains, including those located in the ER (57),
are usually cholesterol enriched (7, 9, 18, 56), our findings could
be connected to the role(s) of membrane microdomains enriched
in cholesterol in flavivirus infections (28, 31, 58–60). SL-enriched
membrane microdomains have functional properties directly
linked to their lipid composition, such as coalescence and the
promotion of budding processes during virus assembly (7, 9) or
exosome biogenesis (18). Indeed, flavivirus assembly by invagina-
tion of ER membrane shares topological features with the forma-
tion of exosomes, since both processes mainly consist of budding
outward from the cell cytoplasm. Supporting this hypothesis, the
parallelism between viral budding processes and exosome biogen-
esis has already been documented (61, 62). An important point
that must also be considered in these analyses is that in the RSP
system, HeLa3-WNV cells express viral prM and E proteins in the
absence of any other viral protein. Since viral nonstructural pro-
teins (such as NS4A) induce membrane proliferation (63, 64),
FIG 6 Impairment of nSMase function inhibits the release of WNV. (A to C) Treatment with the nSMase inhibitor GW4869 reduces WNV production in
mammalian and insect cells. HeLa (A), Vero (B), or C6/36 (C) cells were infected with WNV (MOI, 1 PFU/cell) and treated with the indicated drug, and the
amount of infectious virus released into the culturemediumwas determined by plaque assay at 24 h p.i. The cellular ATP content of uninfected cells treated with
the different concentrations of the drug is indicated in all graphs as an estimate of cell viability upon drug treatment. (D) Treatment withGW4869 reducesUSUV
production. HeLa cells were infected with USUV (MOI, 1 PFU/cell), and the amount of infectious virus released was determined as described in the legends to
panels A toC. (E) TreatmentwithGW4869 increases SINVproduction.HeLa cells were infectedwith SINV (MOI, 1 PFU/cell), and the amount of infectious virus
released into the culturemediumwas determined by plaque assay (8 h p.i.). (F) Effect of nSMase2 depletion by siRNAonWNV,USUV, and SINV infection.HeLa
cells were transfected with a universal negative siRNA control or with siRNA against nSMase2 for 48 h and infected withWNV, USUV, or SINV, and the amount
of virus released into the culture medium was analyzed as described in the legend to panels A to C. Data are presented as the mean' SD. Statistically significant
differences are indicated: *, P& 0.05; **, P& 0.005.
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their expression is expected to modify cellular lipids in infected
cells. In fact, modification of cellular lipids upon infection with
WNV was confirmed by analysis of the lipids in WNV-infected
cells. Therefore, it is foreseeable that the lipid components from
WNV-infected cells can differ from those of RSP-producing cells,
which may explain some of the minor differences between RSPs
and virions found in the analysis, such as the amount of p-PC or
variations in the specific lipid species found between RSPs and
FIG 7 Inhibition of nSMase function reduces WNV-induced budding. (A) Treatment with the nSMase inhibitor GW4869 reduces WNV release. HeLa cells were
infectedwithWNV(MOI, 1PFU/cell) and treatedwith the drug, and the amount of virus particles released into the culturemediumwas estimatedby an enzyme-linked
immunodotassayusingamonoclonal antibodyagainst theEglycoproteinat24hp.i. (B)Localizationof theWNVEglycoprotein inHeLacells infectedwithWNV(MOI,
1 PFU/cell) and treated with 10 "M GW4869. Immunofluorescence was performed using a monoclonal antibody directed against the E glycoprotein (green) in
combination with a rabbit polyclonal antibody against calnexin (red) to stain the ER at 24 h p.i. Nuclei were stained with ToPro3 (blue). The panels in the rightmost
columndisplay E glycoprotein stainingwith false coloring fromdark purple to bright yellow by use of the fire lookup table (LUT) scheme to highlight differences in the
intensities of the signals. Bars, 10"m. (C) Impairment of nSMase functionwithGW4869doesnot increase the amount of cell-associatedWNV.HeLa cellswere infected
withWNV(MOI, 1PFU/cell), and the amountof virus either releasedor cell associatedwasdeterminedbyplaqueassay at 24hp.i. (D)Theamountof viralRNAreleased
into the culturemediumor cell associatedwas determined by quantitative RT-PCR in cells infected and treated as described in the legend to panel C. (E) Representative
electron micrographs at 24 h p.i. of cells infected withWNV (MOI, 10 PFU/cell) and treated or not treated (control) with 10 "MGW4869 showing the formation of
vesicle packets (VPs) containing virus-induced vesicles (Ve) and electron-dense virions (Vi). Bar, 200 nm. (F)Diameter of virus-induced vesicles detected in the VPs of
cells infectedand treatedornot treatedwith10"MGW4869.Eachpoint represents an individual virus-inducedvesicle. Solid linesdenote themeanvesiclediameter. (G)
Number of virus-induced vesicles per VP detected in the VPs of cells treated or not treated with 10 "MGW4869. Each point represents the number of virus-induced
vesicles detected in an individualVP. Solid lines denote themeannumber of virus-induced vesicles perVP.Unless specified otherwise, data are presented as themean'
SD. Statistically significant differences are indicated: **, P& 0.005.
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virions. However, the major features observed (a reduction of PC
and enrichment in SM) were common between the two systems,
supporting the use of RSPs as a model to study flavivirus bio-
genesis.
The hydrolysis of SM by nSMases converts SM into CER, a
compound with a smaller head size (49). CER induces an asym-
metric membrane tension and segregates into highly ordered do-
mains triggering modifications of membrane shape (65). These
properties have been associated with the promotion ofmembrane
bending and budding processes both on model membranes (50)
and in living cells (18, 51, 66, 67). In this scenario, pharmacolog-
ical inhibition of nSMase activity, which catalyzes the hydrolysis
of SM to CER, impaired the release of RSPs into the culture me-
dium and reduced the level of production of infectious particles of
WNV and the related flavivirus USUV, which parallel the effects
on the production of certain types of exosomes that have been
documented (18, 66, 67). Supporting this observation, depletion
of nSMase2 by RNA interference inhibited the release of RSPs and
the production of WNV and USUV. On the contrary, an increase
in the titer of another arbovirus (SINV) was observed upon inhi-
bition of nSMase function, therefore indicating that the require-
ment for the conversion of SM to CER during the biogenesis of
flavivirus is not shared by this alphavirus. Consistent with these
results, lipid recruitment during alphavirus envelopment has been
proposed to be a process with a low level of selection (8), in con-
trast to the enrichment of SM and the reduction in the level of PC
described here for the flavivirus envelope. Alphavirus biogenesis is
dependent on the functionality of the secretory pathway, since
viral envelope glycoproteins must traffic from the ER through the
Golgi complex to the plasma membrane for viral budding (68).
Thus, the lack of inhibition of SINV release upon pharmacological
inhibition of nSMase2 or siRNA-mediated depletion of this en-
zyme shows the functionality of the secretory pathway in cells
treated with GW4869 or siRNA against nSMAse2. This observa-
tion further supports the specific involvement of nSMase2 in the
biogenesis of flavivirus. Although other nSMases are expected to
be functional in cells depleted of nSMase2 by siRNA, the degree of
inhibition (of RSPs and virion release) achieved with specific
siRNA against nSMase2 was similar to that observed using the
nSMase inhibitor GW4869, thus reinforcing the idea that
nSMase2 is the main nSMase involved in flavivirus biogenesis.
When the effect of nSMase inhibition on virus biogenesis was
analyzed by several approaches, a reduction of the amount of vi-
rus-induced vesicles inside VPs in cells treatedwith an inhibitor of
nSMase function was noticed. Since these vesicles are associated
with flavivirus replication and virion envelopment (5, 43, 55), this
observation supports the role of SM conversion to CER in virus-
induced budding. The diameter of the vesicles found in cells
treatedwith the nSMase inhibitorwas similar to that of the vesicles
observed in untreated cells. A possible explanation for this phe-
nomenon could be that vesicle components others than lipids
(presumably, viral proteins) also contribute to vesicle formation,
although the inhibition of nSMase activity makes this assembly
less efficient. Accordingly, an important role for viral glycopro-
teins in the induction andmaintenance ofmembrane curvature in
flavivirus virions has been proposed (69). Since budding mecha-
nisms are usually driven by a regulated combination of proteins
and lipids (70), our results indicate that, indeed, the lipid compo-
sition of the flavivirus envelope also contributes to this process.
Interestingly, the dhCER content was found to be increased in
WNV-infected cells, as it was one of the molecular species en-
riched in the viral envelope (dhCER, 24:0). This metabolite is an
intermediate in the SL biosynthetic pathway (49), and the pres-
ence of increased levels of dhCERpoints to the upregulation of the
de novo synthesis of SLs withinWNV-infected cells, as reported in
other virus models (17, 26). On the other hand, the involvement
of nSMase in WNV and USUV biogenesis indicates that the pro-
duction of CER by the hydrolysis of SM is also required during
infection with these pathogens, providing evidence of the
functionality of these two pathways for CER production in flavi-
virus-infected cells. However, one must be cautious with the in-
terpretation of the reason for the increase in CER levels in WNV-
infected cells, since this can be due to different factors, such as the
induction of ER stress (71) mediated by the activation of the un-
folded protein response in flavivirus-infected cells (72).
In summary, our results provide additional evidence of the
complex degree of manipulation of host cell lipid metabolism by
WNV. These results also unveil a connection between SL metab-
olism and flavivirus biogenesis. The findings presented here could
contribute to the further development of lipid-based antiviral
strategies to combat these pathogens.
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de	 éstos	 en	 el	 ciclo	 de	 vida	 viral.	 En	 este	 sentido,	 se	 sabe	 que	 los	 primeros	 pasos	 en	 la	
biogénesis	lipídica	implican	la	síntesis	y	elongación	de	ácidos	grasos,	la	cual	es	la	base	para	la	
síntesis	 de	 lípidos	 más	 complejos.	 Por	 tanto,	 en	 el	 Artículo	 II,	 analizamos	 el	 efecto	 de	
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infecciones	 de	 células	 (Vero,	 HeLa	 y	 C6/36)	 con	 virus	 (VNO	 y	 USUTU)	 y	 su	 tratamiento	 con	
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Finalmente	 llevé	 a	 cabo	 parte	 del	 análisis	 de	 los	 datos	 y	 contribuí	 a	 la	 escritura	 del	 artículo	
detallando	los	resultados	obtenidos	
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In	 line	with	our	previous	 investigation	 in	host	 cell	 factors	 inhibition	 (Article	 I),	we	 continued	
manipulating	 cellular	 lipids	 in	 the	 context	 of	 flavivirus	 infection	 with	 the	 aim	 of	 better	
understanding	their	requirement	in	the	virus	life	cycle.	In	this	regard,	it	is	known	that	the	first	
steps	of	lipid	biogenesis	involve	the	synthesis	and	elongation	of	fatty	acids,	which	provide	the	
cornerstone	 for	 the	 synthesis	 of	 more	 complex	 lipids.	 Therefore,	 in	 Article	 II	 the	 effect	 of	
inhibitors	of	 the	enzyme	acetyl-Coenzyme	A	carboxylase	 (ACC)	on	the	 infection	by	WNV	was	
analyzed,	 as	 ACC	 catalyze	 the	 carboxylation	 of	 acetyl-CoA	 to	 malonyl-CoA,	 one	 of	 the	 first	
steps	of	lipid	synthesis.	Article	II	shows	that	ACC	inhibitors	alter	the	cellular	lipid	composition	
and	 reduce	 the	 level	 of	WNV	and	USUV	 infection	 in	 cultured	 cells,	 pointing	 to	 the	ACC	as	 a	
potential	druggable	cellular	 target	suitable	 for	antiviral	development	against	multiple	viruses	
within	the	same	genus	or	family.		
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Modification of the Host Cell Lipid Metabolism Induced by
Hypolipidemic Drugs Targeting the Acetyl Coenzyme A Carboxylase
Impairs West Nile Virus Replication
Teresa Merino-Ramos,a Ángela Vázquez-Calvo,a Josefina Casas,b Francisco Sobrino,c Juan-Carlos Saiz,a Miguel A. Martín-Acebesa,c
Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spaina; Department of Biomedicinal Chemistry,
Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spainb; Department of Virology and Microbiology, Centro de Biología Molecular Severo Ochoa
(CSIC-UAM), Madrid, Spainc
West Nile virus (WNV) is a neurotropic flavivirus transmitted by the bite of mosquitoes that causes meningitis and encephalitis
in humans, horses, and birds. Several studies have highlighted that flavivirus infection is highly dependent on cellular lipids for
virus replication and infectious particle biogenesis. The first steps of lipid synthesis involve the carboxylation of acetyl coenzyme
A (acetyl-CoA) to malonyl-CoA that is catalyzed by the acetyl-CoA carboxylase (ACC). This makes ACC a key enzyme of lipid
synthesis that is currently being evaluated as a therapeutic target for different disorders, including cancers, obesity, diabetes, and
viral infections. We have analyzed the effect of the ACC inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA) on infection byWNV.
Lipidomic analysis of TOFA-treated cells confirmed that this drug reduced the cellular content of multiple lipids, including
those directly implicated in the flavivirus life cycle (glycerophospholipids, sphingolipids, and cholesterol). Treatment with
TOFA significantly inhibited the multiplication ofWNV in a dose-dependent manner. Further analysis of the antiviral effect of
this drug showed that the inhibitory effect was related to a reduction of viral replication. Furthermore, treatment with another
ACC inhibitor, 3,3,14,14-tetramethylhexadecanedioic acid (MEDICA 16), also inhibitedWNV infection. Interestingly, TOFA
andMEDICA 16 also reduced the multiplication of Usutu virus (USUV), aWNV-related flavivirus. These results point to the
ACC as a druggable cellular target suitable for antiviral development againstWNV and other flaviviruses.
West Nile virus (WNV) is a mosquito-borne neurotropic fla-vivirus responsible for recurrent outbreaks of meningitis
and encephalitis affecting humans, horses, and birds in Africa,
Europe, Asia, Oceania, and America (1). A great effort has been
devoted in the past several years to decipher themolecular biology
of WNV and its interaction with the host immune system (2, 3).
Nevertheless, no licensed vaccine or therapy for human use
against this pathogen is yet available.
The flavivirus life cycle (including that of WNV) is intimately
associated with host cell lipids. The replication of the viral
genomic RNA and flavivirus nascent virion assembly take place in
modified membranes from the endoplasmic reticulum (4–7). To
build an adequate microenvironment to support viral replication
and particle biogenesis, flaviviruses rearrange host cell lipid me-
tabolism by promoting the synthesis and accumulation of specific
cellular lipids (i.e., fatty acids, glycerophospholipids [GPLs], sph-
ingolipids [SLs], and cholesterol) (8–15). Thismakes the pharma-
cological manipulation of cellular lipids an attractive antiviral
strategy against WNV and related flaviviruses (13, 14, 16, 17).
The first steps of lipid biogenesis involve the synthesis and
elongation of fatty acids, which provide the building blocks for the
synthesis of more-complex lipids. Hence, fatty acid synthesis and
elongation have become key targets for antiviral therapy (13, 18,
19). Regarding the flaviviruses, the pharmacological blockage of
the fatty acid synthase FASN (which catalyzes the synthesis of
palmitate from acetyl coenzyme A [acetyl-CoA] and malonyl-
CoA into long-chain saturated fatty acids) reduced the viral rep-
lication (11, 13). The enzyme preceding FASN in the fatty acid
biosynthetic route is the acetyl-CoA carboxylase (ACC), which
catalyzes the carboxylation of acetyl-CoA tomalonyl-CoA.Due to
its rate-limiting role in fatty acid synthesis, ACC is currently a
target of increasing interest within the pharmacological industry
(20, 21). However, to our knowledge, the involvement of ACC in
the replication of WNV, or other related flaviviruses, has not yet
been evaluated.
In this work, we have shown that ACC inhibitors alter the
cellular lipid composition and reduce the levels ofWNV infection
in cultured cells. Furthermore, infection by Usutu virus (USUV; a
related emerging flavivirus [22]) was also inhibited by the drugs
used. Our results point to ACC as a potential druggable antiviral
target against WNV and related flaviviruses.
MATERIALS AND METHODS
Cells, viruses, infections, and virus titrations. All infectious virus ma-
nipulations were performed in biosafety level 3 (BSL-3) facilities. Vero,
HeLa, and Neuro2a (N2a) cell lines were cultured as described previously
(10, 23). Cells were incubated with the corresponding virus, WNV strain
NY99orUSUV strain SAAR-1776 (24), for 1 h at 37°C; viral inoculumwas
removed; and infected cells were incubated in culturemedium containing
1% fetal bovine serum (time that was considered 1 h postinfection [p.i.]).
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Viral titer was determined 24 h p.i. by plaque assay in semisolid agarose
mediumusingVero cells (25). Themultiplicity of infection (MOI) used in
each experiment was expressed as PFU per cell and is indicated in the
corresponding figure legend.
Drug treatments. 5-(Tetradecyloxy)-2-furoic acid (TOFA) and
3,3,14,14-tetramethylhexadecanedioic acid (MEDICA 16) were from
Sigma (St. Louis, MO). Control cells were treated in parallel with the
same amount of drug vehicle (dimethyl sulfoxide [DMSO]). Unless
otherwise specified, drugs were added after the first hour of infection,
when viral inoculum was replaced by medium containing 1% fetal
bovine serum. Drug toxicity was examined by measuring the cellular
ATP content with the CellTiter-Glo luminescent cell viability assay
(Promega, Madison, WI).
Microscopy. Antibodies and procedures used for immunofluores-
cence and confocalmicroscopy, as well as sample processing for transmis-
sion electron microscopy, have been described previously (11). The anal-
ysis of fluorescence intensity was performed using ImageJ software (http:
//imagej.nih.gov/ij/).
Quantitative RT-PCR.Viral RNAwas extracted from the supernatant
of infected cultures with the Speedtools RNA virus extraction kit (Bioto-
ols, Madrid, Spain). For quantification of cell-associated viral RNA, su-
pernatants from infected cells were removed, cell monolayers were sub-
jected to three freeze-thaw cycles, and RNA was extracted as described
above. The amount of viral RNAwas determined by real-time fluorogenic
reverse transcriptase PCR (RT-PCR) as reported previously (26). The for-
ward primer 5=-CAGACCACGCTACGGCG-3=, the reverse primer 5=-C
TAGGGCCGCGTGGG-3=, and the probe 5=-FAM (6-carboxyfluores-
cein)-TCTGCGGAGAGTGCAGTCTGCGAT-3=-BHQ-1 (black hole
quencher 1) were used. Quantification was performed using the High
Scriptools-Quantimix Easy Probes kit (Biotools) and Rotor-Gene RG-
3000 equipment (Corbett Research). Genomic equivalents to PFU per
milliliter were calculated by comparison with 10-fold serial dilutions of
viral RNA extracted from previously titrated samples (27).
Lipid analysis. Vero cells were treated with 10 !g/ml TOFA or with
DMSO and infected or not with WNV at a high MOI (50 PFU/cell) to
ensure that all cells were initially infected. Cells were detached from the
flasks and resuspended in phosphate-buffered saline (PBS) at 24 h p.i.
(10). Infections were performed in serum-free medium to avoid possible
biases introduced by lipids present in the serum. The number of cells in
each sample was determined, and aliquots containing 106 cells were sub-
jected to lipid extractions. Procedures for lipid extractions, identification,
and quantification by mass spectrometry have been previously described
(10, 28, 29). Annotation of lipid species followed the recommendations
indicated in reference 30. Glycerophospholipids, diacylglycerol (DAG),
triacylglycerol (TAG), and cholesteryl esters (CHOL) were annotated as
“lipid subclass” followed by “total fatty acyl chain length:total number of
unsaturated bonds” (e.g., PC 36:2). Plasmalogens were annotated as de-
scribed above, except that “p” was added. Lysophospholipids were anno-
tated as described above except that “lyso” was added. Sphingolipids were
annotated as “lipid subclass” followed by “total fatty acyl chain length:
total number of unsaturated bonds” (e.g., CER24:1). If the sphingoid base
residue was dihydrosphingosine, the lipid class contained a “dh” prefix.
For ceramide derivatives containing sugar moieties, the lipid class con-
tained a “hex” prefix to denote monohexosylceramides (glucosylcer-
amides and galactosylceramides) or a “lac” prefix for lactosylceramides.
Data analysis. Data are presented as means " standard deviations
(SDs). Analysis of variance (ANOVA) and Student’s t test were performed
with SPSS 15 (SPSS Inc., Chicago, IL). Bonferroni’s correction was ap-
plied for multiple comparisons. Statistically significant differences were
considered at a P value of#0.05.
RESULTS
Effect of inhibition of ACC on cellular lipid content.TOFA is an
inhibitor of ACC that has been used to evaluate the involvement of
this enzyme in infections by a variety of viruses (18, 31–34). To
determine its effect on the cellular lipid content, Vero cells were
treated with TOFA for 24 h and the lipid content was analyzed by
mass spectrometry and compared to that of control cells treated in
parallel with the same amount of drug solvent (Fig. 1). These
experiments were performed in serum-freemedium to avoid pos-
sible interference of serum lipids in the analysis. Eighteen lipid
classes (3 neutral lipids [NLs], 10 glycerophospholipids [GPLs],
and 5 sphingolipids [SLs]) were included in the analysis (Fig. 1A).
A significant decrease in the amount of NLs (triacyclglycerol
[TAG], diacylglycerol [DAG], and cholesteryl esters [CHOL])was
observed in TOFA-treated cells (Fig. 1A). Among SLs, ceramide
(CER), monohexosylceramide (hexCER), lactosylceramide (lac-
CER), sphingomyelin (SM), and dihydroSM (dhSM) were ana-
lyzed. The amount of CER and its derivatives containing sugar
moieties (hexCER and lacCER) was significantly reduced in
TOFA-treated cells. In contrast, the content of SM and dhSMwas
not significantly reduced by treatment with TOFA (Fig. 1A). To
evaluate the effect of TOFA on the cellular GPLs, we analyzed the
content of phosphatidylcholine (PC), 1-alkenyl-2-acyl-glycero-3-
phosphocholine (referred to as plasmalogen-PC [p-PC; plasme-
nylcholine]), 1-acyl-glycero-3-phosphocholine (lyso-PC), lyso-
plasmenylcholine (lyso-p-PC), phosphatidylethanolamine (PE),
1-alkenyl-2-acyl-glycero-3-phosphoethanolamine(p-PE),1-acyl-
glycero-3-phosphoethanolamine (lyso-PE), lyso-p-PE, phospha-
tidylserine (PS), and 1-acyl-glycero-3-phosphoserine (lyso-PS). A
significant decrease in the amount of PC, p-PC, PE, p-PE, and PS
was noted in TOFA-treated cells, whereas no significant change in
the lysolipids analyzed (lyso-PC, lyso-p-PC, lyso-PE, lyso-p-PE,
and lyso-PS) was induced by treatment with TOFA. The lack of
reduction in the amount of lysolipids can be explained because
lysolipids are produced by the action of phospholipases (35)
rather than by a biosynthetic process. Among the 18 lipid classes
analyzed, a total of 208 different molecular species could be iden-
tified (Fig. 1B to H). From these species, 89 remained unaltered in
TOFA-treated cells (42.8%) and a significant increase was ob-
served in only three of the identified species (1.4%) that corre-
sponded to lysolipids (Fig. 1H). Such an increase could likely cor-
respond to a stress response including the activation of
phospholipases (35). On the other hand, on 116 lipid species
(55.8%) a significant reduction was noted, confirming that inhi-
bition of ACC using TOFA has a major impact on lipid synthesis,
reducing the content of a wide variety of cellular lipids.
TOFA inhibits infection byWNV and USUV.Vero cells were
infected with WNV, and different concentrations of TOFA were
added 1 h p.i. to avoid possible interference of the drug with virus
entry. TOFA inhibited WNV multiplication in a dose-dependent
manner (Fig. 2A and B). Both the production of infectious parti-
cles (Fig. 2A) and the release of genome-containing particles to the
culture medium (Fig. 2B) were significantly reduced by TOFA.
The toxicity of the drug was analyzed in parallel by determination
of the cellular ATP content (Fig. 2C), confirming that the concen-
trations of TOFA tested inhibited WNV infection, exerting small
effects on cell viability. A time course analysis of the production of
infectious virus revealed that TOFA inhibited the multiplication
ofWNV also at time points as early as 12 h p.i. (Fig. 2D). Next, the
effect of TOFA onWNV infection in other cell lines was tested. An
inhibition similar to that observed on Vero cells (Fig. 2A and B)
was noted in TOFA-treated HeLa cells (Fig. 2E and F). Consider-
ing that WNV is a neurotropic virus, the effect of TOFA was also
assayed in the neuroblastoma cell line N2a. TOFA also inhibited
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the infection of WNV in N2a cells, showing also a minor impact
on cell viability (Fig. 2G and H). When N2a cells were used to
address the effect of TOFAaddition to infected cultures at 1, 4, and
8 h p.i., a significant inhibition ofWNV infection was observed in
all cases (Fig. 2I), indicating that treatment with TOFA impaired
WNV infection after virus entry. Even more, TOFA also signifi-
cantly reduced the production of USUV, a related flavivirus, in
Vero, HeLa, and N2a cells (Fig. 2J). These results suggest that the
FIG1 Alterationsof cellular lipid contentupon inhibitionofACCusingTOFA. (A)Relative amounts of different classes ofNLs, SLs, andGPLs inVero cells treatedwith
10 !g/ml TOFA or not treated (DMSO) determined by mass spectrometry at 24 h after drug addition. The experiments were performed in serum-free medium.
Statistically significant differences are indicated: *, P# 0.05; **, P# 0.005. (B toH) Relative amounts of different lipidmolecular species (NLs [B], SLs [C], PC [D], PE
[E], PS [F], plasmalogens [G], and lysophospholipids [H]) in cells treatedwith TOFA as in panel A. Black bars denotemolecular species significantly altered (P# 0.05)
relative to control cells. Gray bars denotemolecular species not significantly changed relative to untreated cells. Bars corresponding to untreated cells have been omitted
from the figure for clarity. Dashed lines, mean value for each lipid in untreated cells. Data are presented as means" SDs (three replicates).
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inhibition of ACC can be also effective against other related flavi-
viruses.
TOFA inhibits the replicationofWNVgenome.The infection
with WNV induces marked changes in the intracellular mem-
brane architecture to create an appropriatemicroenvironment for
viral replication (7, 11). Hence, we analyzed the effect of TOFA on
Vero cells infected with WNV by means of transmission electron
microscopy (Fig. 3A). Mock-infected cells treated with TOFA or
not treated exhibited normal cellular architecture (Fig. 3A, upper
panels). In contrast, control infected cells not treated with TOFA
exhibited characteristic infection-associated ultrastructural alter-
ations, such as convoluted membranes (CM), vesicle packets
(VPs), and electron-dense virions (Vi) (Fig. 3A, lower left panel).
In infected cells treated with TOFA, Vi could be recognized but
properly arranged CM or VPs, such as those observed in control
cells, could not be detected. Instead, disordered VP-like materials
and small cumuli of membranous materials resembling CM were
observed (Fig. 3A, lower right panel). Since the replication of the
flavivirus genome takes place in the VP (4, 36), our observations
could indicate that the alteration of cellular lipids induced by
TOFA impaired the development ofWNV replication complexes.
To support this hypothesis, the amount of double-stranded RNA
(dsRNA) intermediates (a well-characterized marker of flavivirus
replication complex [4, 7]) was analyzed by immunofluorescence
in infected cells treated or not treated with TOFA (Fig. 3B). As
expected, no dsRNA was detected in uninfected cells, treated or
not treated with TOFA (Fig. 3B, upper panels). In contrast,
dsRNA was observed in both control and TOFA-treated cells in-
FIG 2 TOFA inhibitsWNV andUSUVmultiplication. (A) Reduction ofWNV infectious particle production in Vero cells treated with different concentrations
of TOFA. Cells were infected with WNV (MOI of 0.5 PFU/cell), and virus yield in culture supernatant was determined by plaque assay at 24 h p.i. (B)
Quantification by quantitative RT-PCR of genome-containing particles in culture supernatant of Vero cells infected as in panel A. (C) Evaluation of the toxicity
of TOFA on Vero cells by determination of cellular ATP content 24 h posttreatment. (D) Time course analysis of virus production in TOFA-treated cells. Vero
cells were infected withWNV (MOI of 1 PFU/cell) and treated with 10 !g/ml TOFA. The amount of infectious virus in the supernatant of infected cultures was
determined by plaque assay at different times p.i. (E) Reduction of WNV infectious particle production (24 h p.i.) in HeLa cells infected (MOI of 0.5 PFU/cell)
and treatedwith TOFA. (F) Evaluation of the toxicity of TOFAonHeLa cells 24 h posttreatment. (G) Reduction ofWNV infectious particle production (24 h p.i.)
inN2a cells infected (MOIof 0.5 PFU/cell) and treatedwithTOFA. (H)Evaluation of the toxicity of TOFAonN2a cells 24 hposttreatment. (I) Inhibition ofWNV
multiplication in N2a cells by adding TOFA at different times p.i. N2a cells were infected with WNV (MOI of 0.5 PFU/cell), and 10 !g/ml TOFA was added at
the indicated time points. Virus yield was determined by plaque assay at 24 h p.i. (J) Inhibition of USUV infection in different cell lines using TOFA. Vero, HeLa,
and N2a cells were infected with USUV (MOI of 0.5 PFU/cell) and treated with TOFA. Virus yield was determined by plaque assay at 24 h p.i. Data are presented
as means" SDs (three replicates). Statistically significant differences are indicated: *, P# 0.05; **, P# 0.005.
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fected with WNV. However, the intensity of the dsRNA fluores-
cence was lower in infected cells treated with TOFA than in con-
trol infected cells (Fig. 3B, lower panels). The quantification of this
signal confirmed a statistically significant reduction in the cellular
content of dsRNA intermediates in TOFA-treated cells (Fig. 3C).
Furthermore, the analysis by quantitative RT-PCR revealed that
treatment with TOFA induced a statistically significant dose-de-
pendent reduction in the amount of cell-associated viral RNA
FIG 3 Effect of TOFA on replication of WNV. (A) Intracellular membrane rearrangements in WNV-infected Vero cells observed by transmission electron
microscopy 24 h p.i. Upper panels show representative images of uninfected cells untreated (left) or treated with 10 !g/ml TOFA (right). Lower panels display
representative images of infected cells (MOI, 10 PFU/cell) untreated (left) or treated with TOFA (right). VP, vesicle packet; Vi, virion; CM, convoluted
membranes; ER, endoplasmic reticulum. Bars, 200 nm. (B) Visualization of intracellular dsRNA accumulation in cells infected with WNV (MOI, 10 PFU/cell)
and treated with 10 !g/ml TOFA at 24 h p.i. Cells were fixed and processed for immunofluorescence using monoclonal antibody to dsRNA J2 and a secondary
antibody coupled to Alexa Fluor 488 (green). Nuclei were stained with ToPro-3 (blue). Mock-infected cells processed in parallel are also included as a control.
Bars, 10 !m. (C) Quantification of the fluorescence intensity of dsRNA in cells infected and treated with TOFA as shown in panel B. (D) Amount of
cell-associated viral RNA in cell cultures infected withWNV (MOI of 0.5 PFU/cell) and treated with TOFA determined by quantitative RT-PCR at 24 h p.i. Data
are presented as means" SDs (three replicates). Statistically significant differences are indicated: *, P# 0.05; **, P# 0.005.
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(Fig. 3D). Taken together, these results suggest that the alteration
of cellular lipid content induced by TOFA impairs WNV replica-
tion complex assembly and hence viral replication.
TOFA reduces the lipid content of WNV-infected cells. The
amount of lipids in WNV-infected cells was analyzed by mass
spectrometry (Fig. 4). In this case, in order to simplify the analysis,
we focused on 9 lipid classes, including representativemembers of
NLs (CHOL), SLs (CER, SM, dhSM, hexCER, and lacCER), and
GPLs (PC, PE, and PS). These lipid classes included important
membrane components, some of which had been previously as-
sociated with different features of virus infection (8–10, 37, 38).
Relative to infected cells not treated with the drug, a significant
reduction in the content of CHOL, CER, hexCER, PC, PE, and PS
was observed in infected cells treated with TOFA (Fig. 4A). Over-
all, these results supported the idea that, as observed in uninfected
cells (Fig. 1), TOFA inhibited lipid synthesis in WNV-infected
cells. Among the 9 lipid classes compared, a total of 119 different
molecular species could be identified and analyzed (Fig. 4B to F).
FIG 4 Reduction of cellular lipid content in WNV-infected cells treated with TOFA. (A) Relative amounts of different lipid classes in Vero cells infected with
WNV (MOI of 50 PFU/cell) and treated with 10 !g/ml TOFA or not (DMSO), determined by mass spectrometry at 24 h p.i. The experiments were performed
in serum-free medium. Statistically significant differences are indicated: *, P# 0.05; **, P# 0.005. (B to F) Relative amounts of different lipid molecular species
(SLs [B], CHOL [C], PC [D], PE [E], and PS [F]) in cells infected with WNV and treated with TOFA as in panel A. Black bars denote molecular species
significantly altered (P# 0.05) relative to untreated infected cells. Gray bars denotemolecular species not significantly changed relative to untreated infected cells.
Bars corresponding to untreated infected cells have been omitted from the figure for clarity. Dashed lines, mean value for each lipid in untreated infected cells.
Data are presented as means" SDs (three replicates).
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A significant reduction of 59 molecular species was noted in in-
fected cells treated with TOFA (49.6% of species analyzed), 48 of
which (81%of species analyzed) were also significantly reduced in
uninfected cells treated with TOFA (Fig. 1). These findings indi-
cated that the lipid changes induced by TOFAwere similar in both
WNV-infected and uninfected cells.
MEDICA16 inhibits the infectionofWNVandUSUV.Treat-
ment of Vero cells with MEDICA 16, an ACC inhibitor different
from TOFA (39), also resulted in a dose-dependent inhibition of
the production of infectiousWNV(Fig. 5A) at concentrations that
did not severely impair the viability of the cells (Fig. 5B). The
quantification of genome-containing particles by quantitative
RT-PCR revealed that MEDICA 16 reduced the release of these
viral particles to the culture medium (Fig. 5C). Remarkably, the
extent of this inhibition was lower than the reduction produced in
virus yield (compare Fig. 5A andC). This could indicate that treat-
ment with MEDICA 16 was inducing the formation of noninfec-
tious genome-containingWNVparticles, a phenomenon that was
not observed in infected cells treated with TOFA, in which the
decrease in the production of infectious particles was similar to
the reduction in the release of genome-containing particles (Fig.
2). Moreover, the concentration of 50 !g/ml MEDICA 16 that
inhibited the production of infectious WNV and the release of
genome-containing particles did not inhibit accumulation of cell-
associated viral RNA within infected cells. However, a significant
reduction of viral replication was observed at a higher concentra-
tion of 70 !g/ml (Fig. 5D). Nevertheless, MEDICA 16 strongly
inhibited the infection with USUV (Fig. 5E), confirming that this
hypolipidemic agent can also inhibit the multiplication of WNV-
related flaviviruses.
DISCUSSION
Lipids play multifaceted roles during virus infection. In such sce-
narios, the pharmacological manipulation of cellular lipids can
reduce virus infection by different mechanisms. These mecha-
nisms include (i) the impairment of membrane rearrangements
associated with viral replication, (ii) the generation of an unfavor-
ablemetabolic environment for virus replication, or (iii) the alter-
ation of the viral envelope composition and the impairment of
viral particle assembly (8, 17, 18, 31).
Treatment with TOFA reduced the synthesis of multiple cellu-
lar lipids, including those previously described to be involved in
WNV infection, such as GPLs, SLs, and CHOL (8, 10, 15). Our
electron microscopy results showed that TOFA induced a reduc-
tion in the amount of membrane rearrangements associated with
WNV replication. In addition, quantitative RT-PCR analysis in-
dicated that this drug reduced the synthesis of viral RNA, which
was compatible with the reduction of the accumulation of dsRNA
intermediates observed by immunofluorescence in infected cells
treated with TOFA. Taken together, all these results suggest that
the inhibition of lipid synthesis exerted by TOFA could impair the
membrane rearrangements necessary for the replication ofWNV.
This mechanism of action would be similar to that recently re-
ported for hepatitis C virus in cells treated with an inhibitor of the
ACC (34). An additional point to be considered is that although
treatment with TOFA reduced the amount of multiple lipid spe-
cies, it also increased the amount of some lysolipids. Interestingly,
the production of these lysolipids could be related to an activation
of a stress response in TOFA-treated cells (35). The possible con-
FIG 5 MEDICA 16 inhibits WNV and USUV multiplication. (A) Reduction
ofWNV infectious particle production in Vero cells treated withMEDICA 16.
Cells were infectedwithWNV (MOI of 0.5 PFU/cell), and virus yield in culture
supernatant was determined by plaque assay at 24 h p.i. (B) Evaluation of the
toxicity ofMEDICA 16 onVero cells by determination of cellular ATP content
24 h posttreatment. (C)Determination by quantitative RT-PCRof the amount
of genome-containing particles in culture supernatant of Vero cells infected
with WNV (MOI of 0.5 PFU/cell) at 24 h p.i. (D) Amount of cell-associated
viral RNA in cell cultures infected with WNV (MOI of 0.5 PFU/cell) and
treated with MEDICA 16 determined by quantitative RT-PCR at 24 h p.i. (E)
Inhibition of USUV infection in Vero cells using MEDICA 16. Vero cells were
infected with USUV (MOI of 0.5 PFU/cell) and treated withMEDICA 16, and
virus yield was determined by plaque assay at 24 h p.i. Data are presented as
means " SDs (three replicates). Statistically significant differences are indi-
cated: *, P# 0.05; **, P# 0.005.
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tributions of this stress to the antiviral effect of TOFA still remain
to be evaluated.
In the case of the other ACC inhibitor tested, MEDICA 16, the
inhibition exerted by the lowest concentration of this drug assayed
(50 !g/ml) seemed to rely mainly on a reduction of infectious
virions rather than on RNA synthesis inhibition, although at a
high concentration (70 !g/ml) this drug also inhibited RNA rep-
lication. Blockage of infectious virus production has been de-
scribed for other viruses treated with drugs affecting lipid metab-
olism (31, 40). In this regard, it should be considered that
replication and assembly of viral particles are coupled processes in
flaviviruses (5). This may explain our results showing that the
alteration of lipidmetabolism could affect both processes. In con-
trast to what was described for other members of the Flaviviridae
family (41), there is no evidence, to our knowledge, of palmitoyl-
ation ofWNV proteins. Thus, palmitoylation does not seem to be
an antiviral target of action for ACC inhibitors inWNV infection.
Although the strategy of manipulating a major cellular meta-
bolic pathway such as lipid biosynthesis could induce multiple
side effects in vivo, it has to be considered that current antivirals
target other major biosynthetic pathways, such as nucleotide bio-
synthesis (for a discussion, see reference 18). Indeed, the clinical
value of lipid-lowering agents such as the statins, which are cho-
lesterol synthesis inhibitors broadly used against cardiovascular
diseases, supports the feasibility of therapeutic interventions tar-
geting the lipid metabolism (42). Consistently, hypolipidemic
drugs targeting the ACC are being evaluated for the treatment of
multiple human disorders from certain cancers to obesity and
diabetes (20, 21) and even viral infections (18, 34, 43). In addition,
the results obtained with hypolipidemic agents (i.e., nordihydro-
guaiaretic acid) that target cellular factors other than ACC also
support the feasibility of lipid-based antiviral approaches (17, 44).
In this context, the potential of ACC inhibitors reported here to
impair the replication of different flaviviruses, such as WNV and
USUV, could contribute to the development of broad-spectrum
antiflaviviral drugs.
In this work, we have provided further evidence supporting the
idea that pharmacological manipulation of the lipid biosynthetic
route can impair flavivirus infection. Specifically, we have identi-
fied the ACC as a druggable target to be considered for antiviral
development against WNV and related flaviviruses.
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Antiviral Activity of Nordihydroguaiaretic
Acid and Its Derivative Tetra-O-Methyl
Nordihydroguaiaretic Acid against West
Nile Virus and Zika Virus
Teresa Merino-Ramos, Nereida Jiménez de Oya, Juan-Carlos Saiz,
Miguel A. Martín-Acebes
Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA),
Madrid, Spain
ABSTRACT Flaviviruses are positive-strand RNA viruses distributed all over the
world that infect millions of people every year and for which no specific antiviral
agents have been approved. These viruses include the mosquito-borne West Nile vi-
rus (WNV), which is responsible for outbreaks of meningitis and encephalitis. Consid-
ering that nordihydroguaiaretic acid (NDGA) has been previously shown to inhibit
the multiplication of the related dengue virus and hepatitis C virus, we have evalu-
ated the effect of NDGA, and its methylated derivative tetra-O-methyl nordihydro-
guaiaretic acid (M4N), on the infection of WNV. Both compounds inhibited the infec-
tion of WNV, likely by impairing viral replication. Since flavivirus multiplication is
highly dependent on host cell lipid metabolism, the antiviral effect of NDGA has
been previously related to its ability to disturb the lipid metabolism, probably by in-
terfering with the sterol regulatory element-binding proteins (SREBP) pathway. Re-
markably, we observed that other structurally unrelated inhibitors of the SREBP
pathway, such as PF-429242 and fatostatin, also reduced WNV multiplication, sup-
porting that the SREBP pathway may constitute a druggable target suitable for anti-
viral intervention against flavivirus infection. Moreover, treatment with NDGA, M4N,
PF-429242, and fatostatin also inhibited the multiplication of the mosquito-borne fla-
vivirus Zika virus (ZIKV), which has been recently associated with birth defects (mi-
crocephaly) and neurological disorders. Our results point to SREBP inhibitors, such as
NDGA and M4N, as potential candidates for further antiviral development against
medically relevant flaviviruses.
KEYWORDS West Nile virus, antiviral agents, flavivirus, lipid, ZIKV
West Nile virus (WNV) is a member of the Flavivirus genus within the Flaviviridaefamily. Its genome is composed by a single-stranded RNA molecule of positive
polarity about 11,000 nucleotides in length (1). This mosquito-borne flavivirus is
distributed worldwide and causes outbreaks of febrile illness and meningoencephalitis
(2). Although WNV poses a health threat, there is still neither a vaccine nor an antiviral
therapy licensed for human use. Apart from WNV, the Flavivirus genus includes other
well-known pathogens, such as yellow fever virus, dengue virus (DENV), Japanese
encephalitis virus, tick-borne encephalitis virus, and Zika virus (ZIKV). ZIKV has recently
gained attention because it is responsible for a global outbreak infecting millions of
people and has been associated with birth defects (microcephaly) and neurological
disorders like Guillain-Barré syndrome (3, 4). Similar to WNV, there are neither specific
drugs nor vaccines licensed against ZIKV.
Recent advances have revealed that positive-stranded RNA viruses, including the
flaviviruses, rearrange host cell lipid metabolism and coopt for cellular lipids to com-
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plete their life cycle (5–7). Considering this dependence on lipid metabolism during
flavivirus infection, pharmacological modification of the lipid metabolic pathways
appears to be a proper strategy to impair flaviviral replication (7, 8). Along these lines,
the hypolipidemic drug nordihydroguaiaretic acid (NDGA) has been reported to inhibit
replication of the flavivirus DENV (9). In addition, NDGA also inhibited the replication of
hepatitis C virus (HCV), a member of the Hepacivirus genus within the Flaviviridae family
(10), thus becoming an interesting candidate for broad antiviral development against
flaviviruses and related viruses. NDGA is a phenolic compound and the main metabolite
of the desert shrub Larrea tridentata. Nowadays, NDGA is being evaluated to treat a
wide variety of illnesses, including diabetes, pain, inflammation, infertility, rheumatism,
arthritis, and gallbladder and kidney stones (11, 12). Remarkably, a synthetic methyl-
ated derivative of NDGA, termed tetra-O-methyl nordihydroguaiaretic acid (M4N, Tera-
meprocol, or EM-1421), which retains a high similarity in the molecular structure with
its precursor, is currently in phase I/II clinical trials in patients with advanced cancer
(13–15). However, to our knowledge, the potential antiviral effect of M4N has not been
assessed against any flavivirus.
In this work, we have evaluated the antiviral effect of NDGA and its M4N derivative
on the infection of medically relevant flaviviruses. Our results showed that both
compounds inhibited WNV and ZIKV infection.
RESULTS
NDGA and M4N inhibit WNV infection. The antiviral activity against WNV of NDGA
and its synthetic methylated derivative M4N was explored (Fig. 1A). Vero cells were
infected and treated with different concentrations of the drugs (10 or 35 !M) at 1 hour
postinfection (h p.i.), and the virus yield was determined by plaque assay at 24 h p.i.
Both NDGA and M4N reduced significantly the virus yield in a dose-dependent manner
when cells were infected with a highly neurovirulent WNV strain from genetic lineage
1 (WNV NY99) representative of the virus that is currently circulating in the American
continent (Fig. 1B and C). In a similar manner, both NDGA and M4N also reduced
significantly the virus yield of a WNV strain from genetic lineage 2 (WNV SRB-Novi
Sad/12) representative of the highly neurovirulent virus that has recently colonized the
European continent (Fig. 1D and E). The lack of toxicity of the drug concentrations
utilized was analyzed in parallel by determination of the cellular ATP content (Fig. 1F
and G). Results showed no statistically significant reduction of the cellular ATP content
at the drug concentrations used, confirming that the reduction of viral yield was not
associated with major cytotoxic effects of the drugs. Considering that there were no
marked differences on the antiviral effect of NDGA and M4N between the two WNV
isolates analyzed (Fig. 1B to E), the WNV NY99 strain was selected for subsequent
experiments.
Inhibition of WNV infection by M4N is not related to a virucidal effect. To
evaluate a possible virucidal effect of NDGA and M4N, WNV ("1.5 # 109 PFU) was
preincubated with the compounds for 1 h at 37°C in culture medium and then titrated
to determine the remaining infectivity. A significant reduction (Fig. 2A) was observed
only when NDGA was tested at the highest concentration (35 !M); however, this was
lower than that observed in the virus yield assays (Fig. 1A), thus suggesting that the
inactivation of the virions by NDGA was not primarily related to a virucidal effect. No
significant reduction of WNV infectivity was noticed in this assay when M4N was tested
(Fig. 2B), indicating that this compound does not exhibit a virucidal effect against WNV.
NDGA and M4N inhibit genome replication of WNV. To identify the step that was
mainly affected by NDGA and M4N, WNV infection was analyzed by quantitative reverse
transcriptase PCR (RT-PCR). Both drugs significantly inhibited the release of WNV
genome-containing particles to the culture medium (Fig. 3A and B). Moreover, NDGA
and M4N significantly reduced the amount of cell-associated viral RNA, especially at 35
!M (Fig. 3C and D). Overall, these observations support that the reduction in the release
of genome-containing particles was produced by a decrease in viral replication. The
amount of double-stranded RNA (dsRNA) intermediates, which provide a good indica-
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tor of flavivirus replication (16, 17), was also analyzed by immunofluorescence (Fig. 3E).
Concordant with previous results, a major decrease in the amount of dsRNA was
observed in cells treated with NDGA or M4N in comparison to that in untreated cells.
The quantification of this signal (Fig. 3F) confirmed this observation, supporting that
both NDGA and M4N inhibited WNV genome replication. Western blot analysis also
revealed a reduction in the level of the viral E protein within infected cells treated with
35 !M NDGA (34% of control) or M4N (43% of control) (Fig. 3G).
The effect of NDGA and M4N on viral morphogenesis and particle egression was
evaluated using a cell line that expresses WNV structural glycoproteins and constitu-
tively secretes virus-like particles (termed recombinant subviral particles [RSPs]) without
the need for viral replication (18, 19). For this experiment, cells were incubated for 4 h
with the compounds, a time that has been previously shown to be sufficient for the
identification of compounds that impair WNV biogenesis (19), and the amount of RSPs
in the supernatant was analyzed. Immunoblot analysis of the supernatant using anti-E
antibody revealed that no inhibition of RSP egress was observed when cells were
treated with either NDGA or M4N (Fig. 3H). However, the inhibitor of secretion brefeldin
FIG 1 NDGA and its synthetic derivative M4N inhibit WNV infection. (A) Chemical structure of NDGA and
M4N. R corresponds to OH in NDGA or OCH3 in M4N. (B and C) Reduction of WNV infection in Vero cells
treated with NDGA (B) or M4N (C). Cells were infected with WNV lineage 1 strain NY99 (MOI of 1 PFU/cell),
and virus yield in culture supernatant was determined by plaque assay at 24 h p.i. (D and E) Inhibition
of WNV lineage 2 infection in Vero cells treated with NDGA (D) or M4N (E). Cells were infected with WNV
SRB-Novi Sad/12 (MOI of 1 PFU/cell), and virus yield in culture supernatant was determined by plaque
assay at 24 h p.i. (F and G) Evaluation of the cytotoxicity of NDGA (F) and M4N (G) on Vero cells by
determination of ATP content 24 h posttreatment. Data are presented as means $ SDs (n ! 3 to 6).
Statistically significant differences are indicated. *, P % 0.05; **, P % 0.005.
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A (BFA), included as a control, significantly inhibited the release of RSPs into the culture
medium. Taken together, these results support that both NDGA and its derivative M4N
impair WNV infection by reducing genome replication rather than virion morphogen-
esis or particle egress.
Resveratrol, PF-429242, and fatostatin reduce WNV infection. The antiviral
effect of NDGA against DENV and HCV has been associated with the inhibition of
lipogenesis (9, 10). Specifically, in the case of HCV, the antiviral effect of NDGA was
related to its ability to impair the sterol regulatory element-binding proteins (SREBPs)
pathway (10). The SREBPs are the main transcription factors that regulate lipid biosyn-
thesis and lipid homeostasis in mammals (20, 21). To evaluate the involvement of the
SREBP pathway on WNV infection, we selected resveratrol, PF-429242, and fatostatin
(Fig. 4A), which are structurally unrelated compounds that inhibit different components
or regulators of the SREBP pathway (22–25). Treatment with resveratrol resulted in a
dose-dependent inhibition of WNV infectious particle production (Fig. 4B). Likewise
PF-429242 (Fig. 4C) and fatostatin (Fig. 4D) showed statistically significant suppression
of infectious viral titers in a dose-dependent manner. In addition to its effect on the
SREBP pathway, NDGA can also inhibit 5-lipoxygenase (5-LOX) activity in vitro (26, 27).
Therefore, to discard that the antiviral effect of NDGA and M4N was due to 5-LOX
inhibition, the inhibitor of 5-LOX zileuton was used (28). No inhibition of virus yield was
observed when cells were treated with zileuton (Fig. 4E). These results suggested that
whereas the infection of WNV was sensitive to the inhibition of the SREBP pathway, it
was independent of 5-LOX activity. The lack of toxicity of all of the drug concentrations
utilized was analyzed in parallel by determination of ATP content (Fig. 4F to I). All of the
drug concentrations tested displayed cell viabilities higher than 80% of that of control
cells, further supporting that the reductions of viral yields exerted by resveratrol,
PF-429242, and fatostatin were not associated with cytotoxic effects of the drugs.
NDGA, M4N, PF-429242, and fatostatin inhibit ZIKV infection. The current
explosive spread of ZIKV propelled us to test whether the drugs used against WNV
could be used as well to decrease ZIKV infection. To achieve this goal, the effects of
NDGA, M4N, and the two hypolipidemic drugs, PF-429242 and fatostatin, on the
multiplication of ZIKV PA259459, isolated from a human patient in Panama in 2015,
were examined. As described for WNV, a statistically significant reduction in viral yield
was observed for ZIKV when cells were treated with NDGA, M4N, PF-429242, or
fatostatin (Fig. 5). These results confirmed the antiviral effects of these compounds,
including M4N, against other medically relevant flaviviruses such as ZIKV.
Selectivity indexes of NDGA and M4N against WNV and ZIKV. The evaluation of
the balance between safety and efficacy of drugs is important for drug discovery and
development (29), so the selectivity indexes (SIs) of NDGA and M4N were calculated for
WNV and ZIKV (Table 1). This index determines the relative effectiveness of the drug in
FIG 2 Evaluation of the direct effect of NDGA and M4N on the infectivity of WNV. WNV NY99 ("1.5# 109
PFU) was treated with NDGA (A) or M4N (B) for 1 h at 37°C in culture medium. Then, the infectivity in each
sample was determined by plaque assay. Data are presented as means $ SDs (n ! 4). Statistically
significant differences are indicated. **, P % 0.005.
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inhibiting viral replication compared to inducing cytotoxicity. SI was determined by
quantifying the relation between the 50% cytotoxic concentration (CC50; calculated as
the concentration that resulted in the reduction of 50% of the amount of cellular ATP)
and the 50% inhibitory concentration (IC50; calculated as the concentration of drug at
which viral infection was inhibited by 50%). Both compounds showed IC50s in the one
digit micromolar range for WNV and ZIKV. Since the CC50 of M4N was about 1 order of
magnitude higher than that of NDGA (Table 1), the SI of M4N was improved (up to a
value of &100) compared to that of NDGA for both WNV and ZIKV.
FIG 3 NDGA and M4N inhibit WNV replication. (A and B) Reduction of genome-containing particles in culture supernatant
of Vero cells treated with NDGA (A) or M4N (B). Cells were infected with WNV NY99 (MOI of 1 PFU/cell), and the amount
of genome-containing particles in culture supernatant was determined by quantitative RT-PCR at 24 h p.i. (C and D)
Amount of cell-associated viral RNA in cell cultures infected with WNV and treated with NDGA (C) or M4N (D) as described
in A and B. The amount of cell-associated RNA in each sample was normalized by quantification of rRNA 18S. (E)
Visualization of intracellular dsRNA accumulation in cells infected with WNV NY99 (MOI of 10 PFU/cell) and treated with
35 !M NDGA or 35 !M M4N. Infected cells treated with drug vehicle (DMSO) were included as a control. Cells were fixed
and processed for immunofluorescence using J2 monoclonal antibody to dsRNA and a secondary antibody coupled to
Alexa Fluor 488 (green). Nuclei were stained with To-Pro-3 (blue). Bar, 10 !m. (F) Quantification of the fluorescence
intensity of dsRNA in cells infected with WNV and treated with 35 !M NDGA or M4N as shown in E (n ! 89, 36, and 39
cells analyzed for DMSO, DDGA, and M4N, respectively). (G) Western blot analysis of E glycoprotein expression in cells
treated with NDGA or M4N. Vero cells were infected, or not, with WNV NY99 (MOI of 1 PFU/cell) and treated with different
concentrations of NDGA or M4N. Membrane was retested against a "-actin antibody as a control for protein loading. (H)
RSP release into the culture medium by HeLa3-WNV cells treated (4 h) with 35 !M NDGA, 35 !M M4N, or 5 !g/ml BFA was
analyzed by enzyme-linked immunodot assay using a monoclonal antibody against E glycoprotein. The graph displays the
quantification of the amount of RSPs released. For each drug, the cellular ATP content is also depicted as an indicator of
the cell viability upon drug treatment. Data are presented as means $ SDs (n ! 3 to 6). Statistically significant differences
are indicated. **, P % 0.005.
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DISCUSSION
Due to their inability to perform their own lipid synthesis, flaviviruses are forced to
coopt for cellular lipids to complete their replication cycles. Accordingly, pharmaco-
logical manipulation of cellular lipid metabolism is rising as an alternative potential
strategy to combat these pathogens (7, 8). Along these lines, we have shown that the
hypolipidemic compound NDGA and its synthetic derivative M4N exhibit potent anti-
viral activity against WNV and ZIKV. This antiviral effect of NDGA is consistent with
results obtained for DENV and HCV (9, 10). It has to be remarked that the antiviral
effects of NDGA or M4N also have been observed against viruses from other viral
families, such as herpes simplex virus, human immunodeficiency virus, human papil-
lomavirus, cowpox virus, and vaccinia virus (30–34). Regarding the mechanism behind
the antiviral activity of NDGA, in the case of HCV, it was related to an inhibition of the
SREBP pathway (10). Consistent with this hypothesis, our results showed that a panel
of structurally unrelated inhibitors of the SREBP pathway, such as resveratrol, fatostatin,
and PF-429242, also reduced the multiplication of WNV and ZIKV. These results also
supported previous studies that point to the importance of the SREBP pathway for
infections of flavivirus and hepacivirus (9, 10, 35). The reduction observed for WNV
using the SREBP inhibitors resveratrol, fatostatin, and PF-429242 was lower than that
observed for NDGA and M4N (compare Fig. 1 and 3), which may suggest that the
inhibition of the SREBP pathway is not the only mechanism of action of NDGA and M4N
on WNV replication. In the case of the flavivirus DENV, it was proposed that NDGA
FIG 4 Different inhibitors of the SREBP pathway reduce WNV infection. (A) Chemical structure of the SREBP pathway inhibitors
tested: resveratrol, PF-429242, and fatostatin. The structure of zileuton, a 5-LOX inhibitor, is also depicted. (B to E) Quantifi-
cation of WNV infectious particle production in Vero cells infected with WNV NY99 (MOI of 1 PFU/cell) and treated with
resveratrol (B), PF-429242 (C), fatostatin (D), or zileuton (E). Virus yield in culture supernatant was determined by plaque assay
at 24 h p.i. (F to I) Evaluation of the cytotoxicity of resveratrol (F), PF-429242 (G), fatostatin (H), and zileuton (I) on Vero cells
by determination of ATP content 24 h posttreatment. Data are presented as means $ SDs (n ! 4). Statistically significant
differences are indicated. **, P % 0.005.
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inhibited viral infection by the following two different means: through viral genome
replication reduction and virion assembly inhibition (9). In the present report, quanti-
tative RT-PCR data and immunofluorescence analyses supported that both NDGA and
M4N also impaired the replication of the WNV genome. On the contrary, when the
effects of NDGA and M4N were directly evaluated on WNV morphogenesis and egress
by measuring the production of virus-like particles, no significant reduction was
noticed. Therefore, these results support that, in the case of WNV, the inhibitory effects
of NDGA and M4N were more likely due to an inhibition of viral genome replication
rather than to an impairment of virion morphogenesis. Although we cannot exclude
that the drugs also may be acting on entry or viral RNA translation, considering that the
entry of flaviviruses into host cells is a very fast process that includes viral fusion within
5 to 10 min p.i. (36, 37) and that in our experimental approach the drugs were added
1 h p.i., it is reasonable to think that their effect is not primarily due to an inhibition of
early infection steps. In addition, as no virucidal effect of M4N, and only a slight one of
NDGA, was noticed at the highest concentration tested (being markedly lower than
the inhibition caused in the viral yield), it is also unlikely that this will be the main
mechanism of inhibition of these compounds. The difference in the virucidal ability
observed between the two compounds may be because M4N is a methylated derivative
of NDGA. In fact, supporting this view, the direct effect of other phenolic compounds
on viral particles of the related hepatitis C virus has been linked to the presence of
certain hydroxyl groups within the molecules tested (38).
In our experiments, NDGA and M4N showed similar antiviral activities against WNV
and ZIKV at concentrations near to those that can be detected in tissues and plasma of
treated animals (39, 40). However, our CC50 values for each compound evidenced that
M4N displayed a reduced toxicity in comparison to that of NDGA. In fact, despite the
high similarity in the molecular structures of NDGA and M4N, it has been described that
the median lethal dose of M4N for mice was greater than 1,000 mg/kg while that of
FIG 5 Reduction of ZIKV infectious particle production in Vero cells treated with NDGA, M4N, fatostatin,
or PF-429242. Cells were infected with ZIKV PA259459 (MOI of 1 PFU/cell), treated with 35 !M of each
drug, or not (DMSO), and the virus yield in culture supernatant was determined by plaque assay at 24
h p.i. Data are presented as means $ SDs (n ! 3). Statistically significant differences between control
(DMSO) and drug-treated cells are indicated. **, P % 0.005.
TABLE 1 Selectivity indexes of NDGA and M4N against WNV NY99 and ZIKV PA259459
Compound CC50a (!M)
WNV NY99 ZIKV PA259459
IC50b (!M) SI (CC50/IC50) IC50 (!M) SI (CC50/IC50)
NDGA 162.1 7.9 20.5 9.1 17.8
M4N 1,071.0 9.3 115.2 5.7 187.9
aCC50 is the concentration that results in the reduction of 50% of the amount of cellular ATP after 24 h of
treatment.
bIC50 is the concentration of drug at which virus yield (MOI of 1 PFU/cell) is inhibited by 50%. Virus yield was
determined by plaque assay 24 h p.i.
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NDGA was only 75 mg/kg (12, 14, 39). Moreover, it has been reported that patients can
tolerate higher doses of M4N with minimal side effects (15). Thus, the improved SI of
M4N in comparison to that of NDGA may make M4N a more promising antiviral
candidate for further evaluation.
In summary, we have described that treatment with NDGA, and its derivative M4N,
reduced WNV and ZIKV multiplication. Although further studies of its potential cyto-
toxic effects in infected hosts are needed, our results together with the clinical safety
record of M4N point for the first time to this compound as an interesting candidate for
antiviral design against medically relevant flaviviruses.
MATERIALS AND METHODS
Cells, viruses, infections, and virus titrations. All infectious virus manipulations were conducted in
biosafety level 3 (BSL3) facilities. Vero (CCL-81) cells (ATCC) were grown at 37°C in a 5% CO2 atmosphere
in Eagle’s minimal essential medium (EMEM; Lonza, Verviers, Belgium) supplemented with 2 mM
glutamine, penicillin-streptomycin, and 5% fetal bovine serum. HeLa cells stably transfected with a
plasmid encoding the last 25 amino acids of the WNV NY99 C protein followed by the sequence of
premembrane/membrane (prM) and envelope (E) proteins (HeLa3-WNV cells) were grown in complete
culture medium supplemented with 500 !g/ml G418 (18). The origin and passage history of the WNV
lineage 1 strain NY99 has been previously described (18, 41). WNV lineage 2 isolate SRB-Novi Sad/12
corresponds to a virus isolated from a goshawk found dead in Serbia in 2012 (42). The American strain
of ZIKV PA259459 corresponds to a virus isolated from an infected human in Panama in 2015 and was
kindly provided by R. B. Tesh (World Reference Center for Emerging Viruses and Arboviruses, Galveston,
TX). For infections in liquid medium, the viral inoculum was incubated with cell monolayers for 1 h at
37°C, and then the inoculum was removed and fresh medium containing 1% fetal bovine serum was
added. The viral titer was determined by plaque assay in semisolid agarose medium (43). The multiplicity
of infection (MOI) used in each experiment was expressed as PFU per cell as is indicated in the
corresponding figure legend.
Drug treatments. NDGA, M4N, zileuton, fatostatin, resveratrol, and BFA were from Sigma (St. Louis,
MO). PF-429242 was from CliniSciences (Nanterre, France). Unless otherwise specified, drugs were added
after the first hour of infection when viral inoculum was replaced by culture medium containing 1% fetal
bovine serum. Control cells were treated in parallel with the same amount of drug vehicle (dimethyl
sulfoxide [DMSO]). Drug toxicity was examined by measuring the cellular ATP content with the CellTiter-Glo
luminescent cell viability assay (Promega, Madison, WI).
Antibodies. Mouse monoclonal antibody 3.67G and rabbit polyclonal antiserum PA1-4139 against
the WNV E protein were from Millipore (Temecula, CA) and Thermo Fisher (Rockford, IL), respectively.
Mouse monoclonal antibody against "-actin (Sigma) and mouse monoclonal antibody J2 against dsRNA
(English & Scientific Consulting, Hungary) were also used. Anti-mouse IgG coupled to Alexa Fluor 488
(Life Technologies, Carlsbad, CA), anti-mouse IgG coupled to horseradish peroxidase (Sigma), and
anti-rabbit IgG (Dako, Glostrup, Denmark) coupled to horseradish were used as secondary antibodies.
Confocal microscopy. Immunofluorescence and confocal microscopy were performed as described
previously (17, 44). Nuclei were stained with To-Pro-3 (Life Technologies), and images were acquired
using a Leica TCS SPE confocal laser scanning microscope and an HCX PL Apo 63#/1.4 oil immersion
objective. Fluorescence quantification was performed using ImageJ software (https://imagej.nih.gov/ij/).
Enzyme-linked immunodot assay. The amount of E protein released to the culture medium by
HeLa-3-WNV cells was determined using 3.67G monoclonal anti-E antibody and anti-mouse or anti-rabbit
horseradish-coupled secondary antibodies (18, 19).
Western blot. The amount of E protein within infected cells was determined using the PA1-4139
rabbit antiserum against this protein following a previously published protocol (17).
Quantitative PCR. Viral RNA was extracted from the supernatant of infected cultures with the
SpeedTools RNA virus extraction kit (Biotools B&M Labs, S.A., Madrid, Spain). For quantification of
cell-associated viral RNA, supernatants from infected cells were removed and total RNA was extracted
from cell monolayers using TRIzol reagent (Life Technologies). The amount of viral RNA was determined
by real-time fluorogenic reverse transcriptase PCR (RT-PCR) according to previously published protocols
(44, 45). As a control, the amount of rRNA 18S in RNA samples from cell monolayers was determined as
described previously (46). Cell-associated viral RNA copies were normalized to this internal control. The
number of viral RNA copies is given as the number of genomic equivalents corresponding to the number
of PFU per milliliter by comparison with the amount of RNA extracted from previously titrated samples
(47).
Data analysis. Data are presented as means $ standard deviations (SDs). Analysis of the variance
(ANOVA) and Student’s test were performed using SPSS 19 (SPSS Inc., Chicago, IL). Bonferroni’s correction
was applied for multiple comparisons. Statistically significant differences are indicated by one asterisk for
a P value of %0.05 or two asterisks (**) for a P value of %0.005.
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The	 identification	of	 viral	 and	host	 processes	 that	 control	 the	biology	of	 flaviviruses	 such	 as	
WNV,	 USUV	 and	 ZIKV	 is	 important	 to	 improve,	 among	 other	 aspects,	 the	 design	 of	 specific	
innovative	antiviral	strategies		
Cell	lipid	content	alteration	induced	by	WNV	infection.	
As	explained	in	the	introduction,	flaviviruses	depend	on	cellular	factors	to	complete	their	 life	
cycle,	which	is	 intimately	associated	to	host	cell	 lipids.	Nowadays	it	 is	known	that	flaviviruses	
induce	 Intracellular	 membrane	 rearrangements	 to	 develop	 adequate	 platforms	 for	 viral	
replication	and	particle	biogenesis.	Moreover,	flaviviruses	dramatically	orchestrate	a	profound	
reorganization	 of	 the	 host	 cell	 lipid	metabolism	 to	 adequate	 cellular	 functions	 to	 their	 own	
requirements	 (Figure	 9).	 Consistently,	 the	 role	 of	 specific	 lipid	 classes	 in	 flavivirus	 infections	
has	been	recently	addressed.	So	that,	among	other	features,	it	is	already	known	that	fatty	acid	
synthesis	 is	 linked	to	viral	replication,	that	phosphatidylserine	and	phosphatidylethanolamine	
are	 involved	 on	 viral	 entry,	 that	 sphingolipids	 play	 a	 key	 role	 on	 virus	 assembly	 and	
pathogenesis,	 and	 that	 cholesterol	 is	 essential	 for	 innate	 immunity	 evasion	 in	 flavivirus-
infected	cells	(Martin-Acebes,	Vazquez-Calvo,	Saiz	2016).	
In	 this	 line	of	 research,	 to	gain	knowledge	 in	 the	role	of	 the	cellular	 lipids	 in	viral	 replication	
and	 to	 search	 for	 cellular	 antiviral	 targets,	 throughout	 the	 first	 investigations	 of	 this	 thesis	
(Article	 I),	 the	specific	modification	 that	WNV	exert	over	cell	 lipid	metabolism	was	described	
for	the	first	time.	Thereby,	and	consistently	with	that	previously	reported	for	DENV	(Perera	et	
al.,	2012),	where	about	15%	of	the	 lipids	detected	were	changed	between	 infected	and	non-
infected	insect	cells,	it	was	observed	that	in	WNV-infected	mammalian	cells	about	33%	of	the	
molecular	 species	detected	were	 significantly	 increased.	 In	 this	way,	 an	enhancement	 in	 the	
cellular	 content	 of	 glycerophospholipids	 (GPLs)	 and	 sphingolipids	 (SLs),	 remarkably	 of	
phosphatidylcholine	(PC),	lysophospholipids	(lyso-PC),	sphingomyelin	(SM),	and	ceramide	(CER)	
was	observed	(Fig.	1,	Article	I).		At	this	point,	it	should	be	noted	that	CER	provides	the	building	
block	for	the	synthesis	of	more	complex	sphingolipids	and,	in	turn,	constitutes	the	central	core	
of	 SM,	 and	 thus,	 both	 species	 can	 be	 interconverted	 by	 cellular	 enzymes	 (Figure	 6)	 (Gault,	
Obeid	et	al.	2010;	Merrill	2011).	The	observation	that	both	CER	and	SM	are	increased	in	WNV-
infected	 cells	 suggests	 that	 the	 first	 is	 the	 result	 of	 de	 novo	 synthesis	 rather	 than	 the	
degradation	of	SM.	Although	the	lipolytic	pathway	of	ceramide	production	via	the	catabolism	
of	more	complex	SLs	could	also	contribute	to	a	rise	in	ceramide	levels	in	flavivirus	infected	cells	
(Merrill	2011;	Aktepe,	Pham	et	al.	2015).	
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On	the	other	hand,	the	fact	that	all	enriched	lipids,	with	the	exception	of	PC	(a	cylindrical	lipid),	
were	 conical	 strengthens	 their	 role	 in	 the	 establishment	 and	 maintenance	 of	 the	 cellular	
membrane	curvature	needed	for	the	assembly	of	the	viral	replication	complex	().	Likewise,	as	
described	for	DENV	(Perera	et	al.,	2012),	the	observed	enrichment	in	unsaturated	PC	may	be	
related	with	increasing	the	membrane’s	fluidity.	A	similar	increase	in	SLs	to	the	one	observed	
here	have	also	been	documented	for	DENV	and	HCV	(Diamond	et	al.,	2010;	Hirata	et	al.,	2012;	
Perera	 et	 al.,	 2012).	 Therefore,	 overall,	 the	 lipid	 changes	 detected	 in	 WNV-infected	 cells	
resemble	 those	derived	 from	the	 infection	with	other	member	of	 the	 family	Flaviviridae	and	
point	 to	 common	 evolutionarily	 conserved	 ancient	 lipid	 requirements	 in	 this	 viral	 family	
(Martin-Acebes,	Vazquez-Calvo,	Saiz	2016).	
The	lipid	composition	of	WNV	envelope.	
The	 lipid	 composition	 of	 cell	 cultured	 produced	WNV	 virions	 and	 non-infectious	 RSPs	 were	
very	similar	(Fig.	4,	Article	1),	with	a	common	reduction	of	PC	and	an	enrichment	of	SM.	This	
fact	reinforces	the	utility	of	the	RSPs	for	the	study	of	the	virus	biogenesis	without	the	need	of	
BSL-3	 facilities.	Nevertheless,	p-PC	appeared	 to	be	enriched	 in	virions	compared	 to	RSP.	The	
differences	found	between	natural	virions	and	RSPs	size	(50nm	and	30nm	respectively),	could	
be	 explained	 by	 these	 variations	 on	 the	 lipid	 membranes	 compositions.	 It	 has	 been	
demonstrated	 that	 vesicles	 formed	 with	 p-PC	 are	 larger	 than	 those	 formed	 with	 PC	
(Hermetter,	Lohner	et	al.	1985).		
The	way	different	viruses	make	up	their	lipid	membranes	is	quite	diverse.	For	instances,	HIV-1	
and	influenza	virus	show	an	increase	in	SL	when	compared	with	cellular	membranes	(Brugger	
et	al.,	2006;	Gerl	et	al.,	2012),	rhabdoviruses	and	alphaviruses	exert	little	lipid	selection	when	
acquiring	their	envelopes	(Kalvodova	et	al.,	2009),	while	others,	such	as	HCV,	have	envelopes	
that	 resemble	 the	 composition	of	 low	and	 very	 low	density	 lipoproteins	 (Merz	 et	 al.,	 2011).	
Our	lipidomic	analysis	indicate	that	the	envelopes	of	both	WNV	virions	and	RSPs	are	enriched	
in	 SM	 and	 exhibit	 a	 reduction	 in	 the	 content	 of	 PC	 compared	 to	 that	 of	 total	 cellular	
membranes.	These	features	are	characteristics	of	 liquid	ordered	membrane	microdomains	or	
membrane	rafts	(Brugger	e	tal.,	2006;	Gerl	et	al.,	2012;	Trajkovic	et	al.,	2008;	Wubbolts	et	al.,	
2008),	which	are	usually	cholesterol	enriched,	 including	those	located	in	the	ER	(Browman	et	
al.,	2008),	and	thus	point	to	a	role	of	these	microdomains	in	flavivirus	replication.	In	this	sense,	
an	 enrichment	 of	 cholesterol	 is	 also	 observed	 in	 the	 envelope	 of	 bovine	 viral	 diarrhea	 virus	
(BVDV),	a	Pestivirus	 that	also	belongs	to	the	Flaviviriade	 family	(Callens,	Brugger	et	al.	2016).	
Similarly	to	the	WNV	envelope,	and	consistent	with	our	results,	the	pestivirus	envelope	is	also	
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enriched	in	SLs	(i.e.	sphingomyelin)	and	showed	a	reduction	of	phosphatidylcholine.	Thus,	our	
results	 are	 consistent	 with	 common	 lipid	 selection	 requirement	 for	 the	 envelopment	 of	
Pestivirus	and	Flavivirus.	
Flaviviral	biogenesis:	the	role	of	the	nSMase	
As	mentioned	above,	both	CER	and	SM	were	increased	in	WNV-infected	cells,	which	point	to	
de	 novo	 synthesis	 of	 the	 later.	 Moreover,	 the	 fact	 that	 dhCER,	 an	 intermediate	 of	 SL	
biosynthetic	pathway	(Merrill	AH,	Jr	2011),	was	increased	in	WNV-infected	cells	also	suggests	
de	novo	synthesis	of	SL,	as	observed	in	other	viruses	(Hirata	et	al.,	2012;	Perera	et	al.,	2012).	
However,	pharmacological	 inhibition	and	RNA	interference	of	nSMase2,	which	hydrolyzes	SM	
to	render	CER,	diminished	the	release	of	RSPs	into	the	medium	(Fig.	5,	Article	I),	and	drastically	
reduced	the	production	of	infectious	flavivirus,	namely	WNV	and	USUV	(Fig.	6,	Article	I).	These	
data	 point	 to	 nSMase2	 as	 an	 important	 player	 in	 flavivirus	 biogenesis,	 in	 contrast	 to	 that	
observed	 for	 the	 alphavirus	 SINV,	which	 did	 not	 require	 the	 conversion	 of	 SM	 to	 CER	 since	
lipids	 selection	 is	 not	 needed	 during	 its	 biogenesis	 (Kalvodova	 et	 al.,	 2009).	 All	 these	 data	
suggest	 that	 different	 SL-related	metabolic	 pathways	 (de	 novo	 synthesis	 and	 hydrolysis)	 are	
functional	for	the	production	of	CER	in	flavivirus	infected	cells.	In	addition,	other	factors	such	
as	induction	of	ER	stress	by	activation	of	the	unfolded	protein	response	(Blázquez	et	al.,	2014)	
could	contribute	to	CER	production	in	WNV-infected	cells.		
In	brief,	data	obtained	during	 this	 investigations	 (Article	 I)	evidence	 the	manipulation	of	 the	
cellular	 lipid	 metabolism	 during	 WNV	 infection	 and	 the	 link	 between	 SL	 metabolism	 and	
flavivirus	biogenesis,	and	mark	out	possible	druggable	targets	for	new	antiviral	strategies.	
ACC	inhibitors	effect	during	flaviviral	infection.	
It	is	well	known	that	the	first	steps	of	lipid	biogenesis	involve	the	synthesis	and	elongation	of	
fatty	acids,	which	are	necessary	for	the	synthesis	of	more-complex	lipids,	hence,	making	fatty	
acid	metabolism	a	key	 target	 for	antiviral	 therapy	 (Heaton	et	al.,	 2010;	Munger	et	al.,	 2008,	
Nchoutmboube	et	al.,	2013).	 In	 fact,	 the	pharmacological	blockage	of	the	fatty	acid	synthase	
FASN	(which	catalyzes	the	synthesis	of	palmitate	from	acetyl-CoA,	and	malonyl-CoA	into	long-
chain	saturated	fatty	acids)	reduce	flaviviral	replication	(Martín-Acebes	et	al.,	2011;	Heaton	et	
al.,	2010).	The	enzyme	preceding	FASN	 in	 the	 fatty	acid	biosynthetic	 route	 is	 the	ACC,	which	
catalyzes	 the	 carboxylation	 of	 acetyl-CoA	 to	 malonyl-CoA	 and,	 thus,	 ACC	 is	 currently	 being	
evaluated	 as	 a	 therapeutic	 target	 for	 different	 disorders	 including	 cancers,	 obesity,	 diabetes	
and	even	viral	infections	(Zu	et	al.,	2013;	Bourbeau	MP	and	Bartberger	MD	2015).		
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With	 this	 background	 and	 based	 on	 our	 previous	 results,	 the	 involvement	 of	 ACC	 in	 the	
replication	of	WNV,	and	other	 related	 flaviviruses,	was	evaluated	 (Article	 II).	At	 this	point,	 it	
was	 known	 that	 the	 ACC	 inhibitor	 TOFA	 reduced	 the	 synthesis	 of	 multiple	 cellular	 lipids,	
including	 some	 of	 those	 described	 by	 us	 in	 this	 thesis	 (Article	 I)	 to	 be	 involved	 in	 WNV	
infection	 such	 as	 GPLs,	 SLs	 and	 CHOL	 (Mackenzie,	 Khromykh	 et	 al.	 2007;	 Martin-Acebes,	
Merino-Ramos	 et	 al.	 2014).	 Therefore,	 the	 effect	 of	 TOFA	 on	 the	 infection	 of	 WNV	 was	
assayed.	 Lipidomic	 analysis	 of	 TOFA-treated	 cells	 showed	 that	 the	 drug	 reduces	 the	 cellular	
content	 of	 multiple	 lipids,	 including	 those	 directly	 implicated	 in	 the	 WNV	 life	 cycle	 (Fig.	 1,	
Article	 II).	 Consequently,	 TOFA	 treatment	 produces	 a	 dose-dependent	 inhibition	 of	 WNV	
multiplication	in	different	mammalian	cells	without	exerting	a	toxic	effect	at	the	concentration	
assayed	(Fig.	2,	Article	II),	and	inhibits	genome	replication	(Fig.	3,	Article	II),	more	probably	due	
to	 an	 impairment	 of	 the	 proper	 replication	 complex	 assembly	 caused	 by	 the	 lack	 of	 the	
necessary	 lipids.	Similar	 reduction	 in	viral	multiplication	was	observed	 in	USUV	 infected	cells	
(Fig.	 1,	 Article	 II).	 In	 addition,	 lipidomic	 analysis	 of	 WNV	 infected	 cells	 treated	 with	 TOFA	
showed	 a	 significant	 reduction	 in	 the	 content	 of	 CHOL,	 CER,	 hexCER,	 PC,	 PE	 and	 PS	 when	
compared	with	untreated	cells	(Fig.	4,	Article	II),	thus	indicating	that	the	lipid	changes	induced	
by	TOFA	were	similar	in	both	WNV-infected	and	uninfected	cells.	Furthermore,	treatment	with	
another	ACC	 inhibitor,	MEDICA	16,	also	 inhibited	WNV	and	USUV	 infection	 (Fig.	5,	Article	 II).	
However,	the	mechanism	of	action	of	both	drugs	seems	to	be	different,	as	MEDICA	16	mainly	
affect	the	production	of	infectious	virions	and	not	the	RNA	synthesis.	These	may	be	explained	
because	replication	and	assembly	of	viral	particles	are	coupled	processes	in	flaviviruses	(Apte-
Sengupta,	Sirohi	et	al.	2014)	and,	thus,	small	differences	on	the	alteration	of	the	cellular	lipid	
content	specific	for	each	inhibitor	could	result	in	the	inhibition	differences	observed.	
In	 brief,	 as	 demonstrated	 in	 our	 first	 investigations	 (Article	 I),	 data	 from	 this	 second	 work	
(Article	 II)	 confirm	 the	 role	 of	 lipogenesis	 during	WNV	 infection	 and	 validate	 the	 ACC	 as	 a	
druggable	cellular	target	suitable	for	broad-spectrum	antiviral	development	against	WNV	and	
other	flaviviruses.	
SREBP	pathway	inhibitors	effect	during	flaviviral	infection.	
In	relation	with	these	previous	investigations	(Articles	I	and	II),	 it	has	been	reported	that	the	
hypolipidemic	drug	NDGA	inhibits	the	replication	of	viruses	from	different	families	(Chen,	Teng	
et	 al.	 1998;	 Craigo,	 Callahan	 et	 al.	 2000;	 Hwu,	 Hsu	 et	 al.	 2008;	 Khanna,	 Dalby	 et	 al.	 2008;	
Pollara,	 Laster	et	al.	2010),	 including	 some	 from	the	Flaviviridae	 family,	 such	as	DENV	 (Soto-
Acosta,	 Bautista-Carbajal	 et	 al.	 2014)	 and	 HCV	 (Syed	 and	 Siddiqui	 2011).	 NDGA,	 a	 phenolic	
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compound,	is	the	main	metabolite	of	the	desert	shrub	Larrea	tridentate,	and	is	currently	being	
evaluated	 to	 treat	 different	 illnesses,	 such	 as	 diabetes,	 pain,	 inflammation,	 infertility,	
rheumatism,	arthritis,	gallbladder	and	kidney	stones	 (Arteaga,	Andrade-Cetto	et	al.	2005;	Lu,	
Nurko	 et	 al.	 2010).	 Even	more,	 a	 synthetic	methylated	 derivative	 of	NDGA,	 termed	 tetra-O-
Methyl	Nordihydroguaiaretic	acid	(M4N),	which	is	structurally	highly	similar	to	its	precursor,	is	
currently	in	Phase	I/II	clinical	trials	in	patients	with	advanced	cancer	(Chen	2009;	Grossman,	Ye	
et	 al.	 2012;	 Kimura	 and	 Huang	 2016).	 The	 antiviral	 effect	 of	 NDGA	 has	 been	 related	 to	 its	
ability	to	disturb	the	lipid	metabolism	by	interfering	with	the	sterol	regulatory	element	binding	
proteins	 (SREBP)	 pathway,	 since	 the	 SREBPS	 constitute	 the	 major	 family	 of	 transcription	
factors	activating	the	expression	of	genes	involved	in	biosynthesis	of	lipids	(Goldstein,	DeBose-
Boyd	et	al.	2006;	Tang,	Li	et	al.	2011).	
With	 this	base,	and	 following	 the	 research	 line	of	 this	 thesis,	 the	potential	antiviral	effect	of	
drugs	 interfering	 with	 SREBP	 pathway	 against	 two	 flavivirus,	WNV	 and	 ZIKV,	 was	 evaluated	
(Article	III).	NDGA	and	its	synthetic	methylated	derivative	M4N	inhibited	the	multiplication	of	
WNV	 lineage	1	and	2	strains	 (Fig	1,	Article	 III)	and	ZIKV	 (Fig	4,	Article	 III)	 in	mammalian	cells	
without	 exerting	 noticeable	 cell	 toxicity.	 Moreover,	 the	 determined	 CC50	 values	 of	 each	
compound	evidenced	a	reduced	toxicity	of	M4N.	These	results	are	in	agreement	with	previous	
data	reporting	that	the	median	lethal	dose	of	M4N	for	mice	is	much	higher	than	that	of	NDGA	
(>	1000	mg/kg	vs	75	mg/kg)	(Kimura	and	Huang	2016),	and	that	M4N	presented	low	toxicity	for	
human	 usage	 with	 minimal	 side-effects	 (Grossman,	 Ye	 et	 al.	 2012).	 On	 the	 other	 hand,	
quantitative	RT-PCR	and	 immunofluorescence	analyses	demonstrated	that	both	drugs,	NDGA	
and	M4N,	 impaired	 the	 replication	of	WNV	genome,	but	did	not	affect	virion	morphogenesis	
and	 egress,	 as	 no	 significant	 reduction	 of	 virus-like	 particles	 production	 was	 noticed	 (Fig	 2,	
Article	 III).	 Even	 more,	 in	 support	 of	 the	 hypothesis	 pointing	 to	 an	 inhibition	 of	 the	 SREBP	
pathway	 as	 the	 mechanism	 behind	 the	 antiviral	 activity	 of	 NDGA	 (Syed	 and	 Siddiqui	 2011;	
Soto-Acosta,	Bautista-Carbajal	et	al.	2014),	 the	here	obtained	experimental	data	show	that	a	
panel	 of	 structurally	 unrelated	 inhibitors	 of	 this	 pathway	 (Resveratrol,	 Fatostatin,	 and	 PF-
429242)	also	reduced	the	multiplication	of	both	WNV	and	ZIKV	(Fig	3,	Article	III).		
In	 brief,	 in	 agreement	 with	 our	 previous	 observations	 about	 the	 role	 of	 lipids	 in	 flavivirus	
replication	 (Article	 I	 and	 II),	 the	 results	 of	 this	 third	 investigation	 (Article	 III)	 point	 to	 drugs	
targeting	the	cellular	SREBP	pathway	as	new	additional	options	to	fight	flaviviral	infections.		
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Feasibility	of	lipid-targeted	antiviral	strategies		
A	 great	 effort	 aimed	 to	 decipher	 the	molecular	 biology	 of	 flaviviruses	 is	 being	made	 by	 the	
scientific	 community.	 Therefore,	within	 the	 last	 years,	 important	 attention	has	 been	paid	 to	
WNV	and	 its	 interaction	with	the	host	 immune	system	(Brinton	2013;	Suthar,	Diamond	et	al.	
2013),	however,	as	commented	in	the	Introduction,	no	licensed	vaccine	or	therapy	for	human	
use	against	neither	WNV,	nor	USUV,	nor	ZIKV	is	available	yet.	Overall,	during	this	thesis,	it	has	
been	demonstrated	that	flavivirus	multiplication	is	closely	related	to	lipid	metabolism,	as	well	
as	 the	 important	 role	 that	 some	 lipids	 play	 in	 the	 replication	 and	 biogenesis	 of	 different	
flaviviruses.	This	analysis	has	allowed	determining	the	key	role	of	certain	cellular	enzymes	and	
pathways	 and,	 thus,	 evidencing	 the	 potential	 of	 drugs	 targeting	 them	 as	 antivirals	 to	 fight	
flavivirus	infections.	
The	possibility	of	using	lipid	synthesis	inhibitors	as	antiviral	compounds	should	be	disclose,	as	
is	still	a	controversial	subject.	On	the	one	hand,	it	has	to	be	consider	that	metabolic	pathway	
manipulation	could	induce	multiple	side	effects	in	vivo.	On	the	other	hand,	antivirals	currently	
available	 mainly	 target	 other	 major	 biosynthetic	 pathways,	 like	 nucleotide	 biosynthesis.	 In	
addition,	it	is	a	fact	that	commonly	used	drugs	interfere	with	the	lipid	metabolism	or	are	lipid	
related	molecules,	such	as	the	cyclooxygenase-2	inhibitors	(aspirin)	or	the	anti-inflammatories	
(ibuprofen).	 Remarkably,	 some	 of	 the	 host	 targets	 that	 we	 have	 focused	 on	 during	 this	
research	are	already	being	investigated	or	used	for	the	treatment	of	other	pathologies.	This	is	
the	 case	 of	 the	 ACC,	 which	 is	 being	 investigated	 by	 the	 pharmaceutical	 industry	 for	 the	
development	 of	 drugs	 for	 diabetes,	 obesity	 and	 cancers	 due	 to	 its	 rate-limiting	 role	 in	 fatty	
acid	 synthesis	 (Zu,	 Zhong	 et	 al.	 2013;	 Bourbeau	 and	 Bartberger	 2015).	 In	 mammals,	 ACC	
expression	 and	 activity	 is	 regulated	 at	 transcriptional,	 posttranslational,	 and	 metabolite-
allosteric	 levels.	 At	 the	 transcriptional	 level,	 ACC1/2	expression	 is	 regulated	by	 the	 SREBP-1.	
Because	of	this	tight	relation	and	because	aberrant	SREBP	activity	has	been	linked	to	metabolic	
disease	 states,	 such	 as	 obesity,	 fatty	 liver,	 insulin	 resistance,	 hyperlipidemia,	 and	
atherosclerosis	 (Tang,	 Li	 et	 al.	 2011;	 Uesugi	 2013).	 Thus,	 ACC	 and	 SREBP	 constitute	 major	
metabolic	 regulators	 under	 clinical	 evaluation.	 Furthermore,	 SREBP	 is	 under	 investigation	 as	
well	 (Uesugi	 2013;	 Xiao	 and	 Song	 2013),	 it	 has	 been	 described	 that	 SREBP-2	 is	 mainly	
responsible	 for	 the	 regulation	 of	 cholesterol	 related	 genes,	 such	 as	 HMG-CoA	 reductase,	 a	
rate-limiting	enzyme	in	cholesterol	synthesis,	and	low-density	lipoprotein	receptor	(LDLR)	gene	
(Moore,	 Rayner	 et	 al.	 2010).	Moreover,	 statins,	 the	 HMG-CoA	 reductase	 inhibitors	 that	 are	
widely	used	in	human	to	lower	cholesterol	 levels	(Carroll,	Lacher	et	al.	2005),	have	also	been	
tested	 for	 HCV-antiviral	 properties	 (Ikeda,	 Abe	 et	 al.	 2006;	 Delang,	 Paeshuyse	 et	 al.	 2009;	
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Blanchet,	Seidah	et	al.	2012).	Similarly,	the	HMG-CoA	reductase	inhibitor	lovastatin	increased	
survival	rates	for	all	treatment	regimens	in	vivo	against	DENV-2	infection	(Martinez-Gutierrez,	
Correa-Londono	 et	 al.	 2014),	 nevertheless,	 reduced	 viraemia	 could	 only	 be	 observed	 in	
pretreated	animals.	Considering	the	broad	usage	and	good	tolerability	of	statins,	they	could	be	
candidates	for	an	emergency	prophylactic	antiviral	regimen.	In	any	case,	compared	with	DENV	
or	HCV,	 the	effort	 for	WNV	drug	discovery	has	been	much	 lower,	more	probably	due	 to	 the	
relatively	 lower	mobility	and	mortality	 rates	of	 this	virus,	as	only	about	1%	of	 cases	develop	
severe	neuroinvasive	disease	(encephalitis,	meningitis	or	flaccid	paralysis).	However,	it	is	quite	
probable	that,	due	to	the	high	homology	among	different	flaviviruses,	antivirals	developed	for	
one	may	 potentially	 be	 useful	 for	 others.	 In	 this	 sense,	 ideally,	 the	 best	 antivirals	would	 be	
repurposed	 drugs,	 as	 they	 have	 established	 safety	 and	 pharmacokinetic	 profiles;	 however,	
their	 activity	 spectrum	 should	 also	 be	 taken	 into	 account,	 being	 preferable	 drug	 candidates	
that	 can	 be	 active	 against	 the	 largest	 number	 of	 viruses.	 In	 relation	 with	 this,	 as	 the	 lipid	
requirement	is	quite	conserved	among	viruses,	lipid-based	host	target	antiviral	strategies	could	
confer	 broad-spectrum	 antiviral	 activity.	 Furthermore,	 there	 is	 an	 obvious	 advantage	 of	 the	
lipid-based	antiviral	strategies	over	DAA;	they	are	less	likely	to	develop	resistance	due	to	viral	
mutations.	However,	we	have	to	keep	in	mind	that	our	main	goal	is	to	fight	flaviviral	infections,	
and	that	DAAs	and	host	target	antiviral	strategies	are	not	restrictive	each	other,	and,	thus,	new	
antiviral	strategies	should	be	developed	in	combination	and	not	just	in	monotherapy,	as	they	
would	be	much	more	effective	against	viral	infections.	In	brief,	it	is	reasonable	to	think	that	the	
drugs	 tested	 along	 this	 research	 could	 inhibit	 different	 circulating	 viruses,	 as	 well	 as	
(re)emerging	viruses.	
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Las	conclusiones	obtenidas	en	esta	tesis	fueron	las	siguientes:	
1. El	contenido	de	una	amplia	variedad	de	metabolitos	lipídicos	se	encuentra	alterado	en	
células	infectadas	con	VNO.		
2. Algunos	 glicerofosfolípidos	 (fosfatidilcolina,	 plasmalógenos	 y	 lisofosfolípidos)	 y	
esfingolípidos	 (ceramida,	 dihidroceramida	 y	 esfingomielina)	 se	 encuentran	
aumentados	en	células	infectadas	con	VNO.		
3. Las	 envueltas	 lipídicas	 de	 los	 viriones	 de	 VNO	 naturales	 y	 de	 las	 partículas	 virales	
recombinantes	 están	 enriquecidas	 en	 esfingolípidos	 (esfingomielina)	 y	 muestran	
niveles	reducidos	de	fosfatidilcolina.		
4. La	 inhibición	 de	 la	 esfingomielinasa	 neutra	 (la	 cual	 cataliza	 la	 hidrólisis	 de	 la	
esfingomielina	a	 ceramida)	 reduce	 la	 liberación	de	viriones	de	 flavivirus	así	 como	de	
partículas	subvirales	recombinantes.	
5. El	metabolismo	de	los	glicerofosfolípidos	y	esfingolípidos	está	ligado	a	la	infección	por	
el	VNO.		
6. TOFA	 y	MEDICA	 26,	 ambos	 inhibidores	 de	 la	 acetil-CoA	 carboxilasa	 (ACC)	 inhiben	 la	
multiplicación	del	VNO	y	del	 virus	Usutu	mediante	 la	 reducción	de	 la	 replicación	del	
genoma	viral.		
7. El	 ácido	 nordihidroguaiaretico	 (NDGA)	 y	 su	 derivado	 metilado	 el	 tetra-O-metil	
nordihidroguaiaretico	(M4N)	inhiben	la	infección	del	VNO	y	del	virus	de	Zika.	
8. Inhibidores	 de	 la	 vía	 de	 la	 proteína	 de	 unión	 a	 elementos	 reguladores	 del	 esterol	
(SREBP)	 que	 no	 están	 estructuralmente	 relacionados	 con	 el	 NDGA,	 como	 son	 el	 PF-
429242	y	la	Fatostatina,	reducen	la	multiplicación	del	VNO	y	del	virus	Zika.	
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The	conclusions	obtained	with	this	thesis	were	the	following:	
1. The	content	of	a	wide	variety	of	lipid	metabolites	is	altered	in	WNV-infected	cells.		
2. Several	 glycerophospholipids	 (phosphatidylcholine,	 plasmalogens	 and	
lysophospholipids)	 and	 sphingolipids	 (ceramide,	 dihidroceramide	 and	 sphingomyelin)	
are	increased	in	WNV-infected	cells.	
3. The	 lipid	 envelopes	 of	 natural	WNV	 virions	 and	 recombinant	 virus-like	 particles	 are	
enriched	 in	 sphingolipids	 (sphingomyelin)	 and	 show	 reduced	 levels	 of	
phosphatidylcholine.	
4. Inhibition	 of	 neutral	 sphingomyelinase	 (which	 catalyzes	 the	 hydrolysis	 of	
sphingomyelin	into	ceramide)	reduces	the	release	of	flavivirus	virions	as	well	as	that	of	
virus-like	particles.	
5. Glycerophospholipid	and	sphingolipid	metabolism	is	linked	to	WNV	infection.	
6. The	 acetyl-CoA	 carboxylase	 (ACC)	 inhibitors	 TOFA	 and	 MEDICA	 16	 inhibit	 the	
multiplication	of	WNV	and	USUV	by	reducing	viral	genome	replication.	
7. The	 nordihydroguaiaretic	 acid	 (NDGA)	 and	 its	 methylated	 derivative	 tetra-O-methyl	
nordihydroguaiaretic	(M4N),	inhibit	the	infection	of	WNV	and	ZIKV.	
8. Inhibitors	of	the	sterol	regulatory	element	binding	proteins	(SREBPs)	pathway	that	are	
structurally	 unrelated	 to	NDGA,	 such	 as	 PF-429242	 and	 Fatostatin,	 reduce	WNV	and	
ZIKV	multiplication.	
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